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Arboviruses constitute a major public health problem; in particular mosquito-borne 
arboviruses that continuously emerge and re-emerge. Arbovirus infection of mammals is 
enhanced by the presence of a mosquito-bite at the inoculation site, or by the co-inoculation 
of extracted mosquito saliva alongside virus, in comparison to virus experimentally 
administered by needle inoculation in the absence of  bite/saliva. Host responses elicited 
against saliva appear to be key in facilitating this enhancement. As such, we have studied the 
mechanistic basis for these observations by investigating mosquito-bite factors, as well as host 
responses, involved in facilitating viral enhancement. Using an in vivo mouse model we 
demonstrate that salivary microbiota does not modulate virus infection. Instead 
proteinaceous salivary factors inside saliva is responsible for enhancing virus infection. We 
have studied whether saliva from different mosquito species successfully enhance virus 
infection. Interestingly, while saliva from Aedes genus enhance virus infection, An.gambiae 
saliva does not. This could partly explain why An.gambiae mosquitos are unsuitable vectors 
for transmitting most arboviruses. By comparing the effects that saliva from these different 
species have at the inoculation-site, we have further specified which inflammatory responses 
modulate arbovirus infection in the skin. Using an in vivo mouse-model we demonstrate that 
An.gambiae causes significantly less oedema than Ae.aegypti and that histamine induced 
oedema in the absence of salivary-factors also enhances infection. Also, measuring cytokine 
responses to Aedes and Anopheles saliva, showed that several key anti-viral chemokines such as 
CCL5 were significantly more upregulated by Anopheles. Hence, we’re providing important 
insights into how mosquito saliva modulates infection. A better understanding of this will aid 
the development of anti-viral treatments targeting factors within the mosquito bite that are 
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ISGF3 Interferon stimulated gene factor 3 
JAK/STAT Janus kinase/signal transducers and activators of 
transcription 
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JH  Juvenile hormone 
LGP-2  Laboratory of genetics and physiology-2 
LPS  Lipopolysaccharide 
LRR  Leucine-rich repeats 
LTβR Lymphotoxin β receptor 
MAPKs  Mitogen-activated protein kinases 
MAVS  Mitochondrial antiviral signalling protein 
MCSF Macrophage colony-stimulating factor 




MEF Mouse Embryonic Fibroblasts 
MEM  Minimum Essentials Media 
miRNA  Micro RNA 
ml  Milliliter 
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MMPs   Matrix-metalloproteinases 
MOI   Multiplicity of infection 
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NK  Natural killer 
NLR  NOD-like receptor 
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NTS Non-template control 
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TNF  Tumour necrosis factor 
TNFSF  Tumour necrosis factor superfamily 
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1.1 Brief history of infectious diseases 
 
Infectious diseases have plagued humanity throughout our entire existence. They 
have repeatedly swept across the globe devastating communities, forever changing 
the course of human history by causing the deaths of millions and even bringing 
mighty empires, such as the Han and Roman empires, to their knees. Infectious 
diseases have had, and are still having, a tremendous impact on our way of life.   
 
The story of infectious disease stretches as far back as humanity’s own. Historians 
and archaeologists have successfully unsurfaced numerous accounts of infectious 
diseases in literature, at archaeological sites and depicted in art. In Egyptian 
mummies that are over 3000 years old we can detect evidence of outbreaks of 
smallpox, and Egyptian papyrus reveal evidence that Egyptians of the time were 
plagued by infectious diseases such as poliomyelitis [1]. Also in literature, we can find 
accounts of previous outbreaks of disease along with humanities earliest attempts at 
understanding them; one notorious example being the “Cough of Perinthus” cited 
in the Corpus Hippocratium, thought to be referring to the first account of an 
influenza outbreak in human history [2].  
 
Hippocrates, commonly referred to as the “Father of Medicine”, was the first to 
correctly suggest various routes of transmission of disease including air, water and 
food whilst Thucydides was the first to draw the conclusion that infectious disease 
could be contagious between individuals; a conclusion he drew from his observations 
during the plague of Athens in 430-427 B.C.E [3]. In the 1600s, Leeuwenhoek, also 
known as the “Father of Microbiology” invented the microscope, enabling the 
visualisation of microorganisms for the first time whilst the 18th century brought us 
the development of the first vaccine by Edward Jenner [4] [5]. Despite these 
advances, it was not until the 19th century that “germ theory” became widely 
accepted following the work of Louis Pasteur who demonstrated that infectious 
disease was caused by microorganisms [6]. The existence of viruses however was not 
confirmed until the late 19th century by Dmitri Ivanovsky and scientific and medical 





From the mid to the end of the 20th century there was a common belief that the battle 
on infectious disease was largely won. In 1948, the US secretary of State, George 
Marshall, stated that “the conquest of all infectious diseases was imminent”, a point 
of view that was shared by many at the time [8]. This belief had been brought on by 
the successful development of numerous vaccines, the discovery of antibiotics, the 
eradication of smallpox and rinderpest and the development of DDT 
(dichlorodiphenyltrichloroethane) which was believed to be the solution to the 
malaria problem. These scientific breakthroughs wrongly instilled a sense of hubris 
amongst scientists and world leaders alike whom in the end were surprised that 
instead of a continuation of the trend, they saw a re-emergence of old diseases 
previously believed to have been controlled and the emergence of completely new or 
resistant variants of previously known diseases.  
 
1.2 Understanding Emerging and Re-emerging Infectious Diseases 
 
The word disease, originating from the old French word of “desaise” (lack of ease), 
can refer to any condition that disrupts the normal function of the body. The 
aetiology of disease can however vary greatly; some diseases, such as cystic fibrosis, 
are caused by mutations in the genetic code whilst infectious diseases are acquired 
when a host has become infected with an outside agent that causes the disease, hence 
the term “infectious disease”.  
 
Infectious diseases can be further divided into emerging infectious disease or re-
emerging infectious disease; the former referring to the appearance of novel, 
previously unheard of diseases whilst the latter group refers to the reappearance of 
infectious disease that was previously believed to have been eradicated or kept under 
control, an infection that re-appears with new disease symptoms or simply a disease 
that materializes in a completely new, previously unheard of geographical location. 
Whilst the possibility of emerging novel diseases was widely accepted by scientist for 
an extensive period of time, it was not until the appearance of a range of 
haemorrhagic fevers, including the Crimean-Congo haemorrhagic fever and Ebola 
in the mid 1970s, that emerging diseases received an increase of attention. The first 
documented use of the terms “emerging and re-emerging disease” was by Joshua 




One of the most renown examples of an emerged infectious disease is the HIV/AIDS 
epidemic. Acquired immunodeficiency syndrome (AIDS) which is caused by the 
lentivirus HIV (Human immunodeficiency virus) is thought to have originated from 
the closely related SIV (simian immunodeficiency virus) which primarily infects 
primates and only overcame the species barrier via repeated contact of humans with 
infected bushmeat in 1910 in Kinshasa [10]. AIDS was officially recognized as a new 
disease in 1981 and since then, despite the tremendous progress that has been made 
in combating the disease, over 25 million people have died due to AIDS related 
illnesses [11].  
 
1.2.1 Factors determining emergence or re-emergence of disease 
 
In order to understand the concept of emergence and re-emergence of disease it is 
important to comprehend the difference between disease and infection. Whilst 
infection refers to the introduction of an agent such as a virus into a host where it 
can then multiply, disease is a word describing the symptoms and signs the host 
typically exhibits by such an introduction. By making this distinction it is possible to 
understand that a host can be infected without actually exhibiting any symptoms and 
therefore the infectious agent can precede the existence of the disease.  Therefore, 
whilst it may seem as if new diseases can just appear randomly, there is almost always 
a reason explaining its occurrence. In fact, most newly emerged diseases originate 
from infectious agents that are already present in our environment and it is estimated 
that the majority of human diseases have their origin in zoonoses, which are animal 
infections that are also transmissible to humans. [12, 13]. It is changes made to the 
environment of these infectious agents, usually by humans, that can cause a new 
disease to emerge or re-emerge.  
 
There are 5 evolutionary stages required for a pathogen to evolve into a human 
specific pathogen. These are: 1) Infectious agent is present in the environment but 
not in humans; 2) The infectious agent can infect humans but it cannot be 
transmitted from one person to another; 3) Transmission between humans is possible 
but infections are limited to smaller outbreaks that tend to die out; 4) Transmission 




still required to constantly enhance infection numbers; 5) The infectious agent is 
human specific and self-sufficient [14].  
 
1.2.1.1 Ecological Changes  
 
Changes in environmental conditions is one of the major drivers for emerging 
diseases. Agriculture appears to be one of the major culprits as it tends to place 
people in close proximity with environments were potential infectious agents are 
present. This exposure of humans to an infectious agent for a prolonged time, 
increases the chances of it successfully infecting and causing disease. An 
environmental change can also cause disruptions of the natural ecosystem potentially 
shifting an infectious agents host preference.  
 
Ebola outbreaks are believed to commonly originate from human contact with 
infected bats either via bushmeat or via infected droppings [15]. Fruit bats were 
confirmed to be the reservoir host of Ebola as viral titres have been detected in three 
separate bat species [16]. Major deforestations of the fruit bats natural habitats could 
have contributed to the likelihood of the 2014 Ebola epidemic occurring, as it altered 
the distribution of the fruit bats as well as bringing humans into closer proximity to 
the virus. The presence of infected fruit bats in human habitats, feeding from the 
same fruit trees eliminated the need for infectious bushmeat being the source of 
infection [17].  
 
In contrast to the deforestation events possibly resulting in the outbreak of Ebola, the 
emergence of Lyme disease in the United States is believed to have been a 
consequence of reforestation. The reforestation caused an increase of deer 
populations and with them an increase of Lyme disease carrying ticks [18]. Similarly 
to the emergence of novel disease, environmental changes can also be the aetiology 
of disease re-emergence and can have a major impact on the prevalence of arthropod 
borne diseases as arthropod vectors constitute a major route of infectious agent 
transmission. In east Asia, flooding of rice fields has become associated with an 
increase in the incidence of  Japanese encephalitis (JE). This is due to the fact that 
the accumulation of water allows for a perfect breeding ground for Japanese 




the virus [20]. These examples illustrate the impact environmental changes can have 
on disease frequency and occurrence and how difficult they can be to predict.   
 
1.2.1.2 Human Populations and Demographics  
 
Approximately 11,000 years ago, humans made a shift from predominantly hunter-
gathering to systematic agriculture and with this change human societies started to 
take form with people living in closer proximity and larger numbers. As a 
consequence, numerous novel infectious diseases emerged specifically targeting 
mankind as diseases could adapt and spread more readily from one person to another 
[21]. Currently, there are over 7 billion people living in the world and it is estimated 
that the global human population will continue to increase to approximately 11 
billion before finally levelling out (see figure 1.1) [22] [23]. Projections also estimate 
that in 2050, 68% of all people on earth will be residing in cities (currently it is about 
55%) [24]. With more than half of the human population living in urban areas 
people are living in closer proximity to each other and in larger numbers than ever 
before and such changes have impacts on infectious disease incidences. 
 
Figure 1.1 World population projection. 
World population projections estimate that there are currently over 7 billion people living 
in the world and the global human population will continue to increase to approximately 11 
billion before finally levelling out [22] [23]. 
 
Urban environments possess the enhanced risk of transmissions of disease as the 
density of the population means the existence of a larger number of potential hosts. 
If an emerging infectious disease gets into a major city, it can quickly become a hot 




incidence in isolated rural areas resulting in a very low number of infected 
individuals. The outbreak in 2014 however resulted in over 10,000 peoples deaths 
as it managed to spread to the capital of Guinea and from there on to the capitals of 
Sierra Leone and Liberia [25]. Apart from environments with higher population 
density, major cities can also create more temperature stable environments which 
can indirectly expand the season when vectors are able to transmit disease [26] [27]. 
The evolution of dengue virus (DENV) has been closely linked with the development 
of urban areas as it has benefited from both the density of humans but also of the 




The last decades have seen an immense increase in aviation and goods 
transportation with the numbers of airline passengers exceeding 4 billion in 2017 
and with 53.9 million tons of goods being shipped by air [30]. Increase in 
international travel and commerce has proven to be a very effective way of spreading 
diseases across the globe. With international travel rates being higher than ever, 
diseases have an unprecedented opportunity to reach far off locations, and 
quarantine measures and border screenings have often proven to be inadequate at 
preventing spread, as infectious agents can hitch a ride in travellers not yet presenting 
any symptoms of disease [31].  
 
Due to international travel HIV succeeded in spreading across the entire globe, and 
SARS (severe acute respiratory syndrome) successfully spread to 28 countries in 5 
separate continents claiming almost 800 people’s lives before the epidemic was 
successfully controlled [32]. International shipments have also helped spread diseases 
indirectly by the involuntary transportation of infected animals or stagnant microbe 
containing water.  Hantavirus has been spread across the globe by the introduction 
of infected rats to novel locations [33] and shipping of tires containing infected 
mosquito eggs has been linked to the introduction of the mosquito vector Aedes 
albopictus to parts of North America and the continent of Africa  [34] [35]. Another 
common arthropod-borne disease that is commonly imported via air travel is 







Infectious agents are constantly changing and adapting to their environment in 
response to evolutionary pressures. When a treatment is introduced to help treat an 
infection this can lead to selection pressure for escape mutants to occur. This is 
especially common in bacteria and their constant selection towards antibiotic 
resistant strains due to the widespread misuse of antibiotics. Similarly, fast evolving 
viruses can quickly become resistant to antivirals which is why drugs with differential 
targeting are often required to minimize the risk of resistance occurring as is true in 
the treatment of HIV [38]. Changes can also result in new strains that can cause 
variations in symptoms caused and in the case of influenza, constant genetic drift 
results in the need for new vaccines each year [39].  
 
1.2.2 Socioeconomic Burden of Infectious Disease 
 
Out of the 56.9 million deaths recorded in 2016, 3 million were caused by the 
deadliest infectious disease globally; lower respiratory infections. Diarrhoeal diseases 
contributed to 1.4 million diseases, tuberculosis caused 1.3 million deaths whilst 
deaths from HIV/AIDS were estimated at 1 million individuals in 2016. Whilst the 
impact of infectious diseases is less prevalent in higher income countries, in lower 
income countries infectious disease related deaths are still the most common cause 
of death (see figure 1.2) [40].  
 
Measuring the impact of infectious diseases by looking at deaths alone gives a skewed 
and incomplete picture of the actual socioeconomic burden that infectious diseases 
have. A more complete estimate of impact can be gained by measuring disability-
adjusted life years (DALYs). In this system, one DALY represents the loss of 1 year 
of full health. In the EU/EEA (European Union/European Economic Area) it has 
been estimated that there was a yearly loss of 275 DALYs per 100,000 individuals 
between 2009-2013 due to infectious disease with the highest disease burden 
attributed to influenza with 81.8 DALYs lost yearly [41]. DALYs have a huge 
societal impact as affected people are less capable of working and may need medical 





Figure 1.2. Top 10 causes of death globally and in low income countries.  
Pie charts depicting the percentages of the top 10 global causes of death, or causes of death 
in low income countries in 2016. The top 10 causes of death have been grouped into 3 
categories; infectious disease (green), non-infectious disease (blue) and road injury (yellow). 
Data acquired from world health organization [40].  
 
1.2.3 Future prospects of Infectious disease 
 
The pandemic of 1918, most commonly referred to as the “Spanish flu”, ended up 
wiping out 3-5% of the human population of the time [42]. There is a consensus that 
a new pandemic will occur eventually and humanity must be prepared for the 
potentiality of this unknown danger. The outbreak of SARS in 2003 which led to a 
rapid spread of the previously unheard of coronavirus (SARS-CoV) with a death rate 
of approximately 1:10 infected, led to a wakeup call for the necessity of international 
measures to combat future outbreaks [43]. Up until the 1990s the international 
health regulations (IHR) only required countries to report cases of cholera, yellow 
fever and plague as these were the only diseases recognised for having the potential 
of being an international threat. Due to several outbreaks in the early 1990s, a need 
for a revision of the IHRs was recognized and the incorporation of more accurate 
and timely accounts of ongoing outbreaks were deemed necessary to aid in the 
combat of diseases. Whilst the SARS outbreak, which initially proved to be an 
immense challenge, was controlled within 5 months of its emergence due to 
successful global collaborations, it did also help highlight the flaws of the IHR of the 
time [43]. This led to a new revision that went into effect in 2007. These revisions 
now require countries to report to the World Health Organization (WHO) any new 
cases of smallpox, polio, new subtypes of human influenza, and SARS as well as 
other potential infections depending on the assessment of their public health impact. 














ports such as airports, ports and ground crossings whilst also providing WHO with 
additional powers and duties including a constant global surveillance of epidemic 
intelligence and risk assessments and to investigate all cases of potential concern [44].  
Currently, the most pressing question is, are these measures enough to control future 
threats? 
 
In 2009, with the H1N1 influenza outbreak, the new IHR measures were put to the 
test and whilst the new modifications to the IHR helped, the world continued to be 
vulnerable for future pandemics. Several shortcomings were highlighted including 
the lack of adequate healthcare in low and mid income countries and the lack of 
capability of some countries to successfully monitor disease cases and disease 
progressions [44].  Also, since the implementation of the new IHR measures, many 
countries have proven incapable to meet the requirements needed for compliance. 
Gaps in the system have been detected following several recent outbreaks including 
the Ebola epidemic in Western Africa in 2014. These gaps are related to the lack of 
availability of timely care, limits in early detection of disease occurrences, lacking 
quarantine procedures and also an inefficient timely coordinated global response to 
these occurrences. As these limitations have had severe implications on epidemics 
restricted to certain geographical regions, it is possible to assume that the 
consequences of such gaps in our response to infectious diseases, can be quite severe 
in the case of a full blown global pandemic [45] [46]. It is therefore essential for all 
our benefit that we make a global effort to help lower income countries to meet the 
desired IHR measures, the implementation of a Universal Health Coverage where 
affordable health services are available for everyone, and the continuous monitoring 
and control of zoonotic pathogens in order to prevent any future outbreaks from 
occurring [47] [48].  
 
The complexity between the interactions and dynamics between zoonoses, animals 
and potential human hosts illustrates the difficulty in predicting the occurrence of 
emerging and re-emerging disease. Even if humanity successfully achieves the latest 
goals on IHR, emerging diseases will continue to pose a genuine global threat; 
underlining the importance of scientific research for new treatments and medicines 
for the prevention and treatment of any new emerging or re-emerging pathogens.  




emergence of viruses such as Chikungunya (CHIKV) in La Réunion [50], as well as 
DENV have highlighted the knowledge gap for a specific group of neglected 
emerging and re-emerging pathogens; the arthropod borne viruses.  
 
1.3 Introduction to Arboviruses 
 
Arboviruses is a classification used to characterize arthropod-borne viruses which 
are essentially viruses that successfully replicate in, and transmitted by an arthropod 
vector such as mosquitoes, ticks and sand-flies.  The successful maintenance of the 
transmission cycle of such viruses is dependent on the spatiotemporal interaction of 
the virus, the host and the vector. Most arboviruses retain an enzootic cycle, i.e. the 
virus main host is a non-human vertebrate that only occasionally will spill over and 
infect humans such as in the case of West Nile virus (WNV); certain arboviruses are 
mainly transmitted directly between humans however, such as is the case for dengue 
virus DENV. As a general rule, most arboviruses are named after either the disease 
they cause; such as in the case of yellow fever virus, or of the location it was first 
discovered e.g. ZIKV.   
 
The majority of the non-segmented positive stranded RNA arboviruses belong to the 
Togaviridae and the Flaviviridae virus families, whilst the majority of the segmented 
negative stranded RNA arboviruses belong to the order of Bunyavirales. As an order, 
Bunyavirales contains a large number of approximately 350 genetically distinct viruses 
organised into 9 distinct families: Hantaviridae, Nairoviridae, Peribunyaviridae, 
Phenuiviridae, Tospoviridae, Feraviridae, Fimoviridae, Jonviridae and Phasmaviridae. 
 
Clinical disease typically caused by arbovirus infections can be divided into 4 
separate categories [51];  
- illnesses affecting the central nervous system (CNS) 
- haemorrhagic fevers 
- polyarthritis and rash 







1.3.1 History of arboviruses 
 
Historically, most mosquito borne viruses were restricted to certain geographical 
locations. Ae.aegypti for example, one of the most prevalent mosquito vectors was 
originally only found in parts of Africa and only spread to the rest of the world via 
the slave trade between the 15th and 19th century [52]. This expansion of the 
geographical spread of Ae.aegypti led to the first recorded yellow fever outbreak of the 
new world in 1647 in Barbados, and later, the recording of several epidemics in in 
the southern parts of the US in the 18th and 19th century [53] [54].  
 
Since then, the Americas have been plagued by numerous outbreaks of yellow fever 
and dengue that ranged as far north as New York. An attempt was initiated in 1947 
to try to tackle the issue by the Pan American Health Organization (PAHO). This 
mission was based on a campaign involving emptying of potential mosquito breeding 
grounds and the extended use of DDT (dichlorodiphenyltrichloroethane) and often 
involved direct access to people’s homes to conduct these control measures [55]. 
These measures proved to be highly successful as by 1962 Ae.aegypti had been 
eradicated in approximately 20 countries [56]. However, despite these successes, due 
to the lack of interest of participation in the program by the US government, the US 
provided an easy route of re-introduction of Aedes mosquitoes across the border. In 
addition to this, when the eradication program disintegrated in the 1970s the 
mosquito vector subsequently managed to spread across the continent yet again 








Figure 1.3. Ae.aegypti eradication attempt. 
Map illustrating the spread of Aedes mosquitoes in the Americas; in the 1930s before the 
eradication attempt; in the 1970s after the eradication attempt; and in 2011 after 
abandoning the eradication attempt. Figure edited from Duane et al 2011 [57]. 
 
The ability of mosquitoes acting as transmitters of disease remained undiscovered 
until it was suggested as a concept by a Cuban doctor in 1881 called Carlos Finlay 
[58]. It took another 20 years until this was backed up by scientific evidence by Major 
Walter Reed [59]. During the 1930s several arboviruses were discovered via their 
isolation directly from blood of infected patients or from autopsy samples [60]. Via 
this method, the  first  tick borne virus was discovered in the USSR in 1937 following 
outbreaks of tick borne encephalitis (TBE) by a team of scientists led by Professor 
Lev A. Zilber [61].  
 
1.3.2 Arboviruses today 
 
Whilst arboviruses have been emerging and re-emerging for centuries, in recent 
years we have observed a far swifter global dispersal and emergence of such viruses 
due to globalization, adaptation of mosquito species to human habitats and human 
failure of controlling mosquito populations. Limitations in surveillance and health 
care in common endemic areas are believed to be causing an underestimation of 
arbovirus disease cases, but nevertheless DALYs due to infections with YFV, JEV, 




5,000,000 in 2005 [62]. The most prevalent alphaviruses and flaviviruses as well as 





Alphaviruses are a virus genus consisting of 31 known medically and veterinary 
important viruses. It has recently been suggested that the terrestrial alphaviruses 
originated from the oceans due to the recent discovery of aquatic alphaviruses that 
are most likely transmitted via aquatic lice [63]. Alphaviruses are endemic on 6 
continents with certain viruses being more restricted than others in their 
geographical spread [64]. However as has already been discussed, geographical 
spread of such viruses is forever changing. 
 
1.3.3.1 Taxonomy and distribution 
 
Alphaviruses belong to the family of Togaviridae with 31 virus species having been 
ascribed to this family so far. Phylogenetic studies suggest that they arose in the 
southern oceans only to evolve terrestrial transmission where they were then capable 
of disseminating to the Old and New world. The non-aquatic alphaviruses are 
therefore commonly divided further into New world and Old world alphaviruses; 
two groups which arose following several introductions and re-introductions of 
alphaviruses from the ocean [63]. Eastern equine encephalitis virus (EEEV), Western 
equine encephalitis virus (WEEV) and Venezuelan equine encephalitis virus (VEEV) 
are a few examples of medically relevant New world alphaviruses whilst CHIKV, 
Semliki forest virus (SFV) and O’nyong ‘nyong virus (ONNV) belong to the Old 
world alphaviruses grouping. Neuroinvasive disease is a common manifestation of 
infections with New world alphaviruses whilst Old world alphavirus infections are 
more commonly associated with febrile illness, arthralgia and myalgia.  
 
1.3.3.2 Structure and Replication 
 
Alphaviruses are small enveloped viruses with a size of approximately 65-70nm in 




protein resulting in a  T=4 icosahedral symmetry. The envelope is covered with 80 
glycoproteins made up of 2 or 3 subunits forming a trimer made up of E1 and E2 
proteins [65]. Within the nucleocapsid the virus’ 12kb single stranded positive sense 
(ss+) RNA is located (see figure 1.4).  
 
Figure 1.4. Alphavirus structure 
Alphaviruses are small (700A diameter) enveloped viruses containing a 12Kb positive sense 
RNA genome within an icosahedral protein nucleocapsid. The envelope is host cell lipid 
derived and is decorated with 80 glycoprotein spikes containing E1 and E2 heterodimers. 
 
In order for infection to occur, the virus particle must first successfully enter a 
susceptible cell. This occurs with the attachment of the E1/E2 glycoprotein to a 
specific receptor on the cell surface via protein-protein interaction. The receptors 
facilitating alphavirus entry into host cells remain unclear. However, due to the 
broad cell tropism observed by alphaviruses which is necessary for their dependency 
on their ability to replicate in both vertebrate and non-vertebrate cell lines, it is 
possible that alphaviruses use surface receptors widely expressed on a variety of cell 
types from a wide range of species. Another suggestion is that they potentially possess 
the ability to bind to multiple receptors. Receptors that have been suggested to be 
responsible for aiding viral entry include proteins in the histocompatibility complex 
such as DC-SIGN (dendritic-cell-specific ICAM-grabbing non-integrin) and L-
SIGN, heparin sulphate and, for joint specific alphaviruses, the recently discovered 
cell adhesion molecule Mxra8 [66] [67] [68]. Following binding to cell surface 
receptors, the virus particle will be internalized into the cell via the process of 
receptor mediated endocytosis by the formation of a clathrin-coated vesicle. The 










Lowering of pH triggers conformational changes on the virus particle with the E1 
protein forming a fusion pore with the membrane [70]. An alternative viral entry 
method has recently been proposed for alphaviruses however. This alternative 
suggests a method of viral entry independent of endocytosis and pH-dependent 
membrane fusions. Instead, it is suggested that the virus particle forms a pore-like 
structure directly with the cell membrane via the interaction of viral and cell 
membrane proteins and the direct transfer of the viral RNA into the host cell via this 
method [71].  
 
Alphavirus replication occurs in proximation with cellular membranes which 
triggers the formation of so-called “spherules”. These spherules are essentially 
invaginations of a membrane with a diameter of approximately 50nm and they are 
located in the membranes of cytoplasmic vacuolar structures type I (CPV-1) where 
replication occurs, and also at the plasma membrane where they have potentially 
been directed by nsp1 [72, 73].  
 
The ss+ RNA alphavirus genome consists of a 5’ cap and a 3’ poly(A) tail. There are 
two open reading frames (ORF) within the genome which can give rise to two 
polyproteins (see figure 1.5). The first ORF which is located at the N-terminal, 
encodes the non-structural polyprotein translated by the genomic RNA, whilst the 
structural polyprotein which is encoded by the C-terminal ORF is translated by 
subgenomic 26S RNA. Further cleavage of the polyproteins is achieved by the viral 
protease cysteine as well as host proteases. The non-structural polyprotein can be 
cleaved into 4 separate proteins; nsp1, nsp2, nsp3 and nsp4. Nsp1 is responsible for 
binding replication complexes to cell membranes; nsp2 possesses enzymatic 
properties such as helicase and protease responsible for cleaving the nsp complex; 
nsp3 has phosphatase and RNA-binding activity whilst nsp4 is an RNA-dependent 
RNA polymerase (RdRP) [74].  Initially nsp4 is cleaved from the nsp1234 complex 
via nsp2 to form the nsp123 and nsp4 (-)RNA strand replicase complex. The 
synthesis of (-) strand RNA will eventually trigger the cleavage of nsp123 complex 
into nsp1 and nsp23 which will lead to the formation of a complex in charge of the 
task of replicating the genomic and subgenomic RNA [75]. Some alphaviruses 




nsp4 10% of the time. Interestingly the substitution of this stop codon with an 
arginine base appears to be linked with virulence [76].  
 
 
Figure 1.5. Alphavirus genome layout 
 
Newley synthesized viral RNA is then thought to move into the cytoplasm via the 
pore at the neck of the spherule as it accumulates [72]. Subgenomic RNA will then 
be translated into structural proteins which consist of Cp, p62 (the E2 precursor, 
termed p62 in SFV and pE2 in SINV), 6K, E1, and transframe (see figure 1.5). Cp, 
which is the first structural protein to be constructed, will assemble the genomic RNA 
and form the nucleocapsid [77]. The structural proteins will then assemble into a 
newly constructed virus particle in the cytoplasm. When the virus capsid is fully 
assembled it will bud at the cell membrane, simultaneously gaining an envelope 
leading to the release of the mature virion [75, 78]. 
 
1.3.3.3 Semliki forest virus – an in vivo model 
 
In 1942 in Bwamba, Uganda, 130 mosquitoes of the species Aedes abnormalis were 
collected in the Semliki forest by the Uganda Virus Research Institute, which were 
found to be carrying a previously undescribed alphavirus. This positive stranded 
RNA virus was named after the forest where it was discovered, and was therefore 
given the name Semliki forest virus (SFV) [79]. SFV can commonly be found in sub-
Saharan Africa where it is mainly transmitted by Aedes aegypti and Aedes africanus [80]. 
Whilst the enzootic source of this virus remains unknown, there have been accounts 
of SFV infections in horses, rodents, rabbits, monkeys and even humans [81] [82]. 
In 1976 it proved that an outbreak of equine encephalitis in Senegal was in fact 
caused by SFV [83]. A decade later, samples acquired from patients suffering from 
headaches, fever, arthralgia and myalgia in 1987 in the Central African Republic 
revealed that SFV was the aetiological agent behind the outbreak [84]. Although 
SFV infections in humans are not considered to be fatal, historically there has been 






only one death associated with encephalitis induced by SFV in a laboratory worker 
that was believed to have been immunocompromised [85]. 
 
Since its discovery, SFV has become the staple model for alphavirus infection and a 
well-used tool for understanding the molecular biology of positive sense RNA viruses 
in general. By mere chance, SFV has become the model alphavirus utilised in 
Europe, whilst in the Americas, the alphavirus Sindbis virus (SINV) is more 
commonly used in research [86]. There are many different strains of SFV that have 
been, and that are currently in use in laboratories around the globe. SFV has been 
determined to be neurotropic with the capability of infecting both neurons and 
perivascular oligodendrocytes [87]. Whilst alphavirus infection of the CNS and viral 
dissemination to the brain is a characteristic more commonly associated with new 
world alphaviruses, the neurovirulence observed with certain SFV strains has most 
likely arisen due to passaging of virus through mouse brains. Strains of SFV can very 
roughly be divided into two groups; the virulent strains and the avirulent strains. The 
earliest isolated strain of SFV, now known as L10, belongs to the virulent strain 
grouping as it was discovered to be neurovirulent and causing lethal encephalitis in 
mice by its ability to infect the central nervous system (CNS). Other strains in this 
grouping include V13, SFV4 and SFV6 [88-90]. Strains in the avirulent group cause 
demyelination instead of lethal encephalitis and include the strains A8, A7 and its 
derivative A7(74) and MRS MP 192/7 [80, 90]. As only SFV4 and SFV6 have been 
used for the purpose of this thesis, only these will be discussed further.  
 
L10, which derives from the original isolate of SFV acquired in Uganda, was 
passaged 8 times intracerebrally in adult mice and a further 2 times in baby mice 
[91, 92]. In a murine in vivo model, infection with SFV L10 leads to high viral titres 
detectable in the blood as well as efficient infection of the brain resulting in lethal 
panencephalitis. SFV4 is significantly less virulent and rarely neuroinvasive in mice 
[93]. Sequence data from the different SFV strains were compared in an attempt to 
determine the cause for the difference in virulence and neuroinvasion between the 
strains. 12 nucleotide differences were detected between SFV L10 and SFV4 out of 
which 6 were nonsynonymous. A single amino acid change in the E2 glycoprotein 
at position 162 as well as 247, from glutamine in L10 to a lysine in SFV4 appeared 




This amino acid change results in an alteration in binding efficiency with strains 
containing the charged lysine residue at positions 162 and 247 demonstrating a 
higher affinity of binding to the glycosaminoglycan heparin sulphate. Heparin 
sulphate is ubiquitously expressed on most vertebrate and invertebrate cells and this 
higher affinity in binding likely results in an increased retention of SFV4, minimizing 
its presence in circulation [94]. 
 
These 6 nucleotide differences were used to engineer a new molecular SFV clone 
now known as SFV6. This newly generated strain proved to be highly virulent and 
very neuroinvasive. Unlike L10, SFV6 is genetically homogenous whilst the original 
isolate, L10, consists of a mixture of SFV variants with varying phenotypes and 
pathogenicity and so SFV6 represents the most virulent consensus sequence of L10 
[94]. The SFV4 and SFV6 strains are obtainable as cDNA clones which can be 
transcribed into viral RNA which, when electroporated in to eukaryotic cells will 
result in infectious virus [86].  
 
Several studies have been conducted characterizing the pathogenicity and viral 
dissemination of SFV in mice. Whilst most work has focused on the pathogenicity of 
SFV in neural tissue following intracerebral inoculation, recent studies have 
investigated the pathogenesis of virus infection following the subcutaneous 
inoculation of virus in the skin in the presence of a mosquito bite [95]. Subcutaneous 
injection of SFV4 leads to dissemination of virus 3 to 6 hours following virus infection 
to the draining popliteal lymph node (dLN) and a peak of viraemia 24h post 
infection. Systemic spread of virus can be observed 48h following infection with only 
sporadic episodes of neuroinvasion. If SFV4 is injected alongside a mosquito bite 
however there is a significant increase in amount of viral RNA detected at the site of 
infection and amount of infectious virus particles located in the serum at 24h post 
infection. Whilst certain aspects of infection remain poorly understood, such as 
which the key cellular targets are for viral replication and the trajectory of viral 
dissemination to distal tissues, it has been established that a key aspect of disease 
progression is the early host responses at the bite site and the associated inflammation 
triggered by the bite which result in a significant enhancement of viral replication 





Due to the extensive research conducted on SFV and given how well characterised 
SFV infection is in mice it makes this virus an excellent model for studying arbovirus 
infection in vivo. Another factor that makes SFV an excellent in vivo model system is 
this virus ability to successfully replicate and disseminate effectively in immune 
competent wild type mice (unlike many other arboviruses). Also the fact that it is 
categorised as a biosafety level 2 pathogen, whilst most other medically relevant 
arboviruses are not, allowing for work to be conducted in a lower containment 
setting. Therefore, in terms of the work conducted for this thesis, SFV formed a 
useful tool for studying the modulation of arbovirus enhancement in the skin by 
mosquito saliva. A further benefit of using SFV is the fact that there are numerous 
reporter strains available as plasmids that are easily genetically manipulated and 
grown in bacteria which can be used for the visualization and quantification of 
infection with these viruses such as the SFV6-Gluc strain which was utilised in several 
experiments in this thesis.  
 
1.3.3.4 Chikungunya virus – a medically relevant alphavirus 
 
CHIKV infection in humans leads to the development of chikungunya fever 
(CHIKF) in approximately 75%-95% of affected individuals [96] [97]. CHIKF is 
most frequently associated with high fever, myalgia, arthralgia, polyarthralgia and 
potentially haemorrhage occasionally accompanied by a rash [98]. Chikungunya 
infection was first described following an outbreak of the virus in the early 1950s in 
Tanzania and infectious CHIKV was first isolated in 1953 from human sera of 
infected patients as well as directly from infected mosquitoes of the species Ae.aegypti 
and several species from the Culex family [99] [100]. The virus is named after the 
arthralgia symptoms associated with the disease as chikungunya is a word from the 
Makonde language depicting the crocked posture of a person infected with the virus 
[99]. CHIKV is now classified as an Alphavirus and a member of the Semliki forest 
virus antigenic complex, a complex that also includes other alphaviruses including 
SFV, Ross River virus (RRV) and the closely related ONNV amongst others [101].  
 
Infection with CHIKV is initiated following the deposition of the virus into the skin 
of the host via the help of its mosquito vector which are most commonly Aedes 




are poorly understood, it has been established that following initial infection the virus 
will readily spread to distal tissues as the virus preferentially targets the joints, muscle 
and skin for replication and occasionally also the liver, kidneys and eye [103]. Several 
studies have shown that following infection, replication of CHIKV can occur to very 
high viral titres ranging between 105 to 109 copies of viral RNA per ml. Amount of 
viral load appears to correlate with severity of symptoms [104] [105].  
 
CHIKV is not considered to be classically neurotropic in the sense that it does not 
disseminate readily to the brain and is not commonly associated with manifestations 
of encephalitic disease. Despite that, the virus can occasionally disseminate to the 
CNS and cause infection of the choroid plexus, where it can infect meningeal and 
ependymal cells [106] [107]. Also, there are several accounts of paediatric cases of 
CHIKV infections that have been associated with neurological complications [108]. 
Disease tends to manifest 2-4 days following infection, and depending on the strain 
responsible, in 10% - 20% of infections with CHIKV lead to long lasting 
polyarthralgia and/or polyarthritis that can linger for several years [109] [110] 
[111]. This persistence of polyarthralgia associated with infections of some 
alphaviruses appears to be associated with the persistence of viral antigens in the 
joints and the immune responses triggered by these antigens [112] [109] [111] [113]. 
Viral RNA and antigens can be detected in the synovial tissues of affected patients. 
A study utilising a macaque animal model have demonstrated that virus can infect 
and replicate in synovial macrophages [114]. 
 
Animal models have shown to be key in researching CHIKV immunity and 
pathogenesis, with mice and non-human primates making up the most commonly 
used model systems. Unlike the SFV mouse models where the virus replicates 
efficiently in WT mice, CHIKV does not. Infection of WT immunocompetent mice 
with high-titre CHIKV inoculum leads to a peak of viraemia at 48h post infection 
which is then cleared 5 days following infection. Also, whilst CHIKV is able to 
effectively infect the foot joint close to the inoculation site and cause arthritis and 
localised infection of synovial tissues, the virus is unable to disseminate efficiently to 
distal joints away from the site of inoculation. Therefore, this model fails to closely 
mimic what occurs in CHIKV infections of humans where virus causes disseminated 




the infant and enhanced disease observed in older individuals [115] [116]. In 
addition, CHIKV joint arthritis resolves fairly quickly mice, whilst human infections 
can take several weeks up to several years for virus to completely clear. Alternative 
mouse models have therefore been developed to better study vaccine efficacy and 
antivirals which encompass mice with impaired innate immune responses such as 
interferon receptor null mice [106]. A major drawback of utilising immune deficient 
mice is that it may compromise our understanding of disease progression and 
pathogenesis. 
 
With its enzoonotic transmission cycle between mosquitoes and non-human 
primates, re-emergence is very likely, and with the spread of its mosquito vectors to 
the continent of Europe it is possible that the future will hold CHIKV emergence in 
new geographical locations [117]. The high risk of re-emergence in combination 
with the lack of treatments or vaccines are currently available for CHIKV, 
emphasizes the likelihood of future complications caused by a CHIKV outbreak. 
 
1.3.3.5 O’nyong nyong virus – an exception 
 
ONNV is an alphavirus belonging to the Semliki forest virus complex which is very 
closely related to CHIKV, and the two viruses share a very high percentage of 
sequence similarity [118]. The two viruses appear to have diverged from a common 
ancestor several thousand years ago [119]. ONNV was first isolated in Uganda in 
1959 during the first recorded outbreak with this virus.  The name o’nyong nyong 
originates from the Nilotic language of Uganda and Sudan and roughly translates to 
“weakening of the joints” which is associated with the symptoms triggered by the 
infection with this virus [120]. Three major outbreaks with ONNV have been 
recorded in the past, the first between 1950s and 1960s which initially started in 
north-western part of Uganda only to spread to Kenya, Malawi, Tanzania and partly 
to Senegal affecting more than 2 million people [120]. The second outbreak 
occurred between 1996 and 1997 in Uganda whilst the third outbreak also occurred 
in Chad in 2004 [121] [122] [123]. To date, ONNV has never been detected outside 





Infections with ONNV in humans are associated with symptoms such as fever, 
arthralgia and myalgia accompanied by a rash. The symptoms tend to clear up after 
a few days with occasional individuals suffering from long term arthralgia [124]. 
Unlike CHIKV however, ONNV has never been associated with causing lethal 
disease [125]. As the symptoms associated with ONNV infection closely resemble 
those of other African tropical diseases such as dengue and chikungunya, it is 
believed that there is a recurring underreporting of ONNV infections which means 
that the true prevalence of ONNV infections is unknown. In addition to this, 
antibodies generated against ONNV and CHIKV are highly similar and have almost 
complete cross reactivity [126] [122]. This is of major concern as control measures 
taken against these viruses differ as they are predominantly transmitted via different 
mosquito species.   
 
Dissimilar to most mosquito borne arboviruses that are transmitted predominantly 
by culicine mosquitoes, ONNV is the only known alphavirus that is transmitted 
mainly by anopheline mosquitoes with its main vectors being Anopheles funestus and 
Anopheles gambiae [127] [128]. The reason for this remains unknown. Due to the 
sequence similarity of CHIKV with ONNV, comparison studies between the two 
viruses have been made in an attempt to shed some light on potential differences that 
could help explain the difference in vector competence. Studies comparing ONNV 
ability to infect different cell types in vitro to that of CHIKV have shown that whilst 
ONNV was able to successfully infect the Ae.albopictus cell line C6/36 as well as the 
An.gambiae cell line MOS-55, CHIKV could only successfully infect C6/36 cells 
[129]. Another study, using the construction of a range of chimeric viruses of ONNV 
with CHIKV in order to compare the infection rates of Anopheles mosquitoes to these 
constructs. The study concluded that by replacing the nsp3 of CHIKV with nsp3 of 
ONNV they could observe a significant increase in infection rates of An.gambiae 
mosquitoes suggesting that nsp3 plays an important role in determining the vector 
competence of ONNV [130].  
 
There are a few different strains of ONNV commonly used in research. These 
include SG650, MP30 (Gulu strain) and the Igbo Ora strain. The MP30 strain was 
isolated during the original outbreak in Uganda in 1959 from human serum of 




then once through Vero cells [131]. SG650 was originally isolated from human 
serum during the 1996 outbreak in Uganda, and was passaged once in Vero cells 
[132]. The Igbo Ora strain was initially isolated from an infected individual in 
Nigeria in 1966 and was passaged 6 times in baby mouse brains and once in Vero 
cells [133] [134]. Igbo Ora was originally thought to be a separate virus but sequence 
analysis later proved that it was just a strain of ONNV [135] [132]. Several reporter 
variants of these strains have also been created. For the purpose of this thesis a strain 
called ONNV-2SG-ZsGreen was utilised which was created from the Igbo Ora 
strain where the ZsGreen gene has been placed between the ns-protein and 
structural protein region, under the duplicated promoter. 
 
A lot still remains unknown about ONNV which is a neglected tropical pathogen 
meaning there is very limited research associated with this virus. For example, the 
reservoir host remains undetermined and the course of infection, dissemination and 
pathogenesis of the virus is poorly understood. In addition to this, there are no well 
described animal models available for ONNV. To date there is only one study that 
has investigated ONNVs ability to replicate in mice which demonstrated that 
infection of wild-type, RAG1 KO, and IFNγR KO mice exhibited no signs of illness 
or viraemia. However when inoculating mice subcutaneously (s.c.) in the back with 
100 μL of ONNV (102 to 104 pfu) in STAT1 KO mice and A129 (IFNα/βR KO) 
mice, infection caused 50-55% mortality when infected with ONNV of the strain 
SG650. The study also demonstrated that the SG650 strain was more virulent than 




Flaviviruses have affected humanity for centuries with the first cases of dengue-like 
disease recorded in 1779 [137] [138]. Since then these viruses have become 
prevalent globally as viruses such as dengue have become endemic in over 100 
countries. Today flaviviruses are responsible for affecting millions of individuals 
annually with DENV being the most prevalent causing 20,000 deaths per year [139] 
[140]. Flaviviruses are a genus that belong to the family of the Flaviviridae and consists 
of more than 70 distinct viruses, many of which are of medical importance as they 




DENV, JEV, YFV and ZIKV. The genus is named after the Latin word for yellow, 
“flavus”, which refers to the jaundice commonly associated with yellow fever 
infections [141]. The majority of flaviviruses are transmitted via an arthropod vector 
and infections with flaviviruses are associated with a wide variety of symptoms 
ranging from a mild fever and malaise to haemorrhagic fevers and lethal 
encephalitis.  
 
1.3.4.1 Flavivirus structure and replication 
 
Flaviviruses are icosahedral, enveloped viruses approximately 50nm in diameter. 
The flavivirus single stranded positive sense RNA genome which encodes three 
structural proteins, E (envelope) protein, C (capsid) protein and M (membrane) 
protein, as well as seven non-structural proteins (see figure 1.6) [142]. Unlike the 
alphavirus genome, the flavivirus genome has only one open reading frame which 
encodes for a single polyprotein that is subsequently cleaved to give rise to the 




Figure 1.6  Flavivirus genome structure. 
 
Flavivirus cell entry occurs via receptor mediated endocytosis. For DENV the 
proposed receptors for mediating entry into host cells are DC-SIGN, GRP78/BiP 
(glucose-regulating protein 78), and CD14-associated molecules [141]. Assembly of 
the viral particle occurs on the surface of the endoplasmic reticulum with virions 
maturing in the trans golgi network. Mature virions will then exit the cell via budding 
through the cell membrane whilst simultaneously acquiring their viral envelope 
[143].  
 
1.3.4.2 Zika virus 
 
The flavivirus ZIKV was originally isolated in 1947 from a rhesus monkey in Uganda 
[144]. Whilst infections in humans were known to occur in the 1960s – 1980s, it 
remained a largely neglected tropical virus with very few researchers studying it. It 




was not until 2007 that the first larger ZIKV outbreak would occur, at the island of 
Yap [145]. ZIKV would then grab the attention of the world following its re-
emergence in French Polynesia in 2013-2014 and later in Brazil which suffered from 
major outbreaks in 2015 [146] [147]. Although ZIKV causes a self-limiting infection, 
infection with ZIKV is commonly associated with febrile illness, rash, potentially 
Guillain-Barré syndrome and abnormal neurodevelopment in foetuses of infected 
mothers resulting in incidences of microcephaly in infants [148].  
 
ZIKV is predominantly transmitted via Aedes mosquito species [149]. Unlike most 
other flaviviruses ZIKV can be transmitted via the perinatal route by its ability to 
cross the placenta and can also be sexually transmitted as ZIKV can be detected in 
semen up to 6 months following initial infection with the virus [148] [150].  
 
The first isolated ZIKV strain MR766 which was isolated in 1947 in Uganda and 
has been passaged in mouse brains over 100 times [144]. Following the more recent 
outbreaks of ZIKV several new viral strains have been isolated due to concerns of 
the existence of potential differences between the old and newly emerged variants. 
Such strains include the Asian lineage isolate H/PF/2013, the American lineage 
isolate FB-GWUH-2016, as well as isolates from French Polynesia, Brazil and Puerto 
Rico [151] [152] [153]. In this study the Brazilian strain of ZIKV, ZIKV PE243164, 
was used, which was first isolated in 2015 by the Fundação Oswaldo Cruz, Recife in 
Brazil [154]. 
 
ZIKV is unable to replicate efficiently in immunocompetent mice as WT mouse 
strains such as C57BL/6, CD-1 and BALB/c demonstrated no signs of disease and 
detection of viral RNA or infectious virus in tissues was negligible [152] [153]. In 
humans there is evidence that ZIKV NS5 protein can promote the degradation of 
STAT2, thereby inhibiting the type I IFN response in humans [155] [156].  Studies 
carried out in mice however demonstrate that NS5 fails to degrade mouse STAT2; 
a phenomenon which could explain why immunocompetent mice are resistant to 
ZIKV infection [155]. This has led to the development of ZIKV mouse models that 
are reliant on interferon or STAT knockouts [157]. Such models are unreliable for 
the accurate description of in vivo infection kinetics of the virus as well as for outlining 




macaques and Mauritian cynomolgus macaques have deduced that viraemia peaks 
2-3 days post infection with viral clearance occurring approximately 10 days 
following infection [158]. Interestingly, some studies have demonstrated that 30-40 
days post infection a “viral rebound” where a significant increase in viraemia can be 
observed in the blood [159]. An alternative, immunocompetent mouse model 
modelling ZIKV infection has recently been developed as an alternative. In this 
model STAT2 “knockin” mice where, mouse STAT2, replaced with human STAT2 
where used. When infected with a mouse adapted strain of ZIKV, virus is able to 
replicate efficiently with interferon responses remaining intact [160].   
 
1.3.4.3 West Nile Virus 
 
West Nile virus (WNV) is a flavivirus that is sustained in a zoonotic cycle between 
mosquitoes and avian hosts. It was first discovered in Uganda in 1937 and was later 
involved in several epidemics in the 50s and 60s in the Mediterranean [161] [162]. 
Also, New York saw the emergence of fatal encephalitis in 1999 which was then 
attributed to West Nile virus. Infected migratory birds enabled WNV to spread, in 
less than 5 years, to the southern parts of Canada, South and North America as well 
as the Caribbean [163]. Infection with West Nile virus has since been associated with 
West Nile fever in 1 in 4 infected individuals out of which approximately 1% will go 
on to develop neurological symptoms such as encephalitis, acute flaccid paralysis and 
meningitis which will prove to be lethal in 1 in 10 of affected individuals [164]. As 
there are no current treatments or vaccines available for WNV, future outbreaks are 
likely to cause a problem.    
 
1.3.4.4 Dengue virus 
 
DENV is one of the most globally widespread arboviruses and considered a major 
global health challenge in tropical and subtropical regions. It is estimated to infect 
50-400 million people per year [165]. Dengue fever is known to cause fever, rash, 
myalgia and arthralgia but it can also cause dengue haemorrhagic fever which is 
associated with vascular leakage and thrombocytopenia. There are 4 separate 
serotypes of DENV; DENV-1, DENV-2, DENV-3 and DENV-4 [166].  Secondary 




dengue” out of which 5-20% of cases end up being lethal. Between 1990 and 2015, 
262 outbreaks of DENV have been recorded worldwide with the majority of those 
transpiring in India, China and Brazil [167]. In Europe, the continent least affected 
by DENV, 4 outbreaks took place in France and 2 in Portugal [168]. Lack of 
treatments available leads to the hospitalization of approximately 500,000 
individuals per year, most of which are children which is having a tremendous 
economic burden on affected countries.  
 
1.4 Introduction to vectors and epidemiology 
 
Arthropoda constitutes the most species rich phylum, containing over 80% of all 
living species. Estimations indicate that there are approximately 5-10 million distinct 
species of arthropods on the planet with a small fraction of these making up the 
hematophagous arthropods with more than 14,000 species [169, 170]. 
Hematophagy, which refers to the act of blood feeding, has evolved independently 
1400 times, an adaptation that has had enormous impacts on the co-evolution of 
hematophagous insects with their vertebrate hosts [169]. Blood feeding has allowed 
for the evolution of a range of pathogens that hijack this mechanism of feeding and 
utilise it as an efficient method of their own transmission. These pathogens have a 
profound impact on human health as there are hundreds of diseases of viruses, 
bacteria and parasites that are transmissible to humans via arthropod vectors 
including dengue, malaria and Lyme disease [171]. The maintenance of the 
pathogen transmission cycles is heavily dependent on the spatiotemporal interactions 
of the pathogen, the vector species and the host species. Vector competence and host 
susceptibility to infection adds further complexity. In humans, the majority of 
arthropod borne diseases are transmitted via arthropods such as mosquitoes, ticks, 




Mosquitoes are classified as arthropods under the order of Diptera belonging to the 
family Culicidae. 3,490 species of mosquitoes have currently been identified and they 
are spread across the globe, with species residing in the tropical regions stretching to 




disease as there are approximately 300 different mosquito species that can transmit 
arboviruses. Nevertheless, mosquitoes are the most prevalent arthropod transmitters 
of viral disease, with Aedes and Culex mosquitoes being the most common vector-
competent species; with their ability to transmit 115 and 105 arbovirus strains 
respectively [173].  
 
Figure 1.7. Mosquito diagram. 
Diagram of a female Ae.aegypti mosquito. Ae.aegypti mosquitoes are easily identified by the 
lyre-shaped pattern on their scutum with two lines down the centre of their thorax. The 






























1.4.1.1 Mosquito Life cycle 
 
Whilst the majority of mosquitoes reside in close proximity to ground water, the life 
cycle of mosquitoes can vary greatly between species, with certain species specialised 
to occupy anything from holes in trees, bromeliads and snail shells. Whilst this section 
will only focus on the life cycle and aspects of relevant mosquito vector species, some 
aspects are universal to all mosquito species.  
 
All mosquito species lay their eggs in, or in close proximity of, water. The eggs, less 
than a millimetre in length, whilst initially white in colour darken quickly during the 
course of a day into black or brown. Eggs laid directly in water tend to hatch within 
a couple of days whilst eggs of other species, such as the Aedes, which are typically 
laid just above the water line of stagnant water, will typically hatch when they are 
eventually submerged in water. This delay in hatching prevents the eggs from 
hatching before conditions are right as Aedes eggs are more resilient to fluctuating 
temperatures than hatched larvae and emerged adults, enabling them to potentially 
survive throughout winter [174]. Rain, rising of water levels or even human 
intervention will eventually submerge the eggs enabling them to hatch into mosquito 
larvae. 
 
Figure 1.8. Mosquito larvae. 
Mosquito larvae of different species can be observed lying flat at the water surface, such as 
Anopheles larvae or “hanging” from the surface such as Aedes larvae. 
 
Mosquito larvae reside in water but are entirely dependent on breathing air via a 
breathing tube and must therefore regularly return to the surface. Depending on the 
species, resting larvae can be observed “hanging” from the surface or lying flat at the 
water surface (see figure 1.8). Larvae typically feed on aquatic microorganisms via 
two separate methods of feeding, filter-feeding at the surface or bottom scraping and 





the larvae to grow and undergo three separate stages of shedding, commonly known 
as instar phases. These transitions and the eventual transformation of the larvae in 
to pupae are heavily regulated by the release of hormones such as ecdysteroids into 
the water [177]. Larval molts are triggered by the presence of ecdysteroid and the 
sesquiterpenoid juvenile hormone (JH) whilst the final transformation into pupae is 
initiated by the absence of JH with pupal stages lasting a couple of days depending 
on species [178].  
 
Figure 1.9. Ae.aegypti life cycle.  
Diagram depicting the life cycle of Ae.aegypti from an egg to a hatched larvae, to a pupae to 
a fully emerged adult mosquito. 
 
Adult mosquitoes have sexually matured by 3-5 days post emergence. Whilst the 
majority of mosquitoes feed exclusively on plant nectar, the females of certain species 
are hematophagous as the acquisition of a blood meal plays a key role in their 
gonotrophic cycle of egg maturation and oviposition [179]. Even within the 
hematophagous mosquito group feeding patterns vary greatly between the different 
mosquito species, which exhibit dissimilarities in feeding locations, host preferences 
as well as time of feeding. Certain species of mosquitoes are preferentially nocturnal 
(active at night); such as is the case for the majority of Anopheles mosquitoes [180]; 
while other mosquito species are diurnal (active during the day) or crepuscular (active 
at twilight), and occasionally both diurnal and crepuscular as is the case of Ae.aegypti 
[181] [182]. A better understanding of the ecology and life-cycle of important vector 
species is, and has been vital in the development of specific and more targeted 




1.4.1.2 Arbovirus replication in mosquito vector  
 
Mosquito-borne arboviruses are transmitted via infected mosquitoes and this 
mechanism of transmission relies on the successful infection and viral replication 
within the mosquito [184]. These viruses have therefore acquired specific 
mechanisms in order to successfully replicate within the arthropod vector whilst 
simultaneously overcoming a range of physical and immunological barriers within 
the mosquito (see figure 1.10) [185] [186].   
 
After the ingestion of infected blood following the feeding upon an infected host, the 
infected blood moves into the posterior section of the mosquitoes midgut thereby 
circumventing the diverticula of the gut which are reserved for carbohydrate storage 
[187]. It is of huge importance that the mosquito ingests virus of high enough titre 
in order to override the threshold required for a successful infection. When inside 
the lumen of the midgut virus particles have to successfully infect mesenteronal cells 
via gut microvilli before the formation of the peritrophic matrix which is secreted by 
the midgut epithelium following the ingestion of a blood meal, which once formed 
prevents infection of mesenteronal cells [188]. Whilst it remains unknown exactly 
how viruses manage to overcome the midgut barrier, it has been observed that the 
virus will undergo a genetic bottleneck in the process as only a select few particles 
will succeed [189]. Successful virus will then replicate in the cells of the mesenteron 
until it reaches peak titres when it can successfully spread to the haemocoel by 
crossing the basal lamina [188]. The haemocoel is the primary, haemolymph 
containing cavity of invertebrates and the escape of virus in to the haemocoel cavity 
allows for the spread of viral infection to a multitude of susceptible tissues such as 
muscle, pericardium, fat bodies and ganglia [187].  
 
Finally, for virus to successfully complete its life cycle, it has to infect salivary glands 
which are located in the thorax of the mosquito. This stage of the infection is 
associated with a second genetic bottleneck event as only a few viral genotypes are 
able to successfully infect the salivary glands [189]. Infection of the glands is believed 
to occur via dissemination of virus via the haemolymph, prior infection of adjacent 
organs or via a combination of both [190]. When inside the salivary glands the virus 




vertebrate host during the next blood meal. The virus can require several days, 
depending on the strain, before it reaches optimal numbers. Apart from the salivary 
glands, infection of mosquito ovaries have also been observed providing arboviruses 
with a potential alternative route of transmission; vertical transmission from mother 
to offspring [191].  
 
 
Figure 1.10. Arbovirus replication inside vector. 
Figure depicting the steps of the infectious cycle of arboviruses inside the mosquito vector. 
A. Mosquito ingests virus infected blood from infected mammal. B. Virus travels to the 
midgut. C. Virus enters circulatory system. D. Virus reaches the salivary glands. E. Virus 
injected into new host alongside mosquito saliva following secondary blood feed.  
 
1.4.1.3 Mosquito immune response to arbovirus infection 
 
Mosquito borne viruses are transmitted to vertebrate hosts via bite of an infected 
mosquito. This mechanisms of viral transmission relies on the successful replication 
of the virus inside the arthropod vector. In order for this to occur the virus must 
overcome the obstacle that is the mosquitoes innate immune response. Such 
responses include interfering RNA pathways (RNAi), toll pathway, the immune 
deficiency (IMD) pathway, the Janus kinase - signal transducers and activators of 
transcription (JAK-STAT) pathway as well as apoptosis [192]. Arthropods lack an 
adaptive immune response and are therefore dependent solely on mounting a 










The majority of research investigating the innate immune responses of mosquitoes 
to viral infection have been conducted utilising Drosophila melangoster as a model 
system as drosophila is susceptible to experimental infection with arboviruses. It was 
using this model system that the Toll pathway of arthropods was first described. Toll 
pathway was discovered to play an important role in the protection against fungi, 
viruses and gram positive bacteria [193] [194] [195]. This pathway shares certain 
similarities with the vertebrate NF-kB signalling pathway as it relies on pattern 
recognition receptors (PRRs) to recognise and bind pathogen specific ligands. 
Recognition by PRRs result in the cleavage of Späetzle which is a cytokine released 
by the presence of pathogens. Späetzle will bind to Toll triggering a signalling 
cascade that results in the subsequent transcription of antimicrobial peptides [196]. 
The Toll pathway that is conserved in mosquito species, has a key role in mediating 
responses against DENV infection. Studies infecting Ae.aegypti with DENV have 
shown significant upregulation of Toll post infection is associated with the reduction 
of viral titres in the mosquito midgut [197] [198].  Similarly, knockdown of the IMD, 
which, like Toll upregulates antimicrobial genes in response to PRRs, leads to an 
increase of DENV in the midgut suggesting a role for IMD pathway in the innate 
immune response of mosquitoes against arboviruses [199] [200]. The involvement 
of the JAK/STAT pathway in insect innate immunity was initially observed in 
An.gambiae mosquitoes in response to bacterial infection [201]. Whilst the role of 
JAK/STAT against arbovirus infection remains poorly understood, JAK/STAT 
does play a role in regulating DENV infection in Ae.aegypti mosquitoes [202]. 
 
RNAi is another mechanism that plays a key role in mosquito antiviral immunity. 
The RNAi mechanism can be subdivided into three distinct pathways, namely the 
small interfering (si)RNA, the micro (mi)RNA, and the Piwi-interacting (pi)RNA 
[203] [204]. The RNAi driven immune response is activated via the recognition of 
pathogen associated molecular patterns (PAMPs) such as dsRNA by Dicer 2 (Dcr2) 
which is an RNase III which recognizes and cleaves dsRNA into siRNAs which 
ultimately leads to the initiation of the RNAi pathway [205]. The siRNAs, Dcr2 and 
the dsRNA binding protein R2D2 interact with the RNA-induced silencing complex 
(RISC), the key component of which is Argonaut 2 (Ago2 which functions as the 
catalytic component of RISC) [206] [207] [208]. After degrading one of the siRNA 




Argo2 will degrade it utilising its endonuclease activity which ultimately will inhibit 
viral replication without causing apoptosis [209]. piRNAs are small RNAs that 
protect the genome by regulating the transcription and transposition of transposable 
elements and studies have suggested that they play a role in the defence of mosquitoes 
against arbovirus infections. Although the specific mechanisms remain unclear, 
piRNAs have been shown to be implicated in An.gambiae mosquitoes infected with 
ONNV as well as Ae.aegypti mosquitoes infected with DENV [210] [211].  
 
Whilst these immune responses are broadly similar in most mosquito species there 
are some species-specific variations. Studies of Anopheles gambiae mosquitoes which are 
known to be inefficient vectors of most arboviruses with the exception of ONNV, 
have illustrated key differences in the immune responses to arboviruses to that of the 
main arbovirus vectors, Aedes and Culex. Whilst there is debate about whether 
JAK/STAT and IMD play a role in Anopheles antiviral immunity, studies have shown 
that Toll does not impact infection of Anopheles with ONNV, and that ONNV has 
the ability to actively inhibit the Toll pathway [212] [213] . This is in contrast to 
Ae.aegypti where Toll and JAK/STAT are the key pathways of the immune response 
against DENV [197, 200] [202]. Such differences between mosquito species may 
help explain the differences in vector competence of the different species.  
 
1.4.1.4 Mosquito species  
 
The Culicidae stretch as far back in history as the Jurassic following their split from 
their sister group Chaoboridae [214] [215]. Due to the limited amounts of 
mosquitoes in the fossil records categorization of mosquito species within the Culicidae 
has historically proven difficult. More recently, with the help of genome sequencing 
several advances have been made in this area with mosquito species being split into 
two subfamilies; the Anophelinae and the Culicinae. These can then be subdivided 
further into 11 tribes containing at least 44 separate genera [216] [217]. Studies 
comparing mitochondrial DNA of mosquito species have suggested that the split 
between the Culicinae and the Anophelinae occurred sometime between 145-200 
million years ago (mya) whilst comparisons of specific protein coding nuclear gene 





The Anopheles family underwent radiation during the early Cretaceous and the rapid 
speciation of mosquito species has been linked to the increased speciation of 
mammals as these would have been the main blood source of blood feeding 
mosquitoes [220]. The long evolutionary history of mosquitoes, the huge numbers 
of mosquito species and their co-evolution with arboviruses have resulted in 
numerous differences between the species, including vector competence and 
transmission cycles. In the following section a summary will be made of the main 
mosquito vector families including the Aedes, Culex and the Anopheles.  
 
1.4.1.5 Aedes mosquitoes  
 
The Aedes mosquito genus was named after the Greek word ἀηδής, meaning 
sickening or disgusting, by the German entomologist  Johanh Wilhelm Meigen in 
1818 [221]. Since their emergence, the Aedes mosquitoes, with their recent spread to 
Europe and North America, can now be found on all continents across the globe 
with the exception of Antarctica [222]. Aedes are predominantly known for their 
impact on global health as several mosquito species of this genus spread clinically 
important human afflicting diseases such as Zika, dengue, yellow fever and Ross river 
arthritis. Historically, the species Aedes aegypti has been regarded as the most 
problematic arbovirus vector as it is the main vector of DENV and CHIKV. With 
the recent geographical expansion of  Ae.albopictus, which while originally native to 
South East Asia can now be found on five continents, along with the mosquitoes co-
evolution with arboviruses has resulted in a global threat matching that imposed by 
Ae.aegypti [222]. Aedes mosquitoes can be easily recognized by their distinctive black 
and white stripes on their legs and torso. 
 
Aedes aegypti was originally named Culex aegypti by Carl von Linnaeus protégé, Fredrik 
Hasselqvist who discovered it in 1757 in Egypt [223].  It is believed to have evolved 
from its forest dwelling ancestor Aedes aegypti formosus and that its domestic behaviour 
originated in West Africa. The change in its behaviour provided the mosquitoes with 
benefits such as shelter when resting inside human habitats as well as suitable sites 
for egg laying in stagnant water supplies created by humans [224]. Several strains of 
Ae.aegypti have been used for research purposes including the “Liverpool” strain used 




tropical medicine sometime between 1935 and 1938, the exact origin remains 
unclear. However it is believed that it was originally acquired from Sierra Leone 
[225].  
 
1.4.1.6 Culex mosquitoes 
 
Culex mosquitoes were given their name by Carl von Linnaeus meaning midge or 
gnat in Latin. These mosquitoes are known transmitters of several human pathogens 
such as WNV, JEV and St. Louis encephalitis virus [226] [227]. Whilst originally an 
African species, Culex mosquitoes spread to Norther Europe following the latest 
glaciation event [228]. Today, Cx. pipiens and Cx. quinquefasciatus can be found in the 
majority of human inhabited areas globally. Culex mosquitoes will feed on a variety 
of different hosts, with species ranging from birds to terrestrial mammals such as 
humans. This wide range of host species specificity exhibited by Culex mosquitoes is 
believed to have enabled the role of Culex as a bridging vector between viruses that 
primarily replicate in birds which, with the help of Culex, can cause occasional 
spillovers into human populations such as is the case for WNV. It is believed that a 
hybridization event between two groups of Cx. pipiens, one with a stronger preference 
towards bird biting with one preferentially mammal biting, may have led to the Cx. 
pipiens species we observe today [229] [230]. In contrast to the single domestication 
event of Ae.aegypti mosquitoes, Cx. pipiens was domesticated twice in two separate 
locations; once in North Africa resulting in the evolution of Cx. pipiens form molestus, 
and once in South East Asia resulting in the domesticated Cx. quinquefasciatus [231] 
[232]. 
 
1.4.1.7 Anopheles mosquitoes 
 
Anopheles, like the Aedes genus, were named by the entomologist Johann Wilhelm 
Meigen in 1818. Like Aedes, Johann gave the genus a name with Greek origin, 
ἀνωφελής, meaning “useless” [233]. Since then, Anopheles mosquitoes have gained 
the reputation of being “the deadliest animal on the planet” due to their ability to 
transmit malaria. In terms of arbovirus transmission though, they are known to be 
inefficient vectors of most arboviruses, with the exception of one; the Alphavirus 




Interestingly, research investigating the virome of Anopheles mosquitoes, have 
discovered that these mosquitoes can harbour a large number of different medically 
relevant arboviruses such as the alphaviruses VEEV, WEEV, SINV and SFV as well 
as the medically relevant flaviviruses WNV and JEV [234]. To date, no studies have 
shown successful transmission of any of these viruses by Anopheles mosquitoes making 
it clear that Anopheles species cannot consistently transmit and maintain the 
circulation of arbovirus in the wild, with the exception of ONNV. This suggests that 
Anopheles mosquitoes are less competent arbovirus vectors than the culicinae 
mosquitoes. The reason behind this difference in vector competence remains a 
mystery however, especially in the species that are highly anthropophilic as in the 
case of An.gambiae. Several mechanisms to explain these differences in vector 
competence have been hypothesised including; differences in mosquito species tissue 
barriers; differences in the mosquito microflora; or molecular differences in the 
determinants required for viral replication [235]. There is some evidential support 
for the latter suggestion, as differences which have been observed in the sequence of 
nsP3 gene in ONNV is sufficient to allow for infection of An.gambiae under laboratory 
conditions [130]. However, this fact on its own is insufficient in explaining the reason 
behind the incapability of Anopheles in transmitting genetically-distinct arboviruses, 
suggesting another fundamental reason must exist preventing these mosquitoes from 
efficiently transmitting virus to the mammalian host. For the purpose of this thesis 





Ticks are ectoparasites that are obligatory hematophagous. There are over 900 
species of ticks documented which can roughly be divided into two separate families; 
the hard-bodied ticks Ixodidae or the soft bodied ticks Argasidae. Due to their 
hematophagous nature, tick bites have been associated with the transmission of 
numerous pathogens including several species of Rickettsia bacteria as well as a 
range of arboviruses such as Crimean-Congo haemorrhagic fever virus (CCHFV), 
tick borne encephalitis virus (TBEV) and African swine fever virus (ASFV). 




livestock, such as the Louping ill virus which was associated with encephalitic disease 
in livestock such as sheep [237].  
 
As an example of a tick-borne human inflicting arbovirus pathogen, TBEV is the 
cause of tick borne encephalitis disease (TBE) in humans. TBEV is a flavivirus that 
is primarily spread via Ixodes ricinus and Ixodes persulcatus [238]. Due to the virus 
dependency on its arthropod vector, its current geographical spread is restricted to 
Europe and Asia [239]. TBEV transmission cycle relies on the infection of small 
rodents where nymphs and larvae feed, whilst adult ticks will mainly feed on larger 
mammals such as roe deer with occasional spillover into humans via bites of infected 
ticks. In northern Europe high numbers of roe deer populations have enabled the 
maintenance of very high numbers of ticks. Declines in deer numbers since the 1990s 
have ultimately forced ticks to rely more heavily on rodents which has caused a 
significant increase in numbers of infected ticks [240]. 
 
Highly effective vaccines are available for TBEV with a success rate of approximately 
95-99% [241]. However due to the need of repeated annual injections in 
combination with the relatively high cost of the vaccines, the success rates have been 
variable [242].  
 
1.4.3 Culicoides Midges 
 
Culicoides are biting midges in the family of Ceratopogonidae. Culicoides are 1-3 
mm in size, and unlike mosquitoes they lack a proboscis which prevents them from 
biting through clothing efficiently. They are widely considered the most important 
vectors of arbovirus diseases in livestock with their ability to transmit viruses such as 
bluetongue virus (BTV) and Schmallenberg virus [243]. They can also transmit 
human pathogens such as Oropouche virus. Similar to mosquitoes, the Culicoides 
life cycle consists of instar stages, a pupae stage and the emerged adult. Adult midges 
typically live for 2-3 days and during their life span will only travel a maximum of a 
few kilometres.  
 
BTV is an Orbivirus commonly spread by Culicoides sonorensis and Culicoides imicola 




[244]. Infection is commonly associated with acute disease accompanies by high 
mortality. Signs of disease include febrile illness, face swelling and tongue cyanosis.  
BTV was historically restricted to Africa and the tropics until its spread to Cyprus in 
the 1940s [245]. However, Europe has remained largely unaffected by BTV until 
very recently [246]. Since 1998, 8 out of the 24 existing BTV serotypes have spread 
across Europe causing severe economic damages in its path [247]. A recent outbreak 
in the Netherlands is estimated to have cost €175 million [248]. Effective vaccines 
are currently available which have the potential to help limit the spread of the disease 
if high enough numbers are vaccinated to create sufficient herd immunity [249]. 
 
1.4.4 Phlebotomine sand flies 
 
The Phlebotominae are a subfamily of the Psychodidae, and they include several 
genera of hematophagous flies that are known transmitters of human pathogens such 
as leishmaniasis, bacteria and arboviruses. The majority of arboviruses spread by 
sandflies are Phleboviruses. Phleboviruses, which belong to the family of Bunyaviridae, 
spread by these sandflies include sandfly fever Sicilian virus, sandfly fever Naples 
virus, Toscana virus and Punta Toro virus [250]. The Phlebotomine sandflies are 
spread throughout the tropics and temperate zones with the Mediterranean being 
the most affected region in Europe [251]. Their geographical range has however 
increased in the last few years most likely due to climate change as they are restricted 
to areas with temperatures above 15.6oC for a minimum of three months annually 
[252] [253]. Due to warming temperatures it is estimated that the geographical 
spread of the phlebotomine sandflies will increase further in the coming years 
spreading into northern Europe [254].   
 
1.4.5 Vector control 
 
Despite the medical importance of arthropod borne diseases there are very limited 
treatments and effective vaccines available as their development has proven to be 
difficult. The majority of these diseases can also be considered neglected tropical 
disease which means that a lack of resources have historically been set aside for the 
purpose of research and drug development. Therefore, in an attempt to curb disease, 




have been used collectively in an attempt to regulate vector numbers including the 
use of insecticides, genetic modifications of vector species, release of sterile male 




The use of insecticides for insect control is not a new concept with insecticide use 
dating back to ancient china. In Europe, over 200 years ago Armenian merchants 
were trading “Persian powder” which essentially contained Dalmatian pyrethrum 
used in the extermination of insects such as cockroaches, bedbugs, flies, and 
mosquitoes [255]. Insecticides used specifically in the purpose of disease prevention 
did not start until the discovery of DDT in the 1940s. Insecticide use has since proven 
its efficiency by helping in the eradication of malaria from both Europe and the US, 
controlling the spread of CHIKV in southern Europe as well as for combating WNV 
outbreaks in the US [256] [257]. Despite of the successes achieved by the use of 
insecticides, widespread emergence of insecticide resistances, as well as concern 
regarding bioaccumulation and potential negative impacts on human health, has led 
to a shift in the public’s attitude towards the wide spread use of insecticides [258]. 
This led to a ban of the use of DDT in the US in the 1970s [259].  
 
The use of insecticides remains the key method of combating arbovirus diseases 
today with mainly insecticides of pyrethroid class being used that ultimately leads to 
the emergence of pyrethroid resistant variants [260]. To combat this issue, WHO 
recommends rotation of the types of insecticides used to minimise risk of emerging 
resistance [261]. Another issue is the high cost associated with insecticide use [262]. 
Despite the benefits obtained by the use of insecticides in the fight against vector 
disease, the problems associated with their widespread use highlights the need for 
the development of alternative measures in combating this global issue [261].    
 
1.4.5.2 Alternative methods of vector control   
 
Due to the limitations of traditional insecticide use the development of alternative 
methods for vector control is underway; many of which are under review by the 




alternatives include variations in application of insecticides such as the use of spatial 
repellents which are designed to deter mosquitoes from certain areas, thereby 
limiting human/mosquito contact; mosquito traps and insecticide treated surfaces 
and or sugar sources. In addition, more unconventional methods of vector control 
have been developed that do not rely on insecticide use. 
 
Genetic modifications of mosquito species to confer virus resistance, lethal mutations 
or mosquito sterility are being assessed for efficacy of vector control. The use of sterile 
mosquitoes, commonly referred to as the SIT (Sterile Insect Technique), involves the 
breeding and irradiation of male mosquitoes with chemosterilants that ultimately 
leads to the generation of dominant lethal mutations in the sperm. The concept of 
SIT assumes that during release of these sterilized males in affected areas will result 
in a reduction in the ration of fertile wild type males with that of the released infertile 
males leading to a reduction, and eventually the elimination, of new offspring as the 
new males mate with wild females [263]. SIT has proven very successful in the 
eradication of insect pests in the past including the eradication of the tsetse fly Glossina 
austeni from Zanzibar[264]. Despite these successes, the use of sterilised males in 
mosquito vector control remains limited due to several limitations of the SIT 
including the high costs and effort associated with rearing the vast amounts of 
mosquitoes required for release as well as the infrastructure required to implement 
this technique in endemic countries [265] [266]. Additional problems associated 
with SIT is that current methods used are unable to successfully prevent somatic 
damages during the sterilization process which can lead to a reduction in the overall 
fitness of these mosquitoes, reduction in longevity and sexual activity making them 
less capable at outcompeting their wild counterparts [267].  
 
More recently, an alternative technique has been developed, the Release of Insects 
carrying a Dominant Lethal (RIDL). RIDL utilizes genetic engineering for the 
introduction of a dominant lethal mutation which can only be supressed by an 
antidote. In the absence of the antidote, any larvae born to mosquitoes carrying the 
allele will die [268].  
 
Finally, attempts have been made utilising the bacterial intracellular symbiont 




several insect species is known to reduce the fertility of the infected insect whilst also 
interfering with viral replication in vector species. Indeed, studies have demonstrated 
resistance to infection by DENV and CHIKV of mosquitoes infected with Wolbachia 
[270] [271]. The first attempt at mosquito vector control utilising Wolbachia was 
initiated in Australia in 2011. Following 10 weekly releases of infected Ae.aegypti, 
infection rates of wild populations remained high [272]. It remains unclear however 
how Wolbachia inhibits virus infection and it remains to be seen whether viruses 




Whilst the scientific field of immunology can be considered a relatively new area of 
research, humanities earliest grasps of the concepts of immunity dates back to 
ancient Greece, where, during the plague of Athens, Thucydides noted that previous 
exposure to disease conferred immunity to the contraction of the same disease; or 
has he worded it, became “exempt” [274]. Active attempts to confer immunity to 
infectious diseases was common practice in China in the 10th century were the act of 
“variolation” was used to expose individuals to material from infected lesions of 
smallpox. This practice was also customary in the Ottoman Empire before it was 
picked up by the English [275]. The first vaccine was later developed by Edward 
Jenner in 1798 and mankind have been capitalizing on the concept of conferred 
immunity ever since with the continuous development of modern vaccines [276]. 
With the establishment of “germ theory” by Louis Pasteur and Robert Koch in the 
late 19th century, and with the uncovering of cellular immune responses and the 
existence of “humoral” immunity by Metchnikoff, Von Behring and Kitasato, the 
basic concepts of Immunology were defined by the start of the 20th century [277] 
[278].  
 
Immune responses can be defined as defence mechanisms employed by the host in 
response to a potential invading pathogen, potentially harmful substances or in 
response to tissue damage. This is achieved by the highly specialised recognition 
system that is in place to aid in the detection of potential threats followed by the wide 




system has to be carefully regulated to prevent excessive damage on the host [279]. 
The immune response can roughly be divided into two categories; the innate 
immune response and the adaptive immune response [280] [281].   
 
1.5.1 Organs and tissues of the immune system 
 
The immune system consists of a complex arrangement of organs and tissues 
interconnected by a large network of lymphatic vessels that make up the lymphatic 
system. These organs can roughly be separated into three categories; the primary, 
secondary and the tertiary lymphoid organs. The two main organs classified as 
primary include the bone marrow and the thymus. Bone marrow is a tissue of a 
sponge-like structure that resides within bones where the majority of immune cells 
will originate from haematopoietic stem cells and where the generation of B and T 
lymphocytes occurs, whilst the thymus is a gland located above the heart [282]. The 
secondary lymphoid organs include the lymph nodes, spleen, Peyer’s patches, as well 
as mucosal tissues such as the nasal-associated lymphoid tissue, adenoids, and tonsils. 
Secondary lymphoid organs are mainly responsible for lymphocyte maturation and 
the collection of antigens for exposure to naive B and T cells which reside within 
segregated zones of secondary lymphoid organs. Thousands of lymph nodes are 
distributed around the body lining the lymphatic network with higher concentrations 
around the groin, neck, knees and armpits. Lymph will drain through the nodes 
carrying with it potential antigens that will activate lymphocytes. Activated 
lymphocytes will then exit the nodes to eventually end up in the blood stream. Unlike 
the lymph nodes, the spleen does not filter lymph but instead it filters blood. Similarly 
to the lymph nodes however exposure of lymphocytes to antigens in the spleen will 
lead to activation of said lymphocytes. Macrophages also reside within the spleen 
which are responsible for the removal of pathogens and other debris from the 
circulation [283]. Finally, the tertiary lymphoid organs consist of abnormal immune 
structures which are created at sites of chronic inflammation following the 
accumulation of immune cells at the site. Such structures can be observed in patients 






1.5.2 Innate immunity 
 
The innate immune response is generally thought of as fast acting and activated by 
common pathogen associated molecular patterns. It occurs minutes following 
infection and makes up the hosts first line of defence against invading pathogens. In 
arbovirus infections the innate immune response is crucial for the suppression of viral 
replication and for the containment of viral dissemination across the body of the 
host. Via the use of knock out mouse models where important aspects of the innate 
immune response have been knocked out, such as the type I interferon response, 
studies have shown that the absence of type I interferon greatly affects severity and 
clinical outcome of infection. Susceptibility to arbovirus infections, such as SFV and 
WNV, was significantly increased in type I interferon knockout mice with all mice 
succumbing to disease [285] [286]. Similarly, lack of γδT-cells (innate immune 
lymphoid cell) resulted in an increase in severity of disease following WNV infection, 
suggesting a key role of innate cellular immunity in tackling infection [287]. This, in 
combination with the knowledge that many arboviruses have evolved to circumvent 
the mammalian innate immune response, stresses the significant impact the innate 
immune response has on arbovirus infections. 
 
1.5.2.1 Acute innate immunity 
 
In order for a host to become infected the pathogen has to successfully surpass the 
physical and chemical barriers that are in place to minimize infection risks at the 
epithelial and mucosal surfaces. These epithelial surfaces are stratified with tight 
junctions which help prevent anything from coming through whilst simultaneously 
possessing the ability to produce antimicrobial enzymes and peptides such as 
lysozymes, defensins and histatin which have the ability to digest bacterial cell walls 
[288] [289]. Another acute innate immune response is the complement system which 
consists of three separate complement pathways; the classical, the alternative and the 
lectin pathway. While the three pathways are initiated via different mechanisms they 
will eventually result in the lysis or phagocytosis of the invading pathogen as well as 





Interestingly mosquito borne viruses are able to completely surpass the epithelial host 
defences via the mechanism involved in their deposition into the skin. By hitchhiking 
on the mosquito vectors mechanism of saliva injection during blood feeding, the virus 
is injected directly in to the dermis alongside the mosquito saliva [291]. On the other 
hand, complement activation does appear to play a role in innate immunity against 
certain arboviruses such as in the case of WNV where inhibition of complement 
pathways resulted in earlier viral dissemination to the CNS in mice [292]. 
 
Following the successful bypassing of the earliest innate immune barriers, pathogens  
then encounter a range of immune cells and cytokines that are responsible for the 
initiation of the induced innate immune response. This induction is reliant on the 
recognition of pathogens or pathogen associated molecules by specific receptors.    
 
1.5.2.2 Pattern recognition receptors 
 
In order for the host system to mount a successful immune response to reciprocate 
against an invading pathogen, it has to be able to recognise it. In 1989, Janeway 
refined and proved a long-postulated theory that this recognition is achieved via the 
use of highly specialized receptors now commonly referred to as pattern recognition 
receptors (PRRs). These receptors recognise specific molecules commonly associated 
with foreign pathogens or damage including specific glycans, proteins and nucleic 
acids. Molecules recognized by PRRs are known as pathogen associated molecular 
patterns (PAMPs) or damage associated molecular patterns (DAMPs).  
 
Toll like receptors 
 
Toll like receptors were the first PRRs to be identified, and to date, 10 different TLRs 
have been found in humans whilst mice have 12. Humans have lost TLR11, TLR12 
and TLR13 whilst TLR10 is non-functional in mice due to a retroviral gene insertion 
event. Some of these receptors are located on the cell surface (TLR1, TLR2, TLR4, 
TLR5, TLR6 and TLR10) whilst the remaining (TLR3, TLR7, TLR8, TLR9, 
TLR11, TLR12 and TLR13) are located intracellularly [293]. The localization of 
TLR receptors are important as it tends to affect the patterns they recognize, with 
membrane bound receptors mainly recognizing surface components of invading 




a common structure with leucine rich repeats forming a horseshoe resembling 
ectodomain responsible for PAMP recognition, a transmembrane domain as well as 
a Toll/IL-1 receptor (TIR) domain which is involved in downstream signalling. 
Whilst sharing similar architecture, each TLR has evolved to specifically recognise 
conserved structures expressed by different pathogens such as: TLR4 recognizes 
bacterial lipopolysaccharide (LPS) [294], TLR5 recognizes bacterial flagellin [295], 
TLR7 recognizes single stranded viral RNA, TLR9 recognizes viral CpG RNA 
whilst TLR2 recognizes a wide range of virus, bacteria, fungal and damage 
associated PAMPs [296] [297].  
 
Following recognition of PAMPs or DAMPs the TLRs recruit TIR domain-
containing adaptor proteins such as MyD88, TIRAP, TRIF and TRAM that 
activate signalling pathways that trigger the initiation of specific immune responses. 
These signalling pathways can broadly be divided into two separate groups; MyD88 
dependent and TRIF dependent pathways. MyD88, which was the first adaptor 
protein to be discovered, is used by all TLRs with the exception of TLR3. 
Recruitment of MyD88 results in the transcription of pro-inflammatory cytokines 
via the activation of NF-κB and mitogen-activated protein kinases (MAPKs). TRIF 
is recruited by TLR3 and 4 for the activation of the transcription factor NF-κB and 
IRF3 which ultimately upregulates pro-inflammatory cytokines as well as type I 
interferon. In contrast, the function of adaptor proteins TIRAP and TRAM is to aid 
in the recruitment on MyD88 or TRIF to their respective receptors [298].  
Alphavirus and flavivirus recognition has been suggested to occur via TLR3, TLR7 
and TLR8 [299] [296]. 
 
RIG-I like receptor family 
 
The RIG-I like receptor family is another PRR associated with viral detection which 
consists of the retinoic acid-inducible gene (RIG-I), melanoma differentiation-
associated gene 5 (MDA-5) and laboratory of genetics and physiology-2 (LGP-2). 
These receptors which are located within the cytoplasm, specialize in the detection 
of double stranded RNAs most commonly associated with viral genomes or genomic 
intermediates during viral replication. All three contain an RNA helicase core, 
responsible for the recognition of dsRNA and attached to the core is a zinc-binding 




caspase activation and recruitment domains (CARDs) which are used in signalling 
[300]. However LGP-2, which lacks CARDs but retains its ability to recognise 
dsRNAs, appears to  play a key role in acting as an accessory protein responsible for 
the regulation of RIG-I and MDA-5 and the aiding of their association with PAMPs 
[301].  
 
RIG-I distinguishes between host RNA and viral ssRNA by recognizing 5′-
triphosphorylated uncapped ssRNAs commonly found in viral genomes in contrast 
to the capped ends commonly found in the host, as well as by recognizing the short 
dsRNA bi products of viral replication (typically smaller than 1kb). In contrast MDA-
5 does not appear to recognize uncapped ends but instead distinguishes viral RNA 
by its size by binding to larger strands (over 2kb), as long dsRNA is not normally 
found in the host [301]. Following binding to the receptors, the receptors are 
activated by undergoing a conformational change which will allow for the interaction 
with the mitochondrial antiviral signalling protein (MAVS) which will eventually 
lead to the activation of IRF3/IRF7 and the subsequent transcription of type I 
interferon. MAVS will also activate NFkB via the recruitment of TRADD, RADD 
and caspase-8 and 10. 
 
Studies have shown that MDA-5 and RIG-I are able to detect different viruses with 
MDA-5 recognizing viruses such as encephalomyocarditis virus (EMCV) whilst 
RIG-I can recognize viruses such as JEV and RSV. Both MDA-5 and RIG-I have 
been found to be implicated in the recognition of DENV and WNV [302].  
 
Nucleotide oligomerization domain (NOD) like receptors 
Nucleotide-binding oligomerization domain (NOD) like receptors (NLRs) are 
mammalian PRRs located in the cytoplasm of epithelial and immune cells which are 
able to detect a range of bacterial motifs including flagellum, LPS as well as iE-DAP. 
Humans have 22 different NLRs whilst mice possess 34. NLRs are made up of a 
central NOD domain, an N-terminal homotypic protein-protein interaction domain 
as well as leucine-rich repeats (LRRs) located at the C-terminus which are involved 





Additional cytosolic pattern recognition receptors 
Lastly there are mammalian PRRs specialised in the detection of intracellular 
pathogen associated DNA, known as cytosolic PRRs. These PRRs, which were 
discovered very recently via the observation that TLR9 deficient cells retained their 
ability of producing type I IFN in response to dsDNA [304]. These will not be 
discussed in any further detail in this thesis. 
1.5.2.3 Cells of the innate immune response 
 
Innate immune cells play a key role in facilitating the detection of PAMPs, carrying 
out effector functions such as phagocytosis as well as helping prime and guide 
adaptive immune responses. Immune cells are made up of leukocytes, which are 
white blood cells, which derive predominantly from pluripotent hematopoietic stem 
cells in the bone marrow [279]. There are exceptions of certain subset cell types such 
as some tissue-resident macrophages and Langherans cells that instead derive from 
the embryonic yolk sac and the foetal liver [305]. Hematopoietic stem cells derived 
from the bone marrow can differentiate into two separate differentiation pathways 
including the common lymphoid progenitor cells that give rise to either lymphocytes 
such as T-cells and B-cells, lymphoid derived dendritic cells and natural killer cells 
(NK cells) or the common myeloid progenitor cells that can give rise to the 
granulocytes, monocytes, myeloid derived dendritic cells, mast cells and 
macrophages [306]. A brief descriptions of key innate immune cells will be outlined 




Granulocytes are a group of immune cells originating from the bone marrow derived 
from myeloid progenitor cells characterizes by the dense granules located in their 
cytoplasm. There are three different types of granulocytes; neutrophils, basophils, 
eosinophils which can be distinguished from each other using haematoxylin and 
eosin staining where neutrophils are pink, basophils are blue and eosinophils are red. 
Eosinophils are involved in the host protection against parasitic infections via the 
release of toxic granule proteins, reactive oxygen species (ROS) and pro-
inflammatory cytokines. Basophils, which are the only histamine containing 




to pathogens whilst also being able to directly kill parasites that have been tagged by 
antibodies [307].  
 
Neutrophils, which are the most abundant leukocyte, can be considered one of the 
most important cells of the innate immune response. Originating from the bone 
marrow where they are produced in large numbers of approximately 1011 cells a day 
in humans, these cells will eventually be released into the blood stream following 
their maturation via the increase of the expression of the chemotactic cytokine 
receptor CXCR2 (further discussed in section 1.5.4.7) [308]. Neutrophils can leave 
the blood and migrate into inflamed tissues following chemotactic cues. They are 
considered the “first respondents” to sites of inflammation. Following activation, 
neutrophils can perform several antipathogenic activities including phagocytosis, 
degranulation, and the release of a range of chemotactic and inflammatory cytokines 
which in turn can attract more neutrophils as well as monocytes, dendritic cells and 
T-cells [309]. 
 
In terms of the innate immune response to arbovirus infections, neutrophils play 
different roles in the outcome of infections depending on the virus. During infection 
with mosquito borne viruses, studies have shown that the act of mosquito biting 
accompanied with the simultaneous injection of saliva by the mosquito into the skin, 
induces a rapid CXCL2 driven recruitment of neutrophils to the bite site as early as 
90min post bite with a peak at 180min post bite. In turn, recruited neutrophils release 
a range of inflammatory and chemotactic factors that facilitates the migration of 
other immune cells to the site of inflammation. Some of these newly recruited 
immune cells have been shown to be susceptible to infection by a number of 
mosquito-borne viruses including SFV, DENV and BUNV suggesting that this 
immune response to mosquito biting/mosquito saliva indirectly aids arbovirus 




Mast cells are hematopoietic myeloid cells originating from the bone marrow. 
Progenitor mast cells migrate to mucosal and epithelial tissues spread across the body 




cells. Mast cells are involved in the regulation of a range of functions including 
vasodilation, angiogenesis, vascular homeostasis as well as regulating the action of a 
range of different cells such as dendritic cells, macrophages, T and B cells, 
endothelial and epithelial cells, eosinophils as well as fibroblasts. Activation of mast 
cells can occur in response to a variety of stimuli which can have different outcomes. 
Most frequently, activation leads to mast cell degranulation most notably in response 
to antigen-bound IgE crosslinking of IgE molecules bound to FcϵRI located on the 
cell surface of the mast cell. Degranulation can also occur in response to activation 
of complement, certain toxins as well as neuropeptides [311] [312].  Degranulation 
leads to the release of bioactive amines, proteoglycans, proteases and importantly 
histamine. In addition to degranulation, activation of mast cells leads to the synthesis 
of compounds such as leukotriene C4, prostaglandin D2 and platelet-activating 
factor in addition to specific cytokines and chemokines. Mast cells utilize a number 
of different PRRs that aid them in the detection of pathogens including TLR1-7, 
TLR9, RLR’s and NLR’s. Upregulation in the transcription of inflammatory 
cytokines occurs following binding of PAMPs to the PRRs including TNF-α, IL1β, 
and IL-6 [312] [311].  
 
Whilst the response of mast cells to parasitic and bacterial infections is well 
characterized, the role of mast cells in antiviral responses is much less explored. 
However, studies have shown that mast cell activation and subsequent degranulation 
occurs in response to the detection of DENV in humans, mice and non-human 
primates [313]. Furthermore, activation of mast cells via the detection of DENV, 
results in the upregulation of antiviral immune pathways such as the interferon 
response [314]. It has also been suggested that host responses against mosquito saliva 




Monocytes belong to a family of myeloid cells called the mononuclear phagocyte 
system which consists of monocytes, macrophages and dendritic cells (discussed in 
more detail in the following sections). Monocytes derive from myeloid progenitor 
cells in the bone marrow under the influence of transcription factors such as PU.1 




the majority of monocytes will remain throughout their lifespan, with only a few 
migrating into tissues where they will differentiate into macrophages to replenish 
resident cell populations. Maintenance of monocytes in the blood occurs via the aid 
of several cytokines, the most important being macrophage colony stimulating factor 
(M-CSF). Monocytes can be divided into two separate groups; the migratory 
monocytes and the patrolling monocytes. In mice, these subsets of monocytes can be 
distinguished by the expression of Ly6c which is expressed on the surface of 
migrating monocytes but not on the patrolling monocytes. Ly6chi cells can be 
recruited to sites of inflammation where they rapidly differentiate into macrophages, 
dendritic cells or remain as monocytes with antigen-presenting abilities. Ly6clo 
monocytes on the other hand “patrol” blood vessel walls where they “search” for 
tissue damage and pathogens and they are directly involved in tissue repair and other 
endothelial cell-supporting functions.   
 
In terms of monocytes and arbovirus infections, monocytes appear to play different 
roles during infections depending on the virus. For example, studies with CHIKV 
have shown that monocytes/macrophages are susceptible to viral infection in 
infected joints. With the persistence of infected monocytes in the joints, and their 
continuous release of inflammatory cytokines, chronic inflammation occurs resulting 
in arthralgia [317]. Similarly, monocytes have been established to be susceptible to 
infection with DENV and ZIKV [318] [319]. In contrast, monocytes have also been 
suggested to play a protective role against arboviruses. Utilizing monocyte deficient 
mice, one study demonstrated higher viral titers of CHIKV and RSS in both the 
blood and distal organs. In this model, monocytes inhibited infection by triggering a 
MAVS-dependent upregulation of type I IFN [320]. Similar conflicting roles for 
monocytes in arbovirus infections have been found in WNV infections where one 
study observed enhanced WNV infection accompanied by reduction in survival in 
mice with defective Ly6Chi monocyte recruitment, whilst other studies have shown 
that blocking monocyte migration to the CNS led to improved survival [321]. These 
inconsistent findings highlight the need for further research into whether monocytes 









Macrophages were first described by Elie Metchnikoff in 1884. Macrophages, which 
originates from the words μακρός (large) and φαγείν (to eat), are large, phagocytic 
leukocytes residing in almost all bodily tissues. They derive from the embryonic yolk 
sac and foetal liver during embryonic development and can be continuously 
replenished by the differentiation of Ly6chi monocytes [322]. Being one of the most 
efficient cell types at phagocytosis, macrophages are highly specialized in the removal 
of cellular debris, apoptotic cells as well as pathogens which are degraded in the 
phagolysosome.  
 
Macrophage activation occurs following the recognition of PAMPs or DAMPs by 
the PRRs. Originally, macrophages were believed to differentiate into either 
classically activated macrophages (M1), alternatively activated macrophages (M2) or 
regulatory macrophages. However, more recent studies suggest that this division of 
macrophages is over simplistic as macrophage phenotypes have been found to be 
mixed and context dependent [323].  Due to the irrelevancy of this conundrum in 
the context of this thesis, macrophage differentiation shall not be discussed in more 
detail. 
 
Macrophages can be activated by various stimuli. During infection with a pathogen, 
macrophages are activated by a combination of signals including IFNγ produced 
predominantly by natural killer cells (discussed below) and T helper 1 cells (TH1 
cells) (discussed in section 1.5.3.1), as well as tumour necrosis factor and IFNβ, both 
of which are produced by the macrophage via MyD88 or TRIF dependent 
pathways. Activation of macrophages via these signals will result in the priming of 
the macrophages in the production of superoxide anions, oxygen and nitrogen 
radicals to aid in the killing of bacteria, as well as in an increase in the production of 
specific pro-inflammatory cytokines such as TNF-α, IL-1β, IL-12, IL-18, as well as 
the secretion of inflammatory chemokines such as CXCL10. The production of these 
specific pro-inflammatory chemokines and cytokines will recruit more monocytes 
and other immune cells to the infection site. These types of macrophages, also 
commonly referred to as M1 macrophages, can also produce matrix-




for the degradation of extracellular matrix. Finally, these cells can act as a bridge 
between the innate and adaptive immune response as they will upregulate major 
histocompatibility class II proteins, enabling antigen presentation on the cell surface 
and the activation of primed lymphocytes [324]. 
 
Alternatively, macrophages can adopt the alternative macrophage phenotype, also 
commonly referred to as the wound-healing phenotype which occurs via the 
activation of macrophages by IL-4 and IL-13 secreted by T helper 2 cells (TH2 cells) 
and polymorphonuclear cells. These wound-healing macrophages secrete minimal 
amounts of pro-inflammatory cytokines but produce IL-10 and TGFβ as well as 
extracellular matrix components used for wound healing. Studies have shown that 
these cell types play a protective role during parasitic infections via the production 
of chitinase and chitinase-like molecules such as YM1 and YM2 which could 
potentially degrade the chitin surfaces of some parasites. However evidence 
supporting this hypothesis remains inconclusive.  
 
Macrophages can also adopt a regulatory function. These regulatory macrophages 
are activated by a range of factors including prostaglandins, apoptotic cells, 
dopamine, histamine and IL-10. Once activated they secrete large amounts of the 
anti-inflammatory cytokine IL-10 and will downregulate the expression of IL-12 
[325]. In general, macrophages are known for their high degree of plasticity which 
allows them to respond to specific environmental ques and quickly adapt their 
behaviour.  
 
In terms of infection with arboviruses, macrophages have been found to play either 
protective or pathogenic roles during the course of infection. Skin resident 
macrophages are ideally situated in close proximity to the initial viral inoculation site 
where they can quickly detect invading pathogens with their wide range of cytosolic, 
extracellular and endosomal PRR’s and initiate an antiviral response. However, 
studies have shown that macrophages are one of the key targets for infection by the 
majority of mosquito borne viruses which could explain the mechanism behind the 
local replication of arboviruses in the skin [95, 326]. There is also evidence for 
persistent infection of macrophages in tissues resulting in chronic inflammation. In 




associated with the pathogenesis of chronic arthralgia and/or arthritis, whilst long 
term infections of muscle resident macrophages following RRV infection has been 
linked to chronic pain and muscle damage triggered by uncontrolled cytokine 




Dendritic cells (DCs), which were originally described by Ralph Steinman in 1973, 
were named after the branch like structures they develop during specific 
developmental stages after the Greek word δένδρον meaning tree [328]. Today, DCs 
are known to be professional antigen presenting cells which means that they are 
highly skilled at detecting and capturing antigens which will be presented on the cell 
surface. As DCs are a heterogenous population, they can be sub-divided into groups 
based on their anatomical location, their origin, and based on their main functions. 
Dendritic cells derive from either embryonic progenitor cells which will give rise to 
resident DCs including Langerhan cells (discussed further in section 1.6.1) or from 
specific myeloid derived hematopoietic stem cells known as the macrophage/DC 
progenitors which will give rise to conventional DCs as well as plasmocytoid DCs. 
Ly6Chi monocytes can also differentiate into DCs following tissue migration. These 
sub-categories of DCs, are commonly referred to as conventional DCs (cDCs) and 
nonconventional DCs, which are made up of plasmocytoid DCs (pDCs) and 
monocyte derived DCs. The majority of DCs are derived from the bone 
marrow[329]. 
 
cDCs are highly migratory as they; patrol barrier tissue environments searching for 
pathogens; migrate from peripheral tissues to lymph nodes to help maintain immune 
self-tolerance; and separately shuttle between the T-cell and B-cell zones of lymphoid 
organs. Immature cDCs are competent phagocytic cells, an ability that is 
significantly reduced following pathogen sampling and the subsequent cell 
maturation. Mature cDCs present processed antigens derived from pathogens on 
MHC II, migrate to the T-cell zones of lymphoid organs where they secrete cytokines 
such as IL-12. Naïve T lymphocytes will then be exposed to the antigen carried by 
the cDCs as well as DC-derived cytokines resulting in their subsequent activation 




dissemination, as cDCs, similarly to macrophages, have been found to be primary 
targets of virus infection. Arboviruses known to infect cDCs include RRV, EEEV, 
VEEV, CHIKV and DENV [331] [332]. In addition, there is evidence showing that 
DENV infected DCs are incapable of inducing an antiviral response, as well as 
unable to prime T-cells. This suggests that some arboviruses have evolved immune 
supressing mechanisms that inhibit the DC innate immune functions [333] [334].   
 
Plasmocytoid dendritic cells are notably known for their ability to rapidly secrete 
large quantities of type I interferon in response to the detection of viral RNA through 
TLR7 signalling. Whilst originally located in the bone marrow, pDCs will migrate 
to peripheral tissues in response to chemotactic cues that activate CCR2. TLR7 
signalling leads the subsequent release of IFNα, IFNβ and IFNλ [335] [336]. pDCs 
may also act as antigen presenting cells that can recruit leukocytes via the secretion 
of chemokines. The role of pDCs in arbovirus infections remains unclear, as limited 
research has been conducted on the topic. However, research on DENV infections 
have discovered that infections with DENV lead to an enhanced activation of pDCs 
with higher activation correlating with better clinical outcome in patients suffering 
from severe dengue fever [333].  
 
Innate lymphoid cells 
 
Innate lymphoid cells (ILCs) are a recently discovered cell type that can be 
considered the innate counterparts of T cells (discussed in further detail in section 
1.5.3.1) which, in contrast to T cells, lack antigen receptors[337] [338]. These ILCs, 
which are derived from bone marrow lymphoid precursor cells can be split into two 
separate groups; the cytotoxic ILCs and the non-cytotoxic ILCs. The only known 
cytotoxic ILC are the Natural Killer cells (NK cells) which were originally identified 
in 1975 [339]. As suggested by their name, NK cells are “naturally” cytotoxic that 
do not require previous antigen exposure unlike cytotoxic T cells. Instead, they are 
filled with cytotoxic granules which are released following their binding to specific 
target cells. [340]. Similarly to many other innate immune cells that have been 
discussed previously, ILCs can play either a protective or pathogenic role during 
arbovirus infection depending on the species and cell tropism of the invading virus. 




1.5.3 Adaptive immunity 
 
In contrast to the rapid unspecific responses of the innate immune response, the 
adaptive immune response in naïve animals offers a delayed, but specific, response 
to invading pathogens that can take several days, following initial encounter with a 
pathogen, to develop. Importantly adaptive immune responses enable the 
acquisition of immunological memory to infection. This section will cover the basic 
mechanisms of the adaptive immune response, the main cell types involved in 
adaptive immunity as well as the role of the adaptive immune response during 
arbovirus infections.  
 
1.5.3.1 Cells of the adaptive immune response 
 
Adaptive immune responses can be both humoral and cellular and it is dependent 
on the clonal selective process of specific B-cells and T-cells. B-cells and T-cell are 
both lymphocytes that are derived from multipotent hematopoietic stem cells. These 
cell types will develop into multiple distinct cellular lineages whilst located in separate 
anatomical compartments within the bone marrow. Developed B-cells and T-cells 
can then undergo recombination of their antigen receptor genes which will produce 
new antigen receptors that can bind to essentially any antigen. During this 
procedure, the T-cells and B-cells that efficiently recognize a foreign antigen, and 
MHC molecules in the case of T cells,  are selected and cloned to enable highly 
specific responses to pathogens. B-cells and T-cells that have encountered antigen 
can remain as memory cells in the body, in order to offer a swift and a significantly 
more efficient response to the same specific pathogen during any subsequent 
infections. This phenomenon is known as immunological memory which can be 
viewed as the hallmark of the adaptive immune response.  
 
T-cells 
T-cells are bone marrow derived cells which migrate to the thymus where they 
undergo maturation and selection before they are shuttled to remote tissues. Whilst 
in the thymus, T-cells with the classical α/β T-cell receptor (TCR) undergo stages of 
selective pressures. The first selection stage comprises of the positive selection of T-
cells with a receptor that can recognize self MHC, where, T-cells with receptors that 




cells will die at this stage. The second selection stage of T-cell maturation involves 
negative selection during which, T-cells with receptors with high affinity towards self 
MHC undergo apoptosis. These selective pressures result in antigen specific T-cells 
that can be divided into two lineages based on their TCR; CD4+ and CD8+ cells 
where CD4+ T-cells where selected on MHC class II molecules whilst CD8+ cells 
where selected with MHC class I. Both lineages will migrate into the circulation 
following maturation as antigen naïve cells . 
CD4+ T-cells make up the majority of T cells within the human body. CD4+ T-
cells are also commonly called T helper cells due to their main function as producers 
of specific cytokine signaling targeted to other immune effector cells as well as in 
order to aid in the production of antibodies of high affinity by B-cells (see section 
below). In terms of arbovirus infections, research has shown that during CHIKV 
infection, Th1 T-cells are the main producers IFNγ by producing approximately 
50% of all IFNγ detected during acute CHIKV infections [341] [342]. CD8+ T-
cells are circulating T-cells who’s main function is the killing of infected cells. Due to 
this, CD8+ T-cells are commonly referred to as cytotoxic T-cells. Cytotoxic T-cells 
have an antigen specific TCR, with high affinity to MHC class I molecules (primarily 
derived from cytosolic proteins) which are displayed on the cell surface of infected 
cells [343]. During arboviral infections, CD8+ T-cells have been shown to play a 
key role in viral clearance by attacking cells infected with the virus. For example, it 
has been established that CD8+ T-cells are essential for viral clearance during acute 
phase CHIKV infection [344]. Additionally, CD8+ T-cells appear to be responsible 
for viral clearance in the CNS during avirulent SFV infections [80]. In contrast, 
cytotoxic T-cells can also play a pathogenic role during arboviral infection. Infection 
with SFV for example, can lead to demyelination in the CNS caused by CD8+ T-
cell activity [345].  
Finally, there are a small subset of T-cells, most of which do not express neither CD4 
nor CD8, known as the γδ T-cells. These T-cells make up less than 5% of 
lymphocytes in human tissues, although they are more concentrated within the 
gastrointestinal epithelium. During alphavirus infection with SFV and CHIKV, γδ 




out mice observed enhanced infection with an increase in inflammation-mediated 
oxidative damage in the joint [346] [347].  
B-cells 
 
B-cells are antigen presenting lymphocytes who’s main function is playing a key role 
in the humoral immunity via the production of antibodies whilst also being able to 
produce pro-inflammatory cytokines. B-cells, which are bone marrow derived cells, 
will undergo several developmental stages including pro-B, pre-B and immature B. 
During this development B-cells will acquire antigen specificity [348]. Mature B-cells 
express antigen specific B-cell receptors (BCR) which consist of an immunoglobulin 
as well as CD79a/b adaptor proteins [349]. Similarly to T-cells, B-cells will undergo 
selective pressures during maturation and the surviving cells will exit the bone 
marrow and migrate to secondary lymphoid organs such as the spleen, where they 
will develop into marginal zone B-cells or follicular B-cells [348]. Following B-cells 
encounter with antigen, in combination with exposure to specific cytokine stimuli, 
B-cells will become memory B-cells which can be activated in the future, or it can 
turn in to long lived plasma cells which undergo rapid clonal expansion and which 
possess the ability to produce large amounts of antibody. Further signalling via B-
cell interaction with CD4+ T-cells can aid in the production of antibodies of higher 
affinity. This interaction allows B-cells to switch their production of antibodies of the 
immunoglobulin classes IgM and IgD to other isotypes such as IgG, IgA and IgE via 
a process known as class switching [350]. Class switching is partially regulated by 
cytokines as expression of IL-4 and IL-13 promote switching to IgE for example 
[351]. Simultaneously, point mutations occur in the heavy and light chain variable 
regions of the immunoglobulin via a process known as somatic hypermutation 
(SHM). SHM is responsible for affinity maturation of antibodies which leads to the 
production of high affinity antigen binding antibodies [352]. These highly specific 
antibodies will aid the body’s immune response by either direct neutralization of 
invading pathogen, marking pathogen for phagocytosis by other immune cells or by 
providing the scaffold required for the activation of the complement system. For 
example, IgE antibodies are highly associated with hypersensitivity reactions 




[353], whilst IgG antibodies, the most common antibody isotype in the body, are 
known to directly neutralize viruses and toxins [354].  
 
In terms of B-cells role in the immune response towards arbovirus infections, there 
is evidence that B-cells can either be protective or contribute to pathogenicity. For 
example, studies have shown that IgM and IgG antibodies activated in response to 
SFV A7(74) in mice were protective [345]. In contrast, B-cells and B-cell derived 
antibodies are speculated to be implicated during pathogenic antibody-dependent 
enhancement of dengue virus infection. During this process, antibodies derived from 
a previous DENV infection will bind to DENV of another strain during a secondary 
infection which results in the subsequent infection of monocytes via the antibody 
directed binding of virus particles to Fc receptors located on monocytes [355].   
 
1.5.4 Cytokines and chemokines of the innate and adaptive immune 
response 
 
Cytokines and chemokines are small molecular weight proteins which play a 
fundamental role in the signal communication of both the innate and the adaptive 
immune response in addition to contributing to the regulation of cell migration and 
cell positioning during vertebrate development. Whilst cytokines were originally 
believed to originate exclusively from lymphocytes, it is now known that cytokines 
and chemokines are secreted by a wide range of cells. Cytokines can act in an 
autocrine, paracrine or endocrine manner by binding to cell surface receptors, which 
will in turn initiate a plethora of effects depending on the target cell type.  Based on 
their structure and main function, cytokines can be sub-divided into different groups. 
This section will briefly cover key cytokines and chemokines implicated in the innate 
and adaptive immune response with particular focus given to the type I interferon 
family due to their role in innate immune responses to viruses.  
 
1.5.4.1 IL-1 Family 
 
Interleukin 1 (IL-1), is a family of proinflammatory cytokines that are mainly 
associated with innate immune responses. The IL-1 family is made up of IL1α, IL1β, 
IL-1 receptor antagonist (IL-1RA), IL-18 as well as IL-33. During an inflammatory 




and IL1β are produced by cell types such as monocytes, neutrophils, macrophages, 
hepatocytes, as well as tissue resident macrophages located throughout the body 
[356]. IL1β is one of the members of the IL-1 family that are initially synthesized as 
a precursor of its active form, commonly referred to as pro-IL1β, which must be 
subsequently cleaved in order to become activated. Cleavage of the IL1β precursor 
is carried out by either the IL-1-converting enzyme (ICE), or caspase-1, the 
activation of which is mediated by a multiprotein cytosolic complex known as the 
inflammasome. The inflammasome, which was first described in the early 2000s, 
refers to a group of different cytosolic complexes which are all activated by different 
PAMPs and DAMPs [357]. However, due to the complexity of the inflammasome 
and because it does not feature prominently in this thesis, it shall not be discussed in 
further detail. Secretion of both IL1α and IL1β lead to the activation of neutrophils 
and macrophages as well as T and B lymphocytes [358]. When bound to IL-1 
receptors, these cytokines will also activate the secretion of additional cytokines 
including IL-6 and TNF, and can help induce Th17 adaptive immune response 
[359].  
 
1.5.4.2 Common γ Chain Family 
 
Cytokines that bind to cytokine receptors containing the common γ chain are known 
as the common γ chain family of cytokines. This family consists of  IL-2, IL-4, IL-7, 
IL-9, IL-15, and IL-21. These cytokines are mainly implicated in the differentiation 
and activation of lymphocytes whilst also functioning as growth factors for various 
leukocytes. IL-2, which is mainly secreted by activated T-cells, B-cells, NK-cells and 
neutrophils, causes cell proliferation whilst also promoting Th1, Th2 and Th9 
differentiation. IL-4, which is mainly involved in immune responses against 
helminths as well as allergy, promotes differentiation of B-cells and class switching to 
IgE. It also promotes differentiation of Th2 and Th9 as well as triggering 
proliferation of tissue resident macrophages. IL-7 is a hematopoietic factor 
responsible for the development and homeostasis of T-cells whilst IL-9 promotes the 
proliferation of mast cells. Lastly, IL-15 is required for the development and survival 
of NK cells whilst IL-21 promotes the differentiation of B-cells to plasma cells and 






1.5.4.3 Common β Chain family 
 
Cytokines that bind to a cytokine receptor that contain the cytokine-specific α chain 
as well as the common β chain are known as the common β chain family. This family 
consists of  IL-3, IL-5, and GM-CSF. As a family, these cytokines are mainly 
responsible for the differentiation and regulation of myeloid cells with a particular 
role in the allergic response. Specifically, IL-3 and GM-CSF are implicated in the 
development of immune cells such as macrophages, mast cells and 
polymorphonuclear cells whilst IL-5, which is derived from T-cells, is responsible for 
promoting the growth and differentiation of B-cells [361].  
 
1.5.4.4 Tumour Necrosis Factor Superfamily 
 
The tumour necrosis factor superfamily (TNFSF) consists of over 20 cytokines and 
close to 30 cytokine receptors. These receptors and corresponding cytokines make 
up signalling pathways involved in processes such as immune regulation, cell 
proliferation and differentiation as well as apoptosis. The best described tumour 
necrosis factor (TNF), is TNFα. TNFα, which is produced by macrophages and T-
cells, can be secreted either as a soluble molecule or in a membrane bound form. It 
binds to TNF receptor TNFR1 and TNFR2 where TNRF1 is expressed on the cell 
surface of leukocytes as well as on stromal cells, whilst TNFR2 is expressed on B-
cells and T-cells. Binding of TNFα to its receptor triggers the activation of a 




In 1957, two scientists named Isaacs and Lindenmann discovered a molecule that 
they observed to be capable of interfering with viral replication. Due to this 
observation, the molecule in question was named interferon [363]. Today we know 
that there are different types of interferon (IFN) molecules which can be split into 
three groups: type I IFN, type II IFN and type III IFN. Interferons can be secreted 




In this section, each type of interferon will be discussed with a description of their 
key roles in the innate and adaptive immune response. 
 
Type I Interferons 
 
Type I IFN family comprises of IFNα and IFNβ, as well as the more poorly described 
IFNδ (only present in ruminants), IFNε, IFNζ (only present in mice), IFNκ, IFNν 
(only present in cats), IFNτ (only present in porcine species) and IFNω. Type I IFNs 
are key players in the mammalian immune response against viruses [364]. Typically 
activated in response by PRRs in response to specific PAMPs, type I IFNs will bind 
to the homodimeric interferon α receptor (IFNAR) located on the majority of 
leukocytes and stromal cells. Binding facilitates signalling of the Janus kinase -signal 
transducer and activator of transcription (JAK-STAT) pathway which leads to the 
dimerization, translocation (to the nucleus) and binding of specific molecules to IRF9 
which will result in the formation of the interferon stimulated gene factor 3 complex 
(ISGF3). ISGF3 will bind to interferon stimulated response element (IRSE) inside 
the nucleus resulting in the subsequent activation of the transcription of numerous 
interferon stimulated genes (ISGs) (see section below) [365]. IFNα, unlike the other 
type I IFNs, can be further subdivided into 13 partially homologous subtypes of IFNs 
(14 distinct subtypes in mice). Despite their highly homologous nature (70-99% 
homology), each subtype has a different affinity for IFNAR [366].  
 
Despite our limited understanding of the functions of many of these IFNs, it remains 
clear that type I IFNs are critical in facilitating an effective antiviral response. In 
terms of arboviral disease, recent studies with SFV have shown that IFNAR 
knockout mice succumb to infection within 24h post infection in comparison to wild 
type mice where lethality was delayed for a minimum of another 3 days [286]. In 
fact, all strains of SFV are lethal in KO mice, including the A7(74) strain which is 








Type II Interferons 
 
The type II IFN family consists of only one IFN type; namely IFNγ. IFNγ, which is 
secreted by NK cells, Th1 cells and CD8+ T-cells and interacts with the interferon 
gamma receptor (IFNGR) present on the majority of nucleated cells [367]. IFNγ has 
a range of activities including macrophage maturation and stimulation of 
macrophage phagocytosis, enhancing antigen presentation molecules of both MHC 
I and MHC II, induction of apoptosis of infected cells, activation of NK cells, 
stimulating class switch recombination of B-cell immunoglobulins to IgG and IgE as 
well as triggering differentiation of CD4+ T-cells into Th1 cells. The versatile 
activities displayed by IFNγ, demonstrate its importance in facilitating a robust 
antiviral response whilst also providing a bridge between innate and adaptive 
responses. Studies utilising IFNγ knockout mouse models observed significant 
increase in viraemia following WNV infection in comparison to wild type mice, with 
virus disseminating earlier to the CNS in the knockout mice suggesting that IFNγ 
plays a protective role during WNV infection [368].  
 
Type III Interferons 
 
Originally discovered in 2003, the type III interferon family consists of IFNλ1, 
IFNλ2, IFNλ3 and IFNλ4. Whilst functionally similar to type I IFNs, for signalling, 
it interacts with a different heterodimeric receptor complex which consists of the 
IFN-λR1 chain and the IL-10R2. Interaction of IFNλ with their receptor results in 
upregulation of similar antiviral ISGs as Type I IFNs, as well as causing inhibition 
of epithelial and glioblastoma cell proliferation [369]. 
 
1.5.4.6 Interferon Stimulated Genes 
 
Detection of the majority of viral infections via PRR will result in the production of 
interferons which will subsequently lead to the secretion of specific interferon 
stimulated genes (ISGs) which can exhibit antiviral effector functions. As mentioned 
in the section above, Type I and type III interferons play an important role in 




virus infections which will eventually result in the transcriptional regulation of 
hundreds of ISGs. Whilst the mechanistic activities and anti-viral effector functions 
of the majority of ISGs remains unclear, it has been established that in general, in 
response to virus infections ISGs can inhibit infection in a number of ways including; 
interfering directly with viral replication, arresting protein synthesis machinery, 
reducing apoptosis threshold of implicated cells, inhibition of cell metabolism, MHC 
class I upregulation as well as driving cell migration. With each ISG having different 
effector properties, the profiles of ISG expression in response to virus infections is 
virus species specific with further variations observed between cell types. The 
observation of highly specific ISG expression profiles targeted at different viruses was 
recently described by Schoggins et al, were the expression of 380 different ISGs were 
monitored in response to a range of different virus infections including HCV, YFV, 
WNV, CHIKV, VEEV and HIV-1. Via this method, they were able to demonstrate 
that certain ISGs had a collective antiviral effect, whilst in contrast, the effect of 
certain ISGs had a pathogenic effect. These contradictive findings, emphasise the 
complex nature of ISG responses and the necessity of further research investigating 
ISG responses to viruses. This section will cover key ISGs that have been well 




Radical SAM domain containing-2 (RSAD2) is a gene of 331 amino acids in length 
which encodes viperin (virus inhibitory protein, endoplasmic reticulum associated, 
interferon inducible) which is an interferon inducible protein, 43kDa in size. The 
expression of viperin is highly conserved with its expression having been detected in 
a wide variety of mammalian species as well as in certain fish and reptiles [370]. 
RSAD2 is made up of three domains: a species variable N-terminal domain, a central 
domain containing a “radical SAM domain” which is highly conserved between 
species as well as a conserved C-terminal domain. In terms of antiviral activity, 
studies have observed that the central domain appears to play a key role in viperins’ 
antiviral effector function against HIV and BUNV, although the exact anti-viral 
mechanisms involved remain unclear [371] [372]. Similarly, the highly conserved 




infections with flaviviruses such as HCV and DENV, where DENV budding was 
inhibited by viperin [373] [374]. 
 
Whilst further research is required in order to enable a complete understanding of 
the antiviral effector functions of viperin, studies suggest that viperin may be 
responsible for the inhibition of either viral protein function or synthesis as well as 
inhibiting viral soluble protein transfer from the ER. Recently, it has been 
demonstrated that viperin can catalyzes the conversion of the previously unheard of 
molecule, cytidine triphosphate (CTP). In this the catalyzed CTP acts as a chain 
terminator of RNA-dependent RNA polymerases, thereby inhibiting viral 
replication of several flaviviruses such as ZIKV [375]. In terms of viperins role in 
other arbovirus infections, a study looking at transcriptional profiles of PBMCs 
acquired from CHIKV infected patients, observed an upregulation of viperin in 
monocytes. In addition, in RSAD2 knock out mice, enhanced viraemia 
accompanied by exaggerated joint inflammation was observed. In this system, the 
N-terminal domain of RSAD2 appeared to be the key factor involved in the antiviral 




ISG15 is widely considered one of the most strongly and rapidly induced ISGs in 
response to pathogen invasion. ISG15 is a ubiquitin like ISG which can conjugate 
with other proteins in a formation known as ISGylation. However the function of 
this conjugation remains elusive. ISG15 can also exist on its own as an unconjugated 
protein which can function as a cytokine. In terms of antiviral activity during 
arboviral infections, attenuated ISG15 has been demonstrated to inhibit Sindbis 
virus replication when given to IFN-αβR knockout mice as well as delay ISG15 
knockout mice from succumbing to infection following administration of attenuated 
ISG15 [377]. In addition, ISG15 has been demonstrated to play an important role 
during CHIKV infection. A study investigating CHIKV infection in ISG15 deficient 
mice, observed enhanced lethality in response to infection in the ISG15 knockouts 




proinflammatory cytokines. This indicates that ISG15 has an anti-inflammatory role 




IFIT are a group of ISGs which encode for interferon-induced proteins 
with tetratricopeptide repeats (IFIT). Whilst humans have 4 separate IFIT genes, 
mice have only 3, and generally IFIT genes have been found to have major 
variability between species. IFIT has the ability to bind specific proteins including 
cellular and viral proteins as well as viral RNA. This ability plays an important role 
in antiviral immunity as IFIT can bind to proteins essential for translation initiation 
which ultimately results in the inhibition of viral protein production. Furthermore, 
IFIT can capture viral RNA by binding to the 5’ ends of RNA lacking 2′-O-
methylation, a feature which is especially common in RNA viruses; a mechanism 
that appears to be important in antiviral responses against arbovirus infections [379]. 
However, recent studies have questioned the occurrence of this in alphaviruses as 
VEEV and SINV, were demonstrated to have successfully evolved secondary 
structures in their 5’- UTR region in order to prevent IFIT1 binding [380]. In 
flavivirus infections, WNV has evolved to incorporate a 2′-O methylated 5’ cap in 
order to successfully avoid IFIT binding [381]. In vitro studies utilising A549 cells 




Apart from proteins that exhibit antiviral effector functions, multiple pathogen 
recognition receptors which are stimulated by the interferon response are also 
incorporated into the ISG classification. Such PRRs include TLR3, TLR7, TLR9, 





Chemotactic cytokines (chemokines) are a subgroup of cytokines that implement 
control over the migration and positioning of immune cells. The immune system is 




migration as well as promoting interactions between different immune cells. There 
are 50 known chemokines in both humans and mice, all of which are 8 to12 kDa in 
size, with the ability to control cell migration by binding to a group of approximately 
20 chemokine G-protein coupled receptors (GPCR’s) [383]. These chemokine 
receptors have varying degrees of specificity and promiscuity with multiple 
chemokines binding to the same receptors. Chemokines can be further subdivided 
into four separate groups based on the spacing of their first cysteine residues. These 
four groups include CC chemokines, CXC chemokines, XC chemokines as well as 
CX3C chemokines. CC chemokines are therefore distinguishable by their two 
adjacent cysteine residues whilst CXC chemokines are characterised by the 
positioning of a random amino acid located in between the first two cysteine residues 
[384]. As the latter two subgroups will not be part of this thesis they shall not be 
discussed in further detail.  
 
CC chemokines, which make up the majority of chemokines with their 28 members 
(CCL1 to CCL28), are mainly responsible for regulating leukocyte migration during 
the inflammatory response [384]. Out of these 28 chemokines CCL6, CCL9, 
CCL10 and CCL12 do not exist in humans but can be found in mice, whilst the 
opposite is true for CCL13 and CCL16[385]. Whilst all CC chemokines have 
different roles, CCL2 is known to trigger monocyte recruitment to sites of 
inflammation via its interaction with chemokine receptor CCR2, whilst CCL3 is 
responsible for polymorphonuclear cell recruitment by interacting with CCR1, 
CCR4 and/or CCR5 [386]. CCL5, which is secreted by a number of immune cells 
such as macrophages, plays an important role in the recruitment of a range of 
leukocytes including anti-viral Th1 T-cells, macrophages, eosinophils and basophils 
to sites of inflammation. This thesis will mainly look at expressions of CCL2 and 
CCL5 [387]. 
 
The CXC chemokines group contains 17 distinct chemokines (CXCL1 to CXCL17). 
Similarly to CC chemokines, certain CXC-chemokines exist in humans but not in 
mice such as in the case of CXCL6 and CXCL8, whilst CXCL15 exists only in mice 
but not in humans. Certain CXC chemokines play a key role in regulating 
homeostasis such as in the case of CXCL12 which is ubiquitously expressed in the 




and stem cells via its interaction with receptor CXCR4. CXC chemokines also play 
an important role during inflammation as CXCL1 and CXCL2, which are 
expressed by immune cells such as macrophages, are responsible for neutrophil 
recruitment which can then go on to produce more CXCL1 and CXCL2 thereby 
amplifying the immune reaction. In addition, CXCL9 and CXCL10 are both type 
I and type II IFN inducible in a range of cell types and interact with receptor 
CXCR3 which is located on a range of anti-viral immune cells such as certain NK 
cells and Th1 and CD8 T-cells [388]. This thesis mainly studied the expressions of 
CXCL2 and CXCL10. 
 
In terms of chemokines and arbovirus infections, studies have demonstrated an 
upregulation of chemokines such as CCL2, CCL5, CCL3, CCL4, CCL7, CCL8, 
CXCL9 and CXCL10 in response to infections with SFV and WNV. Studies in mice 
investigating arbovirus induced encephalitis, determined that chemokine receptors 
CXCR3, CCR2, and CCR5 are key in the triggering of CNS inflammation by 
coordinating leukocyte migration to the brain during viral infection. In this study, 
infection with SFV resulted in the upregulation of CC and CXC chemokines which 
resulted in the directed influx of CD8+ T cells, macrophages and NK cells into the 
CNS. Contradictory, this influx of immune cells into the CNS, which was originally 
believed to be essential for viral clearance, has been demonstrated to be contributing 
to pathogenesis and one of the main causes of lethal encephalitis during SFV 
infection. The blocking of receptors CCR2 and CXCR3 prevented the influx of 
immune cells to the CNS thereby preventing encephalitic infection [389]. 
Furthermore, infections with ZIKV and DENV have shown to upregulate 
chemokines such as CCL2 and CXCL12 as well as other chemokines which 
collectively play a role in cell migration of monocytes and T-cells. Specifically, 
CXCL12 expression was observed to be significantly higher in monocytes during 
ZIKV infection which could help explain brain inflammation and the associated 
brain abnormalities observed in infected foetuses as CXCL12 has been associated 
with the retention of white blood cells in the CNS as well as initiating migration of 
CD8+ T cells into the brain during WNV infection [319] [390]. Similarly, another 
study by Pingen et al observed CCL2 production in the skin following exposure to 




to become infected with SFV and BUNV [95]. Mosquito bite dependent 
enhancement of arboviral infections will be discussed in more detail in section 1.7. 
 
1.5.5 Immune evasion by arboviruses 
 
In order for a virus to maintain a productive infection within a host and potentially 
develop persistence, it is essential that it avoids detection by the immune system, at 
least long enough to allow for viral replication to occur. Arboviruses have therefore 
developed mechanisms specifically evolved for the purpose of suppression and/or 
evasion of the hosts innate and adaptive immune responses. These mechanisms tend 
to vary greatly between different virus species. This section will therefore only cover 
a few key immune evasion mechanisms utilized by arboviruses. 
 
Alphaviruses contain a gene known as nsP2. This gene, in alphaviruses such as SFV 
and CHIKV, has been discovered to have the ability to inhibit antiviral gene 
transcription via the degradation of the a subunit of the host cells RNA polymerase 
II complex known as Rpb1 which is essential for gene transcription. This occurs from 
6 hours post infection [391]. Similarly, new world alphaviruses have also evolved to 
interfere with host cell gene transcription although via a separate mechanism. 
Studies on viruses such as VEEV and EEEV, have determined that certain new 
world alphaviruses inhibit gene transcription via the use of an amino-terminal 
fragment of their capsid protein which interacts with host cell polymerases [392]. 
Similarly, utilizing a mutant SFV virus where the localization of nsp2 inside the cell 
nucleus has been inhibited, it was demonstrated that mutated virus resulted in a 
significantly higher IFN response in comparison to its response to WT virus [393]. 
 
Apart from inhibiting gene transcription of host cells arboviruses exhibit a wide 
range of other mechanisms for immune evasion. For example, some mosquito-borne 
flaviviruses are believed to evade the immune system by inhibiting the immune 
responses of specific immune cells. Studies on DENV have demonstrated  its ability 
to supress haematopoiesis in the bone marrow [394] whilst CHIKV and other 
alphaviruses have been shown to hijack immune mechanisms responsible for the 
induction of cellular apoptosis as a means of infecting neighbouring cells. This 




phagocytosis of the cellular debris that contains virus particles. In this way, the virus 
is able to spread without the threat of exposure to immune cells present in the 
extracellular environment. [395]. In addition, DENV, and other flaviviruses such as 
WNV, have also been shown to interfere with the phosphorylation of STAT1 in 
order to prevent the induction of type I IFN which can be induced in a STAT 
dependent manner [396]. Furthermore, the highly conserved flavivirus protein NS5 
which plays an important role in the replication of viral RNA, also produces an N7 
and 2′-O methylation viral RNA 5′ cap which is used by flaviviruses as a hiding 
mechanism as this enables them to resemble mammalian host RNA and thereby go 
undetected by certain PRRs [397]. Finally, subgenomic RNAs present in flaviviruses 
have also been demonstrated to inhibit antiviral immune responses by binding to 
molecules involved in the regulation IFN and ISG response [398].  
 
Numerous more examples could be listed, but from this brief overview of arboviral 
immune evasion it is possible to conclude that an evolutionary arms race exists 
between host immune responses and viruses that has enabled the evolution of a range 
of variable mechanisms that target immune responses. 
 
1.5.6 Antivirals, vaccines and treatments  
 
As of the time of writing this thesis, no specific antivirals targeting arboviral disease 
have been licensed and few vaccines have been developed. Due to this, the only 
available treatments for the majority of arboviral infections are analgesics, anti-
inflammatory and antipyretic drugs.  
 
There are several obstacles at play that hinder the development of antivirals and 
vaccines targeting arboviral disease. Such obstacles include the vast number of 
different arboviruses, with more than 550 described out of which more than a 100 
are known to infect humans. As symptoms of disease tend to overlap, accurate 
diagnosis are problematic. Another major obstacle is the spontaneity and 
unpredictability of arboviral outbreaks, which complicates development and 
stockpiling of virus species-specific medications. As was the case for the recent 
epidemics of CHIKV in the Pacific islands and ZIKV in South America, there is no 




emergence can also occur very rapidly. During the recent Zika epidemic for 
example, WHO was initially notified of sporadic infections with ZIKV in March 
2015. Within 9 months, the virus had already spread widely to an additional 10 
countries including El Salvador, Mexico and Paraguay. Due to these factors, the 
possibility of stockpiling drugs for each arbovirus in case of a potential outbreak is 
likely to be unfeasible. Furthermore, research and development required for drug 
discovery, as well as the requirement for extensive clinical trials, makes drug 
development a time consuming laborious process, estimated to take approximately 
10 years, which makes the emergence of sporadic new outbreaks difficult to deal 
with. In addition, the entire process of developing a new drug is very expensive with 
an estimated total cost of $2-3 billion USD per drug [399]. As, the majority of 
incidences affect people in less affluent countries, there has been a historical lack of 
incentive for pharmaceutical companies to develop vaccines and treatments.  
 
The accumulation of all these obstacles have hindered the development of effective 
vaccines and treatments and so novel ideas are required for treatment discovery. 
Currently, much hope is given to broad-spectrum antivirals. Such putative 
compounds would have the ability to inhibit a broad range of distinct virus infections 
by targeting different aspects of the virus life cycle such as inhibition of viral cell 
entry/exit, disruption of viral replication or even by directly lysing the virus particle. 
One such example for arboviruses is compound 3′-fluoro-3′-deoxyadenosine which 
can supress infection of several viruses including SFV and VEEV, whilst 2,6-
diaminopurine derivatives have been found to prevent infections with ZIKV and 
DENV in vitro [400] [401] [402]. One of the major benefits of broad-spectrum 
antivirals would be eliminating the need for accurate diagnosis, reduce the number 
of drugs required for stockpiling as well as the potentiality that already developed 
drugs could be efficacious against newly emerged diseases as well. 
 
In terms of vaccine development, the only licensed vaccine currently available 
against mosquito borne viruses is the JEV, DENV and Yellow fever vaccine, known 
as the 17D vaccine [403]. Despite the vaccines efficacy however, the cost and time 
associated with its development in combination with lack of education of the public 
regarding its existence, current vaccine cover falls far below the estimated 80% 




targeting other mosquito borne viruses has so far been largely unsuccessful. Attempts 
made for the development of an effective DENV vaccine have been complicated by 
the existence of 4 separate viral serotypes. As immunity to one serotype does not 
automatically confer immunity to the remaining 3 serotypes, and as immunity to one 
serotype is known to cause enhanced infection via antibody dependent enhancement 
if ever infected with another serotype, a DENV vaccine must confer immunity to all 
4 serotypes simultaneously without instigating antibody dependent enhancement. A 
recently developed DENV vaccine known as Dengvaxia, which was approved in 
2015 following a phase 3 clinical trial, was recently re-evaluated as it appears as if 
the vaccine is only effective in individuals who have already been infected with 
DENV previously, whilst it simultaneously aggravates DENV infection in DENV 
naïve individuals. Therefore, all individuals vaccinated with Dengvaxia have to be 
tested for seroprevalence [405].  
 
Lastly, following the ZIKV epidemic, attempts have been made for the development 
of a Zika vaccine. However, due to the reduction of ZIKV cases world-wide many 
vaccine development projects have been cancelled for economic reasons [406]. Also, 
instigating a phase III clinical trial is problematic without an active outbreak. On the 
positive side, the efficiency with which alternative vaccine targets were developed is 
promising for future vaccine developments during future outbreaks.  
 
1.6 Skin Biology  
 
Arboviruses are initially deposited into the skin of the host by a blood feeding vector. 
Host inflammatory responses to the bite, and virus inoculum in the skin, appear to 
be an important factor in facilitating virus spread and infection (discussed in more 
detail in section 1.7). Therefore it is important to understand the fundamental aspects 
of cutaneous biology, which will be the focus of this section, which will cover skin 
structure, skin vasculature and basic skin immune responses as well as the current 







1.6.1 Skin structure 
 
As the bodies largest organ, the skin is a dynamic system comprised of an extensive 
ligament, nerve, blood vessel and lymphatics network that effectively protects the 
body from the external environment. But it does not simply act as a static barrier to 
the outside world; there is continuous communication between epithelial, stromal 
and immune cells which help regulate homeostasis and inflammatory responses 
towards pathogens [407]. The skin is comprised of three main layers; the epidermis, 
the dermis, and the hypodermis; with a layer of subcutaneous fat underneath (see 
figure 1.11) [408].  
 
Figure 1.11. Mosquito biting. 
Diagram illustrating how mosquitoes will probe through the epidermis and deposit saliva 
and virus into the dermis [408]. 
 
The epidermis, which refers to the uppermost layer of the skin, is 75-150μm thick in 
humans and can be further subdivided into the basal cell layer, the spinous cell layer, 
the granular cell layer, and the stratum corneum. It is mainly made up of 
keratinocytes which make up approximately 95% of all cells and are continuously 
undergoing self-renewal [409]. Professional antigen presenting Langerhans cells are 







provides mechanical strength and elasticity, can be further subdivided into two 
distinct layers; the superficial papillary dermis and the deeper reticular dermis. These 
are made up mainly of dermal fibroblasts as well as adipocytes which are mainly 
distributed throughout the superficial papillary as well as surrounding blood vessels, 
hair follicles and the nerve endings which are also located in this area. Lastly, the 
hypodermis is mainly made up of connective tissue and adipose tissue with the 
majority of cells being fibroblasts and adipocytes [409]. 
 
1.6.1.1 Cells of the Epidermis 
 
As mentioned above, the most numerous cell type of the epidermis is the 
keratinocyte. These cells are required for structural support and will differentiate as 
they migrate from the basal layer to the stratum corneum where they stop 
proliferating, increase in size and die in order to form the water impermeable dead 
skin layer [411]. They also play a role in innate immune recognition mainly via 
TLR1-6 and TLR9 whilst also playing a role in anti-bacterial and anti-viral 
immunity via the secretion of β-defensins and type I IFN [412]. Due to their 
numbers, keratinocytes have historically been regarded as one of the key cell 
susceptible to arbovirus infection as they have been shown to susceptive to infection 
with a range of different viruses including WNV, SFV and DENV [413]. However, 
during probing, mosquitoes will probe right through the epidermis and deposit 
arbovirus within the dermis which lacks keratinocytes [291]. Therefore it remains 
unclear if keratinocyte susceptibility to arbovirus infection is of any relevance. 
Another prevalent cell type located in the epidermis are the Langherans cells which 
possess a range of PRRs including TLR1-3, TLR5-6 and TLR10, as well as foetal 
derived γδ T-cells [305] [412] [414]. As in the case of keratinocytes, as virus 
inoculum is deposited into the dermis, it remains controversial whether the cells of 
the epidermis play a role in the immune response during arboviral infection. 
 
1.6.1.2 Cells of the Dermis 
 
Anatomically, the dermis consists of an extracellular matrix which is has collagen 
and elastic fibres filling any extracellular spaces, functioning as a scaffold for the 




fibroblasts which are responsible for the production of matrix proteins such as elastin 
and collagen, as well as responding to inflammatory signals. Dermal fibroblasts have 
been shown to be susceptible to arboviral infections of viruses such as CHIKV and 
DENV, where fibroblasts will induce an IFNβ response [106] [332] [415]. In 
addition, the dermis possess at least 5 distinct populations of dendritic cells; the most 
common being CD11b + DC which make up approximately 50% of the dermal DC 
population. Dermal cDCs are implicated in phagocytosis and MHC class II 
presentation of antigen. DCs will then migrate to the lymph nodes where they will 
activate T cells resulting in the subsequent production of pro-inflammatory 
cytokines. Furthermore, populations of dermal macrophages are also located within 
the dermis which play an important role in pathogen recognition via PRR, triggering 
the release of proinflammatory cytokines and chemokines,  responsible for neutrophil 
recruitment, upon activation [416]. The role of dermal DCs and macrophages in 
arbovirus infections remain largely unclear. Studies have however shown that CD1+ 
DCs are responsible for the initiation of a type I IFN response during DENV 
infection whilst macrophages were observed to have a pathological effect [417]. 
Similarly, ZIKV can successfully infect immature dendritic cells generated from 
human derived peripheral blood mononuclear cells, suggesting an important role for 
dermal DCs in sustaining infection in the skin [418]. 
 
Populations of mast cells can also be found within the dermis (discussed in section 
1.5.2.3) which play an important role in the immune and allergic response by 
releasing histamines and proinflammatory cytokines (discussed more in section 
1.5.4). Finally, the dermis also contains a γδ T-cell population which are capable of 
producing IL-17 and IL-22 [419]. 
 
1.6.2 Skin blood vasculature and oedema  
 
Throughout the extracellular matrix of the dermis, there is a network of blood and 
lymph vasculature which play an important role in inflammatory responses as the 
recruitment of immune cells to sites of inflammation occurs via the vascular systems. 
Blood vessels in the dermis can be split into four separate groups; arteries, capillaries, 
postcapillary venules and collecting venules. The majority of blood endothelial cells 




restrict the crossing of any plasma proteins exceeding 70kDa. However, during 
inflammation, endothelial cells lining the postcapillary venules become separated as 
their tight junctions and adherence junctions diminish, allowing for the crossing of 
fluid, along with albumin and immunoglobulins, to accumulate in the tissue at the 
site of inflammation which inevitably leads to tissue swelling and the formation of 
oedema. As this only occurs in the postcapillary venules, they are considered the 




Figure 1.12 Endothelial cell permeability.  
Endothelial cells lining the blood vessels have tight adherence junctions between them 
restricting the crossing of any plasma proteins exceeding 70kDa. During an inflammatory 
state, endothelial cells become separated as their tight junctions and adherence junctions 
diminish, allowing for the crossing of higher molecular weight proteins (green) and 
immunoglobulins (red), to accumulate in the tissue at the site of inflammation which leads 
to tissue swelling and oedema formation. 
 
Surrounding the endothelial cells of the postcapillary venules are pericytes and the 
basement membrane, with macrophages and mast cells located in close proximity. 
These components function as the perivascular extravasation unit. Recent studies 
have shown that perivascular macrophages play a vital role in neutrophil recruitment 




chemoattractant [420]. T-cell recruitment and activation is also dependant on 
postcapillary venules. Following their recruitment in response to inflammation in the 
skin, T-cells will form clusters with DCs and perivascular macrophages, known as 
iSALT. iSALT is essential for initiation of the adaptive immune response as it 
functions mainly as an antigen presentation site [421]. The formation of oedema 
during the acute inflammatory response can be split into two sections; immediate 
reaction and late-phase reaction. 
 
1.6.2.1 Immediate reaction 
 
The immediate reaction, which occurs within seconds following antigen exposure, is 
instigated by the activation of mast cells, usually triggered by IgE recognising its 
cognate allergen in antigen-experienced individuals. In the absence of IgE (i.e. as 
occurs with non-allergic oedema), mast cell activation can occur in response to 
polycationic compounds including 48/80, substance P, bradykinin, mastoparan, 
polyethyleneimine as well as in response to pathogens. Activation of mast cells leads 
to degranulation which results in the release of large quantities of bioactive amines, 
proteoglycans, proteases and histamine as well as the synthesis of leukotriene C4, 
prostaglandin D2 and platelet-activating factor in addition to specific cytokines and 
chemokines [422] [423]. Prostaglandins, which are a group of active lipid 
compounds known as eicosanoids, are located in the majority of tissues where they 
function as locally acting vasodilators [424]. Leukotrines, which are also part of the 
eicosanoid family, are responsible for cell signalling regulating the inflammatory 
response [425].  
 
Histamine, which is arguably the most important oedema-activating amine, is a 
known mediator of the allergic response and the key instigator of the early phase 
reaction. Following its synthesis in the golgi apparatus, it is transported for storage 
inside granules. Mast cells, which are the only histamine carrying cell type (with the 
exception of basophils), contain approximately 2-5 pg of histamine per cell. In the 
skin, released histamine will act on the H1 receptors of local blood vessels which 
triggers the immediate increase in vascular permeability and fluid extravasation. 
Histamine will also act on the H1 receptors of local nerve endings which leads to 




reddening of the skin and the potential formation of skin lesions known as the wheal 
and flare reaction [426]. Apart from its effects on dermal blood vessels and nerves, 
studies have shown that histamine can also bind to cell receptors which can in turn 
activate and attract neutrophils and eosinophils. Histamine also induces the 
expression of CXCL8 [427]. The combined actions of histamines, prostaglandins, 
leukotrienes cause a rapid increase in extravasation allowing for the movement and 
activation of leukocytes, including neutrophils and monocytes, to cross from the 
blood vessels into the infected tissue guided by chemokines mainly expressed by 
macrophages. This contributes to the development of the late-phase reaction.  
 
1.6.2.2 Late-phase reaction 
 
The late-phase reaction will develop sometime between 2-6h following initial 
allergen exposure and will peak sometime between 6-9 hours following exposure 
depending on allergen dose. In contrast to the early phase reaction, which is 
characterised by the formation of a wheal and flare lesion, the cutaneous late phase 
reaction is characterised by the oedematous, firmer lesion which usually resolves 
within 24 hours (occasionally swelling can be observed up to 72h post allergen 
exposure) [428]. It is triggered by the continuous synthesis of mediators of the 
inflammatory response. These mediators, which are mainly produced by mast cells, 
include the calcitonin gene related peptide (CGRP) and the vascular endothelial 
growth factor (VEGF) which cause vascular permeability and the formation of 
oedema. CGRP, which is part of the calcitonin family of peptides, is a highly efficient 
vasodilator inducing endothelial permeability indirectly via the aid of histamine 
[429]. VEGF, the expression of which is partially regulated by CGRP, mainly acts 
upon endothelial cells by promoting cell proliferation, migration and maintenance. 
VEGF is also known to be chemotactic for monocytes [430]. Recent studies have 
demonstrated that CGRP and VEGF can be secreted by immune cells infiltrating 
the skin during the inflammatory response. CGRP is expressed by neutrophils in 
response to inflammatory cytokines such as IL-1 and TNF-α, and CD3+ T cells, 
whilst VEGF is expressed by eosinophils, T-cells, and macrophages [431]. In the 
human skin, immune cells commonly recruited to the site during late-phase reaction 
include leukocytes such as Th2 and Th1 cells, granulocytes such as eosinophils, 




1.6.2.3 Chronic allergic inflammation 
 
Continuous or repeated exposure to allergens can lead to chronic or persistent 
inflammation. Persistent inflammation is often accompanied by phenotypic and 
functional alterations in structural cells and in the extracellular matrix in the affected 
area which can have implications on organ functions. Due to study limitations, it 
remains unclear how repeated or prolonged allergen exposure shifts the 
inflammatory response from early and late phase reactions towards a chronic allergic 
reaction. However, it has been established that whilst the main features of the acute 
inflammation continue to occur during chronic inflammation, such as vasodilation, 
extravasation and neutrophil migration, during chronic infection, neutrophils tend 
to become replaced by macrophages and lymphocytes. These immune cells will 
secrete large quantities of pro-inflammatory cytokines and growth factors that will 
eventually result in tissue damage and the subsequent formation of granuloma and 
fibrosis by secondary tissue repair [433] [434]. Examples of chronic allergic 
pathologies include atopic dermatitis, allergic rhinitis and asthma; all of which are 
characterised by the remodelling of affected tissues. For example, in atopic 
dermatitis, the skin barrier becomes weakened, which subsequently results in an 
increased risk of skin infections [435].  
 
1.6.3 Skin immune reaction to mosquito bites 
The immune responses to arbovirus infection by mosquito differs to the immune 
responses elicited by non-vector borne viruses, as arboviruses are always 
accompanied by a bite from a vector. This means that the bite itself will also elicit an 
immune response on its own. In the case of mosquito-transmitted viruses, during 
mosquito feeding, mosquitoes will probe the skin whilst simultaneously injecting 
saliva in order to acquire a blood meal. This will eventually trigger an immune 
response targeting the tissue trauma from the probing of the skin, as well as, against 
the saliva injected by the mosquito, which contains a range of proteins and 
potentially pathogens (discussed further in section 1.7) [95, 436, 437]. Depending on 
the mosquito species, a mosquito bite will typically trigger a skin reaction that can 
range from small papule formations, to larger pruritic lesions. Whilst the specific 




potentially immunomodulatory effects of mosquito saliva are poorly understood, 
there are some studies investigating these responses and how they modulate the 
course of arbovirus infection. Therefore, as it is important to understand the effects 
the bite has on the host immune response, this section will focus on the current 
understanding of the immune responses triggered in response to mosquito bites.  
1.6.3.1 Innate immune responses to mosquito bites 
The mosquito bite quickly triggers immune responses in the skin including the 
expression of cytokines, degranulation of mast cells as well as the expression of 
neutrophil attracting chemokines [95, 438]. Reactions to mosquito bites are highly 
dependent on mast cell activation and degranulation and the accompanied 
vasodilation, extravasation and the recruitment of polymorphonuclear cells. In the 
absence of mast cells, mice no longer exhibit upregulation of the neutrophil 
chemoattractant CXCL2 in response to mosquito bites. Neutrophils attracted to the 
site of inflammation secrete high levels of IL1β, and studies utilising neutrophil 
deficient mice observed reduced expression of pro-inflammatory cytokine and 
chemokines chemotactic for CCR2 expressing myeloid cells [95]. 
Interestingly, mast cell activation in response to mosquito bites does not seem to rely 
exclusively on IgE mediated activation, as studies have demonstrated mast cell 
degranulation occurrence in naïve mice in response to Anopheles mosquito bites. In 
this study, An. stephensi saliva directly induced mast cell degranulation in connective 
tissues in the absence of IgE [315]. TNFα and MIP-2 were also significantly 
upregulated in this system as they were secreted by mast cells [439]. A similar study 
investigating cytokine and chemokine responses against Anopheles bites in naïve mice 
observed upregulation of MIP-2 in the skin as well as upregulation of IL-10 
expression in the draining LN [440]. 
A recent study investigating the effect of  Ae.aegypti mosquito bites on host immune 
responses observed an increase in NK cells, and myeloid cells such as DCs, 
monocytes, macrophages and neutrophils as well as CD8 + T-cells 6 hours post bite 
in the serum [441]. In terms of cytokines, an upregulation of pro-inflammatory IL-
1α was observed in the serum, accompanied by the downregulation of other pro-




addition, enhanced quantities of VEGF was observed [441]. 24h post bite, Tregs 
were observed to have migrated from the spleen to the serum. The authors suggest 
that this could result in an enhanced secretion of anti-inflammatory IL-10. 
Interestingly, in vitro studies have shown that mosquito saliva appears to inhibit 
cytokine production such as CCL5 in human PBMCs. 
In terms of oedema, mosquito salivary gland extract induces endothelial 
permeability of the skin when injected into mouse ears, as well as disrupting human 
endothelial cell junctions in vitro when given at high doses. This, in combination with 
the observed degranulation of mast cells discussed earlier, suggests that mosquito bite 
induced oedema formation occurs from the direct action of saliva on endothelial cells 
as well as via its instigation by mast cells [310]. The relevance that each has for 
modulating host susceptibility to arbovirus infection is not known. 
1.6.3.2 Adaptive immune responses to mosquito bites 
 
It has been observed that humans bitten by mosquitoes for the first time do not 
always display an obvious reaction. With exposure to repeated biting however, an 
allergic reaction with an accompanied itch can develop. In mice, studies have shown 
that repeated injections of recombinant mosquito salivary allergen caused an 
increase in detectable IgE and IgG in serum and caused the induction of an 
immediate skin reaction [442]. Similarly, other studies in mice have observed 
enhanced extravasation following repeated exposure in comparison to naïve mice 
[443].  
Whilst mosquito saliva will be discussed in greater detail in the following section, it 
should be noted that mosquito saliva is very complex as it contains hundreds of 
molecules with varying, and often unknown, functions. There is a lot of controversy 
regarding whether mosquito bites elicit a pro-inflammatory or putative anti-
inflammatory response in the host, with certain compounds exhibiting either pro-
inflammatory or anti-inflammatory responses.  In summary, exposure to mosquito 
bites induce mast cell degranulation and neutrophil recruitment with a subsequent 
influx of monocytes. More studies are necessary in order to gain a better 
understanding of the immune response to mosquito bites and in order to determine 




1.7 Vector saliva and infection 
Bloodsucking arthropods have evolved to overcome specific host physiological 
responses in order to better acquire a successful blood meal. These include 
haemostasis, inflammation and immunity to saliva. To aid them, biting vectors will 
inject a cocktail of molecules present in their saliva during feeding.  
In terms of arboviral infection, it has been established that arboviruses inoculated 
via a mosquito bite, or administered with mosquito saliva cause a more severe 
infection compared to virus inoculated in the absence of a mosquito bite (or mosquito 
saliva) [95, 444, 445]. This is also true for other vector borne diseases transmitted by 
different vector species as the saliva of hematophagous arthropods contains a wide 
range of compounds, the majority of which are used to facilitate blood feeding. For 
example, mosquito saliva contains a mixture of anti-haemostatic, anti-coagulant, 
vasodilatory, as well as compounds that can elicit or inhibit host immune responses. 
Whilst transcriptome analysis have been conducted, the function of the vast majority 
of these compounds remains unknown. 
Originally it was hypothesized that the enhancement of arbovirus infection by 
mosquito bites is caused by a similar mechanism observed in tick-bites. Biting ticks 
have been found to immunosuppress its host at the bite site by suppressing 
mammalian chemokine function [446]. It has been postulated that if this was also 
the case for mosquito-borne virus infection, this would then explain why mosquito 
bites are able to enhance viral infections in the host. However, in comparison to ticks 
that have evolved a range of immunosuppressive factors  (such as Evasins which bind 
to chemokines), these factors appear to be absent in mosquitoes. This difference is 
perhaps not surprising as ticks must remain attached to a mammal’s skin for days, 
while mosquitoes feed for only a brief few minutes. Therefore, host immune 
responses triggered in response to mosquito bites are unlikely to have a major effect 
on the efficiency of mosquito-feeding to push for the evolution of mosquito-derived 
immunomodulatory factors. In fact, for mosquitoes, the majority of evidence for 
immunosuppression by mosquito saliva has been found in vitro [445, 447]. In the 
previous section, focus was given on the current understanding of immune responses 
elicited towards mosquito bites and mosquito saliva. This section will focus on the 




1.7.1 Mosquito saliva 
 
The co-injection of virus alongside a mosquito bite, in comparison to the inoculation 
of virus (in an exclusively experimental setting) in the absence of a bite, results in an 
enhanced and more rapid dissemination of virus to remote tissues. This has been 
demonstrated for a range of arboviruses including DENV, WNV, SFV and BUNV 
[447] [95]. More specifically, the co-administration of mosquito saliva alongside 
virus is sufficient to enhance infection, suggesting that saliva is responsible for 
arboviral enhancement. Although mosquito saliva dependent viral enhancement has 
been established, the mechanisms involved facilitating the enhancement remain 
unknown. This section will therefore focus on our current knowledge to date of the 
mechanisms believed to be involved. 
 
1.7.1.1 Inflammatory responses elicited against mosquito bites enhance 
arbovirus infection 
 
Mosquito bites and mosquito saliva trigger an inflammatory response that triggers 
an influx of immune cells to the site of inoculation. However, as has been described 
previously, many of these immune cells are susceptible to arboviral infection. Recent 
studies in mice have demonstrated that mosquito bites upregulate the expression of 
neutrophil chemoattractant chemokine CXCL2 as well as IL1β which result in an 
enhanced influx of neutrophils, and subsequently macrophages, to the site of 
infection [95]. In addition, neutrophil depletion and the inhibition of IL1β 
expression has been observed to inhibit viral enhancement by bites. Similarly, 
another study demonstrated that SGE (salivary gland extract) triggers the 
recruitment of inflammatory neutrophils and monocytes which may cause enhanced 
infection with DENV, as some recruited immune cells become infected [310].   
 
1.7.1.2 Vascular response against mosquito saliva may also enhance 
viral infection and dissemination 
 
As discussed in section 1.6, mosquito bites will trigger early and late phase cutaneous 
inflammation with the associated formation of oedema and pruritic lesion that can 




response to mosquito bites also occur at the same time as arbovirus enhancement. 
For example, a study investigating SFV infection in an in vivo mouse model observed 
delayed viral dissemination to draining lymph nodes when virus inoculation was 
accompanied by a mosquito bite and the formation of oedema. This suggests that 
oedema may retain SFV in the skin for prolonged period of time, thereby facilitating 
the infection of dermal cells [95]. Importantly however, the role, and relative 
importance, that bite/saliva-induced oedema has in enhancing SFV infection is not 
clear. 
 
In addition, it has been hypothesised that the disruption of endothelial barriers by 
mosquito saliva may facilitate virus dissemination. As has already been mentioned, 
mosquito bites and saliva induce vascular leakage, potentially via the use of serine 
proteases which can break down the extracellular matrix of fibroblasts which 
increases the permeability of endothelial cells [310] [444]. Studies have suggested 
that the enhanced permeability of endothelial barriers may aid virus dissemination; 
in terms of DENV, enhanced endothelial permeability may increase the association 
of virus particles to potential circulating antibodies, which can facilitate DENV 
antibody dependent enhancement. In addition, enhanced permeability of blood 
vessels allows for an increase in the extravasation of monocytes and neutrophils to 
the site of infection which can indirectly aid the virus by providing new cells that are 
susceptible to infection by virus [310]. 
 
1.7.1.3 Inhibition of innate immune responses by mosquito saliva 
 
Another hypothesis involving mosquito saliva dependent enhancement, suggests that 
mosquito saliva may aid virus infection by inhibiting host immune responses at the 
site of infection. Specifically, this has been suggested to occur via the inhibition of 
the expression of type I IFN by mosquito saliva. One study, investigating the effect 
of salivary gland extract (SGE) on DENV infection of human keratinocytes observed 
inhibition of type I IFN and IFNγ by SGE [448]. Similarly, a 34-kDa protein, found 
to be ubiquitous in Ae.aegypti mosquito saliva, also inhibited the expression of type I 
IFN and IFNγ in human keratinocytes via the suppression of IRF-3 and IRF-7[449]. 




mosquito saliva, as studies have demonstrated that mosquito saliva enhances DENV 
infection in the absence of type I IFN [310] [450]. 
 
In addition, the suppression of T-cell responses by mosquito saliva has also been 
hypothesised to be responsible for arbovirus enhancement. As mentioned in section 
1.6, mosquito saliva has been found to enhance Th2 related cytokines as well as IL-
10 [440] [451] [436]. In addition, the addition of recombinant IL-4 has been found 
to enhance DENV infection in vitro [417]. However, as mosquito bite dependent 
enhancement occurs very quickly in mosquito bite-naïve mice, it is unlikely that the 
adaptive immune responses would play a significant role in arboviral enhancement 
in these models. This, in addition to the fact that mosquito bite driven enhancement 
of arboviruses has been observed in mice that lack adaptive immune responses, 
suggests that alternative mechanisms must be responsible for mosquito bite 
dependent arboviral enhancement [95]. 
 
1.7.1.4 Alternative mechanism suggestions to arboviral enhancement 
 
Apart from the hypothesis mentioned above, there are a few other speculations on 
the mechanisms by which mosquito saliva enhances arbovirus infection. It has been 
speculated that the microbiota present in mosquito saliva may elicit the 
inflammatory response required for arboviral enhancement. This idea was 
strengthened by the discovery that the salivary glands of Anopheles culicifacies 
mosquitoes harbour a larger diversity of microbiota than the gut [452]. Whilst this 
is an interesting theory, it has yet to be investigated. Another study suggested that 
serine proteases present in mosquito saliva may alter virus infectivity by proteolyzing 
extracellular matrix proteins that aid infection of cells by increasing cell attachment 
and cell entry [450].  
 
1.7.1.5 Pre-existing immunity to vector saliva 
 
In terms of the adaptive immune response, it remains unclear whether it plays a role 
in mosquito bite dependent arboviral enhancement. Whilst a couple of studies have 
demonstrated that mosquito bites trigger a Th2 immune response which enhances 




that bite mediated enhancement occurs too early for the adaptive immune response 
to play an important role in naïve individuals. Furthermore, a study investigating the 
pre-sensitization of mice to Culex tarsalis mosquito saliva and its subsequent effect on 
WNV infection by mosquito saliva, observed no significant difference between naïve 
and pre-sensitised mice [447]. 
 
1.7.1.6 Mosquito saliva composition 
 
Mosquito saliva is a complex cocktail of molecules. Transcriptome analysis of female 
Ae.aegypti mosquito salivary gland transcripts have identified hundreds of individual 
genes; with the function of many remaining unknown [453]. As a general rule, all 
hematophagous arthropods contain at least one compound each with anticlotting, 
antiplatelet, and vasodilatory properties; with the majority containing multiple 
molecules with similar properties which can vary greatly between species. For 
example, Aedes mosquito saliva has been found to contain a vasodilatory tachykinin 
decapeptide named sialokinin [454], whilst instead, Anopheles mosquito saliva has 
been found to contain a ∼65 kDa vasodilatory peroxidase, which is known to disrupt 
norepinephrine and serotonin which can be skin vasoconstricting agents [455]. In 
terms of anticlotting molecules, the majority of the Aedes genus utilises an inhibitor of 
factor Xa which is a member of the serpin family [456], whilst Anopheles mosquitoes 
utilise a different  smaller anticoagulant which is unrelated to other known peptides 
[455]. There are numerous differences between similarly acting compounds found 
in different hematophagous vector species; differences that can probably be 
attributed to early lineage diversions. For example, as was discussed in section 
1.4.1.4,  Aedes and Anopheles lineages diverged approximately 150mya which is 
approximately 100 million years prior to the expansion of mammals. This is of 
significance as it has been suggested that any hematophagous insects that diverged 
prior to the radiation of mammals have a considerably higher variation in their 
sialome than species that diverged afterwards [457].  
 
Interestingly, certain transcripts appear to exhibit differential expression between 
male and female mosquitoes. In the case of Ae.aegypti mosquitoes, 207 transcripts 
upregulated in the salivary gland were discovered to be female specific. Several of 




implicated in the act of blood feeding and the alteration of host physiology [458]. 
Complicating things further is the observation that infection of mosquito salivary 
glands, as well as the act of blood feeding, appears to alter the levels of transcription 
of certain transcription factors [459] [460] [461] [462]. 
Following the discovery that mosquito saliva enhances arboviral infection several 
studies have attempted to specify which compound of mosquito saliva is responsible 
for this phenomenon. Therefore, I will briefly mention a few examples of individual 
proteins that have been suggested so far, as well as discuss their effects on the host 
host response. 
LTRIN 
One factor that has been suggested to play a role in facilitating arboviral 
enhancement is a factor the authors named LTRIN due to its ability to interfere with 
lymphotoxin-β receptor (LTβR) signalling. LTRIN was discovered to be 
upregulated in the salivary glands of mosquitoes following a blood meal. LTβR is 
involved in the homeostatic maintenance of lymphatic and lymph node structures 
and has previously been found to be implicated in chronic inflammatory disease. 
However, due to the early time point of arboviral enhancement, it remains unclear 
if LTRIN can be playing a key role as the study in question only investigated viral 
enhancement at day 7 following co-injection of Zika with LTRIN [463].  
NeSt1 
Utilizing a yeast-display library accompanied by an antigenic salivary gland screen, 
a recent study discovered a previously undescribed SG protein; NeSt1 (neutrophil 
stimulating factor 1). NeSt1 was found to upregulate IL1β, CXCL2 and CCL2 in 
vivo. Interestingly, passive immunization of mice with NeSt1 antiserum resulted in a 
reduction of the expression of  IL1β, CXCL2 and CCL2 whilst simultaneously 
preventing the infiltration of immune cells such as neutrophils to the site of 
inflammation. Pre-immunization to NeSt1 also significantly reduced the number of 
mice succumbing to ZIKV infection [464]. This study further supports the theory 
put forward in the Pingen et al paper [95], that host responses to bites/saliva are 





Similarly to the discovery of NeSt1, AgBR1 was also discovered using a yeast surface 
display screen. AgBR1, or Ae.aegypti bacteria responsive protein 1, which is 
homologous to An.gambiae bacteria responsive protein 1 (also called AgBR1) was 
found to upregulate IL-6. Injections with AgBR1 antisera also appeared to confer 
some protection against ZIKV infection. However, AgBR1 appeared to have 
minimal effect on ZIKV pathogenesis when co-injected alongside the virus [465]. 
D7 
Another molecule that has been suggested to be implicated in viral enhancement is 
D7. Unlike the previous examples D7 has not been suggested to be implicated in 
host responses to saliva. Instead the 45-kDa sialylated saliva glycoprotein, belonging 
to the D7 protein family, was discovered to form complexes with DENV in vitro 
thereby enhancing its internalization into host cells [466]. However, a contradicting 
study has demonstrated that D7 inhibits DENV infection in vitro and in vivo by direct 
neutralization of virus particles via binding, or, by inhibiting immune cell infiltration 
to the site of inflammation [467]. 
CLIPA3 
CLIPA3 is a serine protease which has been demonstrated to enhance the 
dissemination of DENV. Serine proteases are capable of proteolyzing the 
extracellular matrix proteins of cells, and thereby enabling viral attachment. Authors 
also demonstrated that knocking down CLIPA3 in mosquitoes utilizing siRNAs 
resulted in a reduction of SGE dependent DENV enhancement in vitro [450]. 
As mosquito salivary components are numerous and highly diverse, some proteins 
that appear to be implicated in mosquito saliva dependent arboviral enhancement, 
when tested in isolation, appear to counter act each other; with some factors 
enhancing or inhibiting immune responses. Therefore, this suggests that it is unlikely 
that one single salivary factor is responsible for viral enhancement, but instead the 






1.7.2 Tick saliva 
 
Similarly to mosquitoes, ticks will inject saliva from their salivary glands during 
feeding, and like mosquito saliva, tick saliva also aids the transmission of arboviruses; 
a phenomenon commonly referred to as saliva assisted transmission (SAT)[468]. 
Tick saliva has been found to  consist of a mixture of water, ions, non-peptidic 
molecules, a range of tick peptides and tick proteins, several host proteins as well as 
exosomes. This cocktail of molecules has been attributed to aid in tick water balance, 
ensuring maintained attachment and minimal leakage, modulation of host responses, 
mate guarding and SAT. In order to circumvent host responses, ticks, like 
mosquitoes, also inject a mixture of antihemostatic, vasoconstriction modulators and 
anticoagulants [469]. 
 
Initially, the ability of tick saliva to assist viral transmission, was first discovered in 
the transmission of an influenza like virus known as Thogoto, in guinea pigs. Unlike 
mosquito borne viruses, tick borne virus transmission relies on the co-feeding of 
uninfected and infected ticks on non-viremic hosts. This non-viremic/co-feeding 
transmission mechanism relies on tick saliva for successful transmission between ticks 
[470]. In terms of immune responses triggered in response to tick bites, tick 
attachment results in the activation and degranulation of mast cells. In order to 
circumvent this response, ticks utilise compounds that will remove released histamine 
and serotonin. Tick saliva also directly inhibits the expression of pro-inflammatory 
cytokines via the use of evasins [471]. In addition, tick saliva has been found to 
interfere with DC differentiation, maturation, function and migration [471] [472] 
[473]. Importantly, tick saliva also inhibits the expression of IFNs which indirectly 
aids arboviral infection [474] [475]. Overall, tick saliva appears to predominantly 
supress the immune responses of its host, most likely in order to avoid detection and 
to facilitate blood feeding. This immunosuppression appears to indirectly aid the 
transmission of tick borne disease [476]. 
 
1.7.3 Sandfly saliva 
 
Sandfly saliva, specifically that of Lutzomyia longipalis, was the first type of 




arthropod borne disease infection; specifically that of Leishmania major [477]. The 
composition of sandfly saliva differs between species, but differences can also be 
detected between distinct populations. Similarly to the saliva of other 
hematophagous insects, sand fly saliva contains molecules that will aid in its 
acquisition of a successful blood meal including anticoagulant, vasodilatory and 
immunomodulatory compounds [478]. In terms of immunomodulatory effects, 
saliva of several sandfly species, have been observed to enhance influx of 
macrophages to site of infection which can aid transmission of Leishmania, as this 
parasite preferentially infects and grows within macrophages [479] [480]. Sand fly 
saliva has also been found to enhance the production of anti-inflammatory cytokines 
whilst the secretion of pro-inflammatory cytokines is inhibited [481]. 
 
Generally, it appears as if arthropod borne pathogen enhancement by the 
accompanied saliva during their transmission, is a phenomenon that applies to the 
majority of hematophagous insects. However, evidence shows that saliva 
composition varies greatly between species, and even between different genus, 
populations and between the sexes. This is reflected by the observation that different 
hematophagous insects facilitate pathogen enhancement via different mechanisms. 
Further research is required to improve our understanding of arboviral 
enhancement. 
 
1.8 Thesis aims 
 
Mosquito borne viruses make up a significant medical and economic burden on 
human society. Despite this, very few effective vaccines and treatments are available 
for the majority of arbovirus associated diseases. The unpredictable nature of these 
types of viruses (discussed in section 1.5.6) which makes future outbreaks problematic 
to foresee, in addition to the difficulty in the accurate diagnosis of specific disease 
due to the similarities in clinical manifestations, highlights the need for the 
development of novel treatments targeting arbovirus infections.  
 
Previous studies, as has been discussed in detail in section 1.7, have shown that 
arbovirus infection of mammals is enhanced by the presence of a mosquito bite at 
the inoculation site, in comparison to the experimental administration of virus via 




elicited against the bite appearing to play a key role in this enhancement effect. 
Furthermore, the experimental inoculation, via a needle, of mosquito saliva 
alongside virus inoculum, in the absence of the trauma caused by a mosquito bite, 
also has the ability to enhance viral infections. Considering that mosquito 
bites/saliva modulate the infection of many distinct viruses, investigating and 
subsequently targeting these common aspects of mosquito borne virus infections, 
could provide a strategy that prevents the occurrence of serious disease for multiple 
genetically distinct arboviruses. Therefore in this thesis we have studied the 
mechanistic basis of these observations. 
 
Whilst it has been demonstrated that mosquito bites/ saliva enhance virus infection, 
it remains unclear which specific components of the saliva that are responsible for 
viral enhancement. In addition, whilst previous studies have indicated that host 
responses elicited against mosquito bites/ saliva are important for virus enhancement 
to occur, it remains unclear which specific host responses are required for viral 
enhancement. Determining the factor within saliva that instigates virus 
enhancement, as well as the specific host responses elicited against saliva that will 
trigger virus enhancement, may provide us with potential treatment targets 
preventing serious disease development. 
 
Furthermore, whilst viral enhancement of several mosquito borne viruses has been 
demonstrated to occur by the bites/saliva of their corresponding mosquito vector 
species, to date, no one has investigated whether mosquito bites/ saliva from 
mosquitoes enhance virus infection of viruses that they do not transmit. Investigating 
this would help us understand whether all mosquito species are capable of enhancing 
virus infection, and whether the host mechanisms and salivary components 
implicated are the same for all mosquito species. It is important to understand 
whether this is the case if we are to successfully develop a treatment targeting 
multiple arbovirus infections. It is possible that the enhancement of virus infections 
are highly species/virus specific. This factor could then contribute to the 
determination of mosquito vector competence.  
  
In this thesis we hypothesized that extracted mosquito saliva enhances mosquito 





Therefore the aims of this thesis are: 
 
1. To investigate which components of the mosquito saliva are 
important for facilitating saliva dependent virus enhancement. 
 
2. To investigate which aspects of the host immune response 
against mosquito saliva are important in facilitating arbovirus 
enhancement.  
 
3. To investigate whether the ability of mosquito saliva to modulate 
infection has an impact on mosquito vector competence. 
 
With mosquito bites and the accompanied injection of mosquito saliva alongside 
viral inoculation in the skin being the common aspect shared by the transmission of 
all mosquito borne viruses, a better understanding of the mechanisms responsible for 
arboviral enhancement could lead to the development of a novel treatment that 
blocks the enhancing effect from occurring in the first place; thereby reducing the 


















2.1 General reagents  
 
Plastics: All tissue culture plastics used for experiments were purchased from WVR 
(WVR, USA) or Corning (Corning, Loughborough, UK) unless indicated otherwise. 
1.5 ml microcentrifuge tubes were purchased from Eppendorf (Stevenage, UK). All 
tips were filter tips and purchased from starlabs (UK). QPCR plates were purchased 
from Sigma Aldrich (USA). 
 
PBS: Dulbecco's Phosphate-Buffered Saline (DPBS) without magnesium was 
purchased from Gibco (ThermoFisher Scientific, UK). 
 
PBSA: 0.75% bovine serum albumin (BSA) (Invitrogen) with PBS (Gibco, UK). 
 
PFA: 10% PFA (paraformaldehyde) was purchased from ThermoFisher Scientific 
(ThermoFisher, USA). 
 
10x TAE Buffer: 10x TAE buffer (Tris base, acitic acid and EDTA) was purchased 
from ThermoFisher Scientific (ThermoFisher, USA). 
 
Toluidine Blue: Crystalized toluidine blue was purchased from Merk (Sigma-
Aldrich, USA). Toluidine blue was used as a 0.1% solution by mixing 0.1g of 
toluidine blue in 100ml of deionized water. 
 
Tissue culture media: 
 
DMEM – Dulbecco's Modified Eagle Medium (DMEM) (Gibco, life technologies, 
UK) was supplemented with 10% FCS (Gibco, life technologies, UK), 10% tryptose 
phosphate broth (TPB) (Sigma Aldrich, USA), 5 ml Pen/Strep 
(Penicillin/streptomycin) (Gibco, life technologies, UK) and 5ml Glutamine broth 
(Sigma Aldrich, USA). 
 
GMEM – Glasgows Minimum Essential Medium (GMEM) (Gibco, life 
technologies, UK) was supplemented with 5% fetal bovine serum (Thermo Fisher, 




RPMI – Roswell Park Memorial Institute (RPMI) media was supplemented with 
5ml Glutamax (ThermoFisher, USA), 10% FCS (Gibco, Life Technologies, UK) 1.4 
ml 1M HEPES, 550μl 10-5M β-mercaptoethanol (Sigma Aldrich, USA), 5ml 
Penicillin/streptomycin (Thermo Fisher, USA), 500μl gentamycin (Thermo Fisher, 
USA). 
 
L-15 – L-15 medium was supplemented with 10% FBS (Thermo Fisher, USA), 10% 
TPB (Thermo Fisher, USA) and 2% Pen/Strep (Thermo Fisher, USA). 
 
DMEM/F12 – DMEM (Gibco, life technologies, UK) and Ham’s F12 nutrient 
mixture (Gibco, life technologies, UK) were mixed 1:1 and supplemented with 10% 
FCS, 1% Pen/Strep, 0.1% gentamycin (Thermo Fisher, USA) and 1% Glutamine 
broth (Sigma Aldrich, USA). 
 
Tissue digestion buffer: Tissue digestion media for flow cytometry was made up 
from 0.9ml of Hanks balanced saline solution (HBSS) (Sigma Aldrich, USA), 
1mg/ml of Collagenase D (Roche/Sigma Aldrich, USA) (skin and spleen only), 
0.5mg/ml of Dispase II (Roche/Sigma Aldrich, USA) (skin and spleen only), 
0.1mg/ml DNase I (Roche/Sigma Aldrich, USA) and 0.1mg/ml liberase 
(Roche/Sigma Aldrich, USA) (lymph node only). 
 
FACS buffer: 500 ml PBS without Ca2+ and Mg2+ was mixed with 0.5% FCS 
and 2mM EDTA (Invitrogen). 
 




Wild type C57BL/6j mice bred in-house at the SBS at the University of Leeds were 
used in all in vivo experiments unless stated otherwise. Mice were maintained at SBS 
under specific pathogen free conditions and used between 4 and 12 weeks of age 
unless stated otherwise. BALB/C mice were purchased from Charles River 




procedures were carried out in accordance with the United Kingdom Home Office 
regulations under the authority of the appropriate project and personal license. 
 
2.3 Cell Culture 
 
BHK-21 cells were used to grow-up virus stock and determining viral titres via 
plaque assays. Cells were kept at -195oC for long term storage. For de-thawing, 37oC 
water bath was used following immediate transfer to a T75 flask containing media. 
BHK-21 cells were cultured at 37oC with 5% CO2 in GMEM media supplemented 
with 10% TPB, 5% FCS (Gibco Life technologies) and 1% Pen/strep.  
 
Aedes albopictus mosquito derived C6/36 cells were used for growing virus stocks. Cells 
were kept at -195oC for long term storage. For de-thawing, 37oC water bath was 
used following immediate transfer to a T75 flask containing media. C6/36 cells were 
cultured at 28oC at 0% CO2 in L-15 media (Gibco Life technologies) supplemented 
with 10% TPB, 10% FCS and 1% Pen/strep.  
 
Mouse Embryonic Fibroblasts from C57BL/6 mice (cell biologics, USA) were kept 
at -195oC for long term storage. For de-thawing, 37oC water bath was used following 
immediate transfer to a T25 flask pre-coated with 0.2% gelatine (cell biologics, USA) 
and containing media. MEF cells were cultured at 37oC at 5% CO2 in DMEM 
media supplemented with 10% FCS, 1% Pen/Strep and 1% Glutamax (Gibco Life 
technologies).  
 
2.3.1 M-CSF Macrophages 
 
Macrophages were extracted from C57BL/6 mouse bone marrow by flushing cells 
from the femur using a 26-gauge needle with cold PBS. Cells were then passed 
through a 40μm cell strainer in order to remove any potential debris. Cells were 
cultured at 37oC at 5% CO2 in DMEM/F12 media (Gibco Life technologies) 
supplemented with 10ng/ml M-CSF (Peprotech) to ensure monocytes differentiate 
into macrophages, 10% FCS, 1% Pen/Strep, 1% Glutamax and 0.1% Gentamycin. 
4x105 cells were seeded in 10ml media per sterile plastic petri dish used. New media 
was added to the cells after 3 days. 7 days after extraction cells were pooled by 




enzymatic cell dissociation solution) to each dish. Plates were then incubated in the 
fridge for 5min to make cells constrict. Cells were then gently scraped of the plastic 
whenever necessary. All cells were then pooled, counted and centrifuged at 300g for 
5 minutes before being seeded at a concentration of 2x105 per well in a 24-well plate 




Semliki Forest virus 4 (SFV4) and Semliki Forest virus 6 (SFV6) stocks were 
generated from plasmids containing the genomic sequence provided by Andres 
Merits (University of Tartu). ONNV-2SG-ZsGreen with ZsGreen cloned between 
native and duplicated SG promoters of ONNV icDNA using AvrII (5’, ligated to 
Nhe I) and Eco RI (3’) restriction sites and pCMV-SFV6-2SG-GLuc (Gaussia 
luciferase) plasmid were kindly provided by Margus Varjak (CVR, Glasgow). SFV6 
Gluc has a Gluc marker inserted under a duplicated subgenomic promoter 
positioned at 3’ direction of structural reading frame. Plasmids containing the 
genomic sequence of all viruses were electroporated into BHK cells to generate 
infectious virus with 2 pulses at 250V for 0.8S. Infectious virus of SFV6 Gluc was 
aliquoted with cellular debris to allow for improved virus uptake by macrophages in 
vitro. Wild type Zika virus from Recife, Brazil was kindly provided by Prof. Alain 
Kohl at the university of Glasgow. Virus was grown in Vero cells and BHK-21 cells, 
supernatant was collected then centrifuged to remove cell debris and virus titers were 
determined by plaque assays on BHK-21 cells. All viruses used in vivo were passaged 
once through C6/36 cells. Supernatant from C6/36 cells was collected and 
infectious virus present in the supernatant was titrated via plaque assay in BHK-21 
cells. 
 
2.5 Plaque Assays 
 
For titrating virus stocks and for the quantification of viraemia plaque assays were 
performed. For the plaque assays BHKs were used at an 80% confluency in a 12-
well plate with virus serial dilutions made with 0.75% PBSA (PBS with 0.75% bovine 
serum albumin). 200μl virus was added to each well and left for an hour whilst 
rocking occasionally. 2 ml 2 x MEM medium (Gibco Life technologies) with 4% FCS 




mixed with 1.2% Avicel (FMC Biopolymer, UK), which is a low-viscosity overlay 
medium used in viral plaque assays, was then added to the cells. Cells were incubated 
for 2 days at 37oC with 5% CO2. After 2 days cells were fixed in PFA for an hour 
and stained with 0.1% Toluidine Blue (Sigma Aldrich) for at least 30min. PFU was 
calculated per ml using the following equation: 
 
PFU/ml= average number of plaques (in duplicate) 
amount of inoculum x dilution factor 
 
2.6 Mosquito rearing 
 
Aedes aegypti (Liverpool strain) mosquitoes were kept in incubator with 80% humidity 
at 28oC with a 12-hour light/dark cycle. Eggs on filter paper, kindly provided by Dr. 
Emilie Pondeville at the University of Glasgow, were placed in trays (Dutscher 
Scientific) containing approximately 1.5 cm of water to hatch overnight. Larvae were 
then fed with Go-cat cat food until pupation. Ae.albopictus (La Providence strain) and 
Cx.pipiens (slab strain) were reared under the same conditions as Ae.aegypti. 
 
Anopheles gambiae (Kisumu strain) mosquito eggs were kindly provided by Dr. 
Francesco Baldini at the University of Glasgow. The eggs were hatched the same 
day of arrival by placing in water. Ground Tetramin fish flakes were fed to the larvae 
the first days following which the larvae were fed with tetramin pellets until pupation. 
When pupae formed these were picked and placed in small water filled containers 
and left to emerge into BugDorm mosquito cages (Watkins and Doncaster). All adult 
mosquitoes were fed a 10% sucrose solution. Mosquitoes were ready for salivations 
and biting experiments 21 days post hatching. An.stephensi (SDA-500 strain) were 
reared under the same conditions as An.gambiae. 
 
2.6.1 Mosquito Antibiotic Treatment and validation 
 
An antibiotic treatment was developed and validated. Mosquitoes were given a 10% 
sugar solution containing Penicillin/streptomycin (Gibco) at 200 U per ml, 
Gentamycin at 200 µg/ml Gentamycin (Sigma), and Tetracycline at 100 µg/mL for 
1 week.  The treatments efficiency was then validated by dipping treated and 




were then shaken with one 7mm stainless steel bead on the Tissue Lyser for 10min 
at 50Hz. The samples were then plated on agar plates and left overnight in an 
incubator at 28oC to allow for bacteria to grow before counting. [482] 
 
2.7 In vivo model 
 
Mice were anesthetized with 0.1ml/10g of Sedator/Ketavet via intraperitoneal (I.P.) 
injection and placed on foil on top of the mosquito cages with the dorsal side of one 
or both hind feet exposed to allow no more than 5 mosquitoes to feed. Great care 
was taken to cover the toes with tape to prevent mosquitoes biting. Mosquitoes were 
left to feed until fully engorged. Virus injections of either C6/36 derived SFV6 (250 
PFU) or SFV4 (10000 PFU in 1μl) were then made accordingly directly at the bite 
site with a 5μl 75N syringe, 26ga (Hamilton) using small RN ga33/25mm needles 
(Hamilton). The viruses were diluted in PBSA to 1x107 PFU/ml. Saliva injections 
were made at a concentration of 5 mosquitoes-worth of saliva per injection.  
 
2.7.1 Survival and mice monitoring 
 
Mice subjected to neurotropic virus infections were monitored 4 times daily and 
weighed every morning for the entire duration of the experiment. Mice 
demonstrating 2 or more of the symptoms listed in table 2.1 were immediately culled.  
Surviving mice were culled at day 15 post infection via schedule 1. 
 
Moderate Severe 
Loss of body weight of up to 
20% 
Loss of body weight greater than 25% 
Reduction in food and water 
consumption of up to 40% less 
than normal for 72 hours 
Reduction in food and water consumption of 
up to 40% less than normal for 7 days or 
anorexia (complete inappetence for 72 hours) 
Staring coat-marked piloerection Marked piloerection accompanied with other 
signs of dehydration including skin tenting 
Subdued even when provoked. 
Limited peer interaction 
Unresponsive to activity and provocation 




Vocalisation if provoked Distressed – persistent vocalisation 
Persistent oculo-nasal discharge  Persistent and abundant oculo-nasal 
discharge  
Intermittent abnormal breathing Laboured respiration 
Intermittent tremors Persistent tremors 
Intermittent convulsions Persistent convulsions 
No self-mutilation Self-mutilation 
Intermittent prostration (< 1 
hour) 
Prolonged prostration (> 1 hour) 





Mice were culled via a schedule 1 method. Tissues dissected depended on the 
experiment but most commonly included, skin from foot, popliteal lymph node and 
spleen. Blood samples were also collected from the ventricles. Tissue samples 
collected were stored in 0.5ml RNAlater (Sigma Aldrich, USA) in 1.5ml tubes, with 
the exception of spleen and brain samples that were cut in half and stored in 1ml of 
RNAlater to enable complete permeabilization of the RNAlater in to the tissue.  All 
samples were left in RNAlater for a minimum of 16 hours to prevent RNA 
degradation. Samples were then stored at 4oC short term storage or at -80oC for long 
term storage. Blood samples were centrifuged and serum was collected and stored at 




Vascular permeability, vascular leakage and the formation of oedema can be 
successfully measured by the use of Evans Blue (EB) dye. EB is a dye with a molecular 
weight of 961Da which binds strongly to serum albumin when injected into a mouse 
[483, 484]. The EB that’s bound to albumin will then remain stable in the blood and 
can then spread throughout the entire body of the mouse often causing it to turn 
blue. Selectively permeable barriers, such as the endothelial cell barrier of the blood 
vessels, normally only allow specific micromolecules to pass and not macromolecules 




to an increase in the permeability of the barrier allowing the EB-bound albumin to 
cross causing a blue-stained oedema to form [485]. In order to determine the amount 
of fluid accumulation and vascular leakage in the skin, mice were injected 
subcutaneously with 200μl of 1% Evans Blue. 
 
Skin samples were acquired 30min, 3 hours or 6 hours post challenge and placed in 
250μl of formamide and left to soak overnight at 4oC. Skin samples were then 
removed from the solution and the dye-stained formamide solution was taken and a 
10-fold serial dilution was created by mixing the samples with water. Levels of fluid 
accumulation was then determined using colorimetric measurement of dye 
concentration at 620nm using the Multiskan Ex (Thermo scientific). Blood samples 
were acquired and centrifuged. Amount of dye present in the serum was used as a 
control for amount of dye present in each mouse. 
 
In order to ensure the complete removal of any residual dye from the blood in the 
skin tissue perfusions were carried out immediately after acquiring blood samples. 
During this process, using a 50ml syringe of PBS with a 26-gauge needle which was 
inserted into the ventricles and the PBS pumped in to ensure the flush out of blood 
from the entire circulation. 
 
2.7.3.1 Inhibition and induction of oedema 
 
Oedema was induced in the absence of any mosquito factors via the use of Histamine 
dihydrochloride. For this purpose Soluprick (ALK, UK) was injected as a 1μl sub-
cut injection at a concentration of 10mg/ml using a 5μl 75N syringe, 26ga 
(Hamilton) with a small RN ga33/25mm needles (Hamilton). Oedema was inhibited 
using Adrenaline (Epinephrine) Xylocaine 1% containing lidocaine and adrenaline 
1:200,000 (Aspen, Ireland). 4μl of the substance was given as a local subcutaneous 
injection prior to exposure to potential oedema inducing agents such as mosquito 
bites, saliva or histamine. An additional 4μl of adrenaline were administered 3h post 
exposure. Antihistamines were administered as an IP injection 1 hour prior to 
challenging mice with mosquito saliva or histamine. Antihistamines were 
administered as a mixture of 0.5mg/kg Cetrizine hydrochloride (sigma), 5mg/kg 





2.7.4 Sensitization of mice to mosquito saliva 
 
For sensitization experiments BALB/c mice were utilised. Sensitized mice were 
subjected to 5 mosquitoes worth of saliva injections in 1 μl of PBSA weekly for 4 
consecutive weeks. Injections were made on dorsal side of left hind foot. A group of 
mice were exposed exclusively to PBSA injections weekly to rule out sensitization to 
BSA.  
 
2.8 Saliva extraction 
 
Mosquito saliva was acquired via forced salivation of Aedes aegypti and An.gambiae 
mosquitoes which had been starved for one day prior to salivation. Salivation was 
then done by aspiring mosquitoes with a custom made hand-held hoover and 
sedating them on ice. Females and males were separated based on certain 
characteristics including fluffier antennae of males, larger torso of females (see figure 
2.1).  
 
Figure 2.1. Physical differences between male and female Ae.aegypti 
mosquitoes.  
Illustration highlighting characteristic differences between male and female Ae.aegypti 
mosquitoes. Note the fluffier antennae of the males and the considerably longer palps. These 





Wings and legs were then removed under a dissection microscope and their 
proboscis was placed in a p10 tip containing 0.5μl immersion oil (Cargille 
Laboratories, USA). Mosquitoes were then left to salivate for up to an hour before 
tips were placed in an Eppendorf tube and centrifuged (see figure 2.2). Saliva droplets 
were then pooled and stored at -80oC. Before use, droplets of saliva were carefully 
pipetted out of the oil under microscope and diluted in PBSA. 5 mosquitoes worth 
of saliva was utilised per injection unless stated otherwise. Majority of saliva samples 
were kindly provided by Dr. Emilie Pondeville at the University of Glasgow whilst 
the remainder were extracted at the University of Leeds. 
 
Figure 2.2. Images illustrating the mosquito salivation process.  
 
2.9 Infection of mouse skin explants 
 
Mice were culled via a schedule 1. Skin was then dissected from the hind feet and 
transferred into a 24 well tissue culture plate containing complete DMEM (Gibco, 
life technologies, UK) supplemented with 10% FCS (Gibco, life technologies, UK), 




(Penicillin/streptomycin) (Gibco, life technologies, UK) and 5ml Glutamine broth 
(Sigma Aldrich, USA). Explants were kept at 37oC with 5% CO2. 
2.10 Infection and saliva treatments of cells in cell culture 
 
Extracted and differentiated macrophages and MEF cells were seeded in 24 well or 
48 well plates. Cells were either pre-treated with saliva and then infected, or saliva 
was pre-mixed with the virus for 20min prior to its addition to the cells. 1.8 
mosquitoes worth of saliva was used per well. Cells were infected with SFV6 Gluc 
virus at an MOI (multiplicity of infection) of 0.01, 0.1, 1 or 5. Supernatant was then 
acquired at 6, 24 and 48 hpi in order to monitor the progression of infection. 
 
2.11 RNA purification  
 
2.11.1 Tissue samples 
 
RNA extractions were performed using the RNA mini purification kit by life 
technologies by following the protocol provided with the kit. All tissue samples were 
lysed in 1ml Trizol reagent (QIAGEN, UK) and shaken with 7mm stainless steel 
beads (QIAGEN, UK) on a Tissue Lyser (QIAGEN, UK) at 50Hz for 10 minutes to 
ensure complete lysis of all tissues. 0.2ml chloroform was then added to all samples 
which were then inverted 15 times to allow for gentle mixing of the solutions. 
Afterwards, samples were centrifuged at 12,000g for 15 minutes at 4oC in order to 
separate the mixture into a lower red phenol-chloroform phase and a colourless 
upper aqueous phase. The upper aqueous phase aqueous phase, containing the 
RNA, was transferred to a new tube containing an equal amount of 70% ethanol 
(Sigma Aldrich, USA). The samples were vortexed briefly to ensure no precipitate 
was formed prior to transferring of the sample to the RNA column.  2 wash steps 
each of wash buffer I and wash buffer II were then conducted, were 350μl or 500μl 
respectively was added to the column which was then centrifuged for 15 seconds at 
12,000g and the flow through discarded. An on column DNAse step was included in 
between the first and second wash with wash buffer I to ensure all genomic DNA 
contamination was degraded to prevent SYBR green from binding to it. During this 
step 80μl of DNase mixture (10μl DNase, 70μl reaction buffer) was added to each 




the column was centrifuged for a minute to ensure the column was dry before eluting 
the RNA in RNAse-free water by the addition of 30μl of RNase free water for lymph 
node samples, 60μl for skin samples and 100μl for brain and spleen samples and left 
to incubate at room temperature for 1 minute prior to centrifugation at 12,000g for 




All cell samples were lysed using the lysis buffer contained in the RNA micro kit (Life 
Technologies) with 1% β-mercaptoethanol (Sigma Aldrich, USA). Samples were 
then centrifuged using QIAshredders (QIAGEN) to ensure complete lysis of cells. 
RNA extractions were then made through on column purifications in the same way 
as tissue samples, but using the Purelink RNA micro kit. 
 
2.11.3 Measurement of RNA quality and degradation 
 
RNA samples were routinely analyzed via nanodrop (Spectrophotometer, ND-1000) 
blanked with 1μl. Purified RNA was stored at -80°C.  
 
2.12 cDNA synthesis 
 
Approximately 1μg of RNA in a volume of 9μl of RNAse free water was moved to a 
96 well plate (StarLab, UK) and kept on ice. Using the “Applied Biosystems High 
Capacity RNA to cDNA” kit (AppliedBiosystems, ThermoFisher, USA), an enzyme-
buffer mix was made consisting of 1μl of 20X RT Enzyme Mix which was mixed 
with 10μl of 2X RT Buffer Mix per reaction in a 2ml microcentrifuge tube. 11μl of 
the enzyme-buffer mix was then added to each well containing RNA resulting in a 
final reaction volume of 20μl. After a brief centrifugation of the plate in order to 
ensure  the removal of any bubbles, the plate was sealed with a StarSeal® aluminum 
foil cover (StarLab, UK). The plate was then transferred to the GeneAmp® 
PCRsystem2700 (AppliedBiosystems, ThermoFisher, USA) PCR machine where it 
was incubated at 37°C for 60 minutes then stopped by heating to 95°C for 5 minutes. 








The method of quantitative polymerase chain reaction was utilized in order to 
measure the relative expression of a range of transcripts during this thesis. A list of 
all primers targeting these transcripts can be found in table 2.2. RT-qPCR combines 
the polymerase chain reaction (PCR) technique with detectable fluorescent 
molecules such as SYBR green (used in this thesis) which binds to double stranded 
DNA. Real time detection of fluorescence allows us to correlate the concentration of 
DNA with the florescence intensity. This correlation is measured via the cycle 
threshold (Ct) which indicates the number of PCR cycles required in order for the 
fluorescence to exceed background values. Generally this means that the higher 
DNA concentration, the less PCR cycles are required before the reaction reaches the 
Ct cycle threshold.  
 
2.13.1 Primer design 
 
All primers used in this thesis are listed in table 2.2. Primers were designed using 
Primer3 software, version 4.0 (bioinfo.ut.ee); all of which were designed to meet the 
following criteria:   
 
1. 18 and 23 base pairs (bp) in length 
2. 40% and 65% guanine (G) and cytosine (C) content  
3. Melting temperatures (Tm) of primers between 59.5oC and 61oC 
4. maximum self-complementarity of 2 
5. maximum 3’ prime end self-complementarity of 1  
6. amplicon size of less than 150 base pairs 
7. no GC clamp at the 3’ end  
 
Exceptions to these rules were made if no primers were suggested by the software. 
For example the minimum Tm was altered to 59°C or the maximum self-
complementarity was altered to 3 if no primer was found. 2 sets of primers were 
designed for each gene; the first was used for quantitative PCR and the second was 
used to generate PCR products to be used for the making of standard templates. The 
standards’ primers were designed to amplify a section where the qPCR primers could 




Sigma Aldrich (USA) and reconstituted upon arrival to a final concentration of 
0.1nm/µl. 
 
2.13.2 Generation of DNA standards for absolute quantitative QPCR 
 
In this project relative quantities of the specific genes of interest were used as absolute 
quantities were not necessary due to the fact that all experiments were specifically 
designed to be comparable to internal controls via a fold change analysis. Relative 
quantification was calculated via the use of a standard curve which functions as a 
calibrator where the values estimated for each sample are divided by the arbitrary 
value that has been assigned to the standard. The standards used were generated via 
a PCR reaction of a random sample known to contain the gene of interest in 
combination with specific primers specifically designed for the gene of interest. 4μl 
of the sample were mixed with 0.5μl each of the forward and the reverse primers as 
well as 45μl RED PCR master mix Rovalab, VH-Bio, UK) containing MgCl2, 1mM 
dNTPs and Taq DNA polymerase. A PCR reaction was then undertaken using a 
GeneAmp 9700 (Applied Biosystems, ThermoFisher, USA) or Venti 96 (applied 
Biosystems, ThermoFisher, USA) using the following programme:  
 
1. 3 minutes at 94°C  
2. 15s at 94°C for denaturing of DNA 
3. 10s at 60°C for annealing of primers  
4. 50s at 72°C for extension 
5. 7 minutes at 72°C 
6. Held at 4°C  
 
The PCR product was run on a 2% agarose gel with ethidium bromide at 80 -100V 
for 1 hour. A DNA ladder was used to determine the molecular weight of the product 
and the bands were visualized using the ChemiDoc XRS+ gel imager (BioRad, 
USA). Primers were only purified if clear single bands were detected at the correct 
molecular weight. In the cases were no or multiple bands were observed new primers 






QIAQuick PCR product purification kit (Qiagen, Germany) was used for the 
purification of the PCR products. During this procedure the product was mixed with 
5 x volume of buffer PB. The mixture was then added to the spin column before 
being centrifuged. 750μl buffer PE was then added before a second centrifugation. 
After discarding the flowthrough the membrane was dried by the spinning of the 
column for 1 minute at 13,000g. The product was finally eluted in 50μl of elution 






Name    





18S Forward gactcaacacgggaaacctc 124 NR_003278.
1 Reverse taaccagacaaatcgctccac 
18S 
Standard 
Forward cgtagttccgaccataaacga 443 NR_003278.
1 Reverse acatctaagggcatcacagac
c 




Forward ccctcaccatcatcctcact 280 NM_013653 
Reverse tcagaatcaagaaaccctcta
tcc 




Forward atccctgcgagcctatcc 524 NM_021274 
Reverse aaacttagaactgacgagcct
ga 




Forward tggctaggctctgtgctttc 385 NM_010504 
Reverse ggaggttcctgcatcacac 




Forward atctggaggaactggcaaaa 597 NM_008337 
Reverse agatacaaccccgcaatcac 




Forward ggcttccatcatgaacaaca 399 NM_010510 
Reverse tcccacgtcaatctttcctc 










IFIT2 Forward tgcaccacactagcttgca 96 NM_008331.
3 Reverse gggatggaagcactcacagt 
IFIT2 
Standard 
Forward gcacctctatgtttgagcagtt 290 NM_008331.
3 Reverse gcagaaaagtcaaggcagga
a 
ISG15 Forward cgcagactgtagacacgctta 80 NM_015783.





Table 2.2. Primer list. List of primers, primer orientation, sequences, product 




Forward gtccgtgactaactccatgac 504 NM_015783.
3 
 Reverse tcccaaaagtcctccatacc 








Zika ENV Forward ggaggctgagatggatggt 148 KX_197192.
1 Reverse cagtgtttcagccgggatct 
Zika ENV 
Standard 
Forward aggcaaactgtcgtggttct 679 KX_197192.
1 Reverse tcagacccaaccacatcagc 




Forward cgcccagacagaagtcatag 484 NM_009140 
Reverse actcaccctctccccagaaa 









 Reverse atgtgctggtgcttcattca 




Forward cgcccagacagaagtcatag 484 NM_009140 
Reverse actcaccctctccccagaaa 
IL-5 Forward tcctgcctcctcttcctgaa 147 NR_003278.
1 Reverse accctgatgcaacgaagagg 
IL-5 
standard 
Forward acagagtgggcaatggaagg 422 NM_010558.
1 Reverse gggtatgtgatcctcctgcg 
IL-13 Forward tgccatctacaggacccaga 146 NM_008355.
3 Reverse cgtggcgaaacagttgcttt 
IL-13 
standard 
Forward gtgtctctccctctgaccct 358 NM_008355.
3 Reverse tgagtccacagctgagatgc 
CCL2 Forward ctcacctgctgctactcattca 153 NM_011333.
3 Reverse ccattccttcttggggtca 
CCL2 
standard 
Forward caccagcaccagccaact 519 NM_011333.
3 Reverse gcatcacagtccgagtcaca 
ONNV 
E1 










2.13.3 qPCR using SYBR green 
 
All RT-qPCR reactions in this project, were done using SYBRÒ green I (Quanta, 
ThermoFisher, USA) for the fluorescent labelling of DNA. SYBRÒ green is a 
fluorescent dye which binds nonspecifically to double stranded DNA whilst unbound 
SYBRÒ does not fluoresce. Unbound DNA can fluoresce when in a complex with 
double stranded DNA – with an excitation (λmax) of 497nm and an emission (λmax) of 
520nm. cDNA was diluted 1 in 5 in RNAse free water. This was done in order to 
prevent the interference of the RT buffer with the PCR reaction. Following this, a 
master mix was created made up of cDNA, primers, water and SYBRÒ green mix. 
For each individual sample, 1μl of cDNA was mixed with 4μl of RNAse free water, 
5μl SYBRÒ green I and 0.15µl of primer mixture containing both the forward and 
reverse primers; making a final volume of 10.15µl. 9μl of this mixture was then 
transferred to a 384 well plate (StarLab, UK). A triplicate or a quadruplicate 
technical replicate was made for each biological replicate. The generation of a 
standard curve was accomplished by the dilution of the 10-2 PCR standard in a10-
fold serial dilution. A non-template control (NTC) consisting of RNAse free water 
and the master mix was also included. After the loading of all the samples into the 
384 well plate the plate was briefly centrifuged at 200G for 15-30 seconds in order 
to ensure the removal of any potential air bubbles. Following centrifugation the plate 
was sealed with StarSeal Advance Polyolefin seals (Starlab, UK). The plate was kept 
at 4°C in the dark until the reaction.  
 
The PCR plates were finally run on an Applied Biosystems 7900HT or Applied 
Biosystems quantstudio 7 flex machine (AppliedBiosytems, USA). The PCR protocol 
consisted of the following steps: 
 
1. 94°C for 10 minutes 
2. 94°C for 3 seconds  
3. 60°C for 30 seconds 
4. Disassociation and melt curve (records fluorescence between the final 







Ct value was calculated automatically by the quantstudio software which detects the 
logarithmic phase of the PCR reaction. The threshold calculated was equal to the 
cycle where fluorescence exceeded background levels. Each samples relative quantity 
was calculated based on their position on the standard curve. The standard curve 
had to have an efficiency close to 100%, which was indicated by the coefficient 
R2³0.998 and a slope of 3.3. Melt curves were conducted in order to investigate the 
specificity of each primer as a single peak on a melt curve indicates that the primers 
are specific.  
 
2.13.4 Normalization of qPCR data 
 
In order to control for any potential differences in absolute quantities of nucleic acid 
between samples, the normalization of samples to a housekeeping gene was 
conducted. Samples can exhibit variations in nucleic acid quantities due to a range 
of different factors including differences in tissue size, partial degradation of sample 
(RNA or cDNA) during freeze thaw cycle. The housekeeping gene used on all 
occasions, unless stated otherwise, was the 18S gene which consists of ribosomal 
rRNA from the 18S ribosomal subunit. Using 18S as a housekeeping gene has the 
advantage that the gene remains stable and ubiquitously expressed in all tissues 
during arbovirus infection. The relative expression of the gene of interest was then 
normalized to that of the housekeeping gene by the division of the quantity of the 
gene of interest with the quantity of the 18S of each sample. The quotient is then 




Analysis of qPCR data was done with Microsoft Excel by the use of the median of 
the technical replicates and normalizing them to the median of the technical 
replicates of the housekeeping genes.  
 
2.14 Luciferase assay 
 
There are a range of different luciferase types used in research. In this project 
Gaussia luciferase (Gluc) was utilised at all times. Gluc is a protein naturally 




based on the oxidative decarboxylation of coelenterazine by Gluc which leads to the 
production of coelenteramide, carbon dioxide, and light. As Gluc is secreted into the 
culture medium by infected cells quantification of Gluc was made in the supernatant 
of infected cell culture. The enzymatic activity detected in the supernatant correlates 
with the amount of infectious particles that are released from the virus infected cells.   
 
2.14.1 Infection of cells in vitro with SFV6 expressing Gaussia luciferase 
 
Luciferase assays were performed with SFV6 virus modified to express Gaussia 
luciferase. Bone marrow derived M-CSF macrophages or MEF cells were seeded at 
a known concentration in 24 or 96 well plates and infected with a known amount of 
SFV6. Cells were either pre-treated with mosquito saliva, or saliva was added pre-
mixed with the virus.   
 
2.14.2 Detection of luciferase 
 
For detection of luciferase in macrophages and fibroblasts infected in vitro Renilla 
Luciferase Assay System (Promega) kit was used and samples were run on Mithras 
LB 940 Multimode Microplate Reader (Berthold Technologies, Germany). 20μl of 
cell supernatant was diluted with an equal amount of 1:5 lysis buffer supplied with 
the kit. Luciferase substrate was mixed with the Luciferase buffer at 1:100. Samples 




ELISA (Enzyme-linked immunosorbent assay) was conducted using Mabtechs 
ELISA development kit. High protein binding ELISA plates were coated with 
2μg/ml of capture antibody diluted in PBS and incubated overnight at 4°C. Plates 
were washed twice with PBS the following day and plates were then blocked with 
reagent diluent containing PBS with 0.05% Tween 20 and 0.1% BSA for 1 hour at 
room temperature to prevent non-specific binding. Plates were then washed 5 times 
with wash buffer containing PBS with 0.05% Tween 20. Standard were reconstituted 
to a concentration of 0.5μg/ml. Serial dilutions were made 1:2 ranging from the 
highest concentration to 10pg/ml. 100μl of sample or standards diluted in incubation 




5 times as previously and then incubated with 100 μl of detection antibody at 200 
ng/ml for 1 hour at room temperature.  Following another washing step the plates 
were incubated with 100 μl of streptavidin-HRP (1:200 diluted) for 20 minutes in the 
dark. The plates were then washed again 5 times and 100μl substrate solution was 
added. The reaction was then stopped utilising Stop Solution (Invitrogen). The plate 
was read on the Multiskan EX microplate reader (Thermo scientific) set to 450 nm 
to measure optical density (OD). Measurement was also taken at 540 nm and values 
were subtracted from 450nm measurements in order to correct for possible optical 
imperfections in the plate.  
 
2.16 Statistical analysis  
 
All data was analysed with GraphPad Prism software (San Diego, CA, USA). Non-
parametric Kruskal-Wallis test was used for comparisons between more than two 
groups whilst non-parametric Mann-Whitney was used for comparisons between 
two groups. Ordinary-ANOVA was performed for comparisons between more than 
two groups of normally distributed data. All differences were considered significant 
at P < 0.05. All plots have statistical significance indicated as follows: *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, ns=not significant. Analysis of survival curves 








CHAPTER 3: Extracted mosquito saliva 












Emerging and re-emerging infectious arthropod borne viruses have a tremendous 
impact on global health. As was discussed in chapter 1, arthropod borne viruses 
constitute an important threat due to continuous emergence and re-emergence 
events as well as due to the limited availability in effective treatments and vaccines. 
Development of novel treatments are required imminently. The discovery of viral 
enhancement by mosquito bites allows for the development of potential treatments 
that specifically target the key aspect of mosquito bites, thereby reducing the 
likelihood of more serious disease. Research investigating the mechanisms 
responsible for viral enhancement triggered by mosquito bites is therefore required 
to pinpoint potential therapeutic targets.               
 
Investigating how mosquito bites enhance arbovirus infection could allow for the 
development of a treatment that blocks this enhancing effect thereby reducing the 
risk of more serious illness associated with mosquito-borne virus infection. Previous 
work, as was discussed in detail in section 1.7 have shown that mosquito bites 
enhance arbovirus infection of mammals with studies suggesting that the injection of 
mosquito saliva specifically into the skin is the key factor responsible for viral 
enhancement. Therefore, in this section we hypothesized that extracted 
mosquito saliva retained the ability to enhance arbovirus infection in 
the absence of a bite with the same efficacy. Here, we established a model 
system that enabled the investigation of the effect of mosquito saliva in an in vivo 
setting.  
 
In order to study this hypothesis, the neurotropic alphavirus Semliki forest virus 
(SFV) was used. SFV, which is a BSL2 human pathogen, is a well-established in vitro 
and in vivo alphavirus infection model. Previous work of the lab have established an 
in vivo model utilising the immunocompetent C57BL/6 mice and the avirulent strain 
SFV4. This work determined the in vivo kinetics of SFV4 replication and 
dissemination following inoculation in the skin in the absence and presence of a 
mosquito bite. Under these circumstances, following subcutaneous inoculation of 
SFV in the absence of a bite, SFV4 replicates rapidly within the skin with 




to remote tissues including non-draining lymph nodes occurring 48 hours and at 96 
hours post infection. Occasionally detection of viral RNA can occur in the brain 
from 48 hours onwards.  
 
Therefore, this in vivo model more closely mimics natural infection by incorporating 
a vital aspect of mosquito borne virus transmission, exposure to Ae.aegypti mosquito 
bites. In particular, a significant increase in viral RNA was detected at 24h post 
infection if inoculated at a mosquito bite compared to resting skin. Furthermore, 
SFV4 disseminated more readily to the brain resulting in enhanced virulence and 
reduced mice survival. However, it remains unclear how the injection of mosquito 
saliva alongside virus, in the absence of a mosquito bite, affects the severity of SFV4 
infection. In the studies in this thesis, infected mosquitoes were not used as infected 
mosquitoes can inoculate a wide range of viral doses whilst probing [486]. In order 
to control for quantity of viral dose as an experimental parameter, virus was 
administered via needle inoculation. 
 
Therefore, in this initial chapter the aims and objectives are: 
 
1. To establish a mouse model that includes injection of mosquito 
saliva with virus. By determining the efficacy of mosquito saliva 
at enhancing arbovirus infection, this work aims to establish 
quantities of saliva required, method of salivary extraction and 
relevant time point post infection for assessing viral titres.  
 
2. Utilising the model system developed, determine the effect of 
mosquito saliva on viral dissemination and animal survival in 
comparison to mice inoculated with virus at mosquito bites. 
 
3.2 Establishing method of mosquito saliva delivery  
 
It has been established that mosquito bites enhance arbovirus infection of mammals 
in comparison to inoculation of virus in the absence of a mosquito bite and it has 
been suggested that the key factor facilitating this enhancement is mosquito saliva. 




arbovirus infection have utilised a couple of different approaches in terms of saliva 
administration; dissection and homogenization of whole salivary glands to generate 
‘salivary gland extract’ (SGE), or forced mosquito salivation of non-dissected 
mosquitoes. Whilst both methods have their pros and cons, the use of SGE has been 
criticized for the inclusion of proteins and molecules that are never injected by the 
mosquito, as the entire tissue is homogenized. On the other hand, the use of 
mosquito saliva acquired via forced salivation has been criticized for potentially not 
containing the same contents as the saliva injected by the mosquito during a blood 
feed. Here, both methods were initially tested and their effect on SFV4 infection 
compared. 
 
To investigate this, SGE was acquired via the removal of the mosquito salivary gland 
which was then processed according to the method utilised by Conway et al 2014 
[450]. This involved freeze thawing the salivary glands three times on dry ice and 
the subsequent removal of insoluble debris via centrifugation at 5000g for 10min. 
Mosquito saliva was acquired via forced salivation of mosquitoes by placing the 
mosquito proboscis in a tip containing a drop of immersion oil. All saliva samples 
were then pooled and spun down. Saliva droplet was pipetted out of oil under a 
dissection microscope. Aliquots of extracted saliva were initially quantified by 
measuring protein concentration via a nanodrop which showed that on average, 1 
female Ae.aegypti mosquitoes worth of saliva contains 0.3714μg/ml of protein (see 
appendix 1).  
 
To investigate whether extracted saliva and salivary gland extract could successfully 
enhance arbovirus infection, C57BL/6 mice were infected with 10,000 plaque 
forming units (PFU) of SFV4 administered subcutaneously in the left foot in 1μl of 
PBSA only, or in combination with either 5 mosquitoes worth of saliva, or SGE from 
5 mosquitoes. In addition, 5 homogenized mosquito ovaries used as a negative 
control of a random non-salivary associated organ. As a positive control, virus was 
inoculated into skin bitten by 5 mosquito bites. 24 hours post infection, mice were 
sacrificed and dissected for tissues of interest as well as the collection of serum. Tissue 
samples were then analysed via RT-qPCR for gene expression analysis of the SFV 




established as a good indicator of viral RNA levels (see figure 3.1 A). Similarly, serum 
was analysed for viral titres via plaque assays (figure 3.1 B). 
 
At 24h post infection significant increase in viral RNA could be detected at the 
inoculation site in mice exposed to mosquito bites immediately prior to infection or 
mosquito saliva co-injected alongside virus as well as significant increase in viral titres 
detected in the serum in comparison to mice with virus injected on its own in the 
absence of a mosquito bite or mosquito saliva. In comparison, injected salivary gland 
extract did not significantly increase virus RNA levels at the inoculation site, 
although significant enhancement was observed in the serum. As injected SGE was 
not as potent at enhancing SFV4 infection in these experiments as extracted 
mosquito saliva, and because it is hard to dissect out the role for injected  unrelated 
proteins, saliva derived from forced salivation into oil was used for all future 
experiments.    
 
Figure 3.1. Extracted saliva and SGE effect on SFV4 infection in vivo. 
 
In order to compare the viral enhancing effect of mosquito bites to extracted mosquito saliva 
and SGE, mice were infected with 10,000 PFU SFV4 subcutaneously on its own, following 
exposure to up to 5 Ae.aegypti bites (green), alongside 5 mosquitoes worth of Ae.aegypti saliva 
(red), alongside 5 SGE (blue) or  alongside 5 ovaries. Expression of viral gene SFV E1 was 
measured using RT-qPCR in the skin (A) at 24 hours post infection. Infectious virus was 
quantified via plaque assay of serum at 24 hours post infection. Data are presented as box 
and whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the 
population median; whiskers extend to show the highest and lowest values. (n=6) (Kruskal 



















































































To ensure that the trauma caused by the needle stick during injection did not affect 
viral enhancement by causing an inflammatory response to needle trauma, an 
experiment was conducted comparing viral titres in mice subjected to inoculation in 
the skin with or without exposure to 10 additional needle sticks. At 24h post infection 
viral RNA was quantified at the inoculation site and virus titrated from the serum. 
No significant difference in viral RNA or viral titres was detected between mice 
subjected to 10 needle jabs at the site of inoculation prior to virus injection in 
comparison to mice injected with virus only (see figure 3.2), meaning that tissue 
trauma caused by the needle injection does not impact arbovirus infection. Note that 
injection of skin with needle was undertaken while mice were anesthetised. 
 
 
Figure 3.2. Impact of needle jabs on SFV4 infection 
To investigate whether tissue trauma from needle injection has an impact on SFV4 infection 
mice were infected with 10,000 PFU SFV4 subcutaneously as a single injection (black) or 
following exposure to 10 needle jabs (green). Infectious virus was quantified via plaque assay 
of serum at 24 hours post infection (A). Expression of viral gene SFV E1 was measured using 
RT-qPCR in the skin (B) at 24 hours post infection. Data are presented as box and whisker 
plots: boxes extend from the 25th to the 75th percentile, with a line at the population median; 








































































3.3 Establishing the efficacy of mosquito saliva in enhancing SFV in vivo, 
by investigating the timeline of virus dissemination and salivary dosage 
response required 
 
In the previous section saliva extracted via forced salivation of mosquitoes was 
observed to significantly enhance SFV4 by 24h post infection. Following this, we 
needed to assess the quantity of saliva required to reach max viral enhancement. To 
investigate this, a dosage curve experiment was conducted where C57BL/6 mice 
were subjected to inoculations of 10,000 PFU of SFV4 in saline or pre-mixed with 
1, 5 or 25 mosquitoes worth of extracted mosquito saliva. Mice were sacrificed 24h 
post infection and viral RNA quantified at the inoculation site by qPCR whilst serum 
was utilised to determine viral titres. Whilst the co-injection of saliva alongside virus 
always enhanced infection regardless of quantity, larger amounts of saliva correlated 
with a larger increase of viral enhancement, with virus titres reaching a plateau at 
approximately 5 mosquitoes worth of saliva (see figure 3.3). Therefore, 5 mosquitoes 
worth of saliva was utilised in all experiments going forward unless stated otherwise.   
 
Figure 3.3. Quantity of extracted mosquito saliva required for peak viraemia 
 
Mice were infected with 10,000 PFU SFV4 subcutaneously on its own (black) or alongside 
1 mosquitoes worth of Ae.aegypti saliva (green),  5 mosquitoes worth of Ae.aegypti saliva (red) 
or 25 mosquitoes worth of Ae.aegypti saliva (blue). Expression of viral gene SFV E1 was 
measured using RT-qPCR in the skin (A) at 24 hours post infection. Infectious virus was 
quantified via plaque assay of serum at 24 hours post infection. Data are presented as box 
and whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the 
population median; whiskers extend to show the highest and lowest values. (n=6) (Kruskal 


































































































After determining the quantity of saliva required to reach maximum viral 
enhancement, the timepoint of peak viraemia and the timepoint of viral 
dissemination to draining lymph node was investigated. As Pingen et al 2016 [95] 
determined that peak viraemia in mice, injected with SFV4 following a mosquito 
bite occurs 24h post infection, we needed to determine whether this also applies for 
virus co-injected with extracted mosquito saliva. Therefore, mice were subjected to 
injections of 10,000 PFU of SFV4 into either resting skin, skin pre-exposed to 
mosquito bite or virus co-injected with 5 mosquitoes worth of saliva. Mice were 
sacrificed at 5h, 10h and 24h post infection. The impact of mosquito bite/ saliva on 
SFV4 infection was assessed by RT-qPCR for the viral gene E1 in tissues such as 
draining lymph node and skin at the inoculation site. 
 
Viral RNA at the inoculation site revealed that viral titres were highest at 24h post 
infection for both mosquito bitten mice and in mice injected with saliva. Both 
mosquito bites and mosquito saliva enhanced virus infection to a similar extent at 
24h (see figure 3.4). Interestingly, virus disseminated much more rapidly to the 
draining lymph node in mice were virus was co-injected with mosquito saliva in 
comparison to resting/mosquito bitten mice, with viral RNA detected in the 
draining lymph node at 5h post infection. Virus disseminated to the draining lymph 
node was slowest in mosquito bitten mice suggesting that mosquito bites retain virus 
in the skin as was also observed by Pingen et al 2016 [95].  
 
Regardless of the rapid dissemination of virus co-injected with mosquito saliva to the 
draining lymph node, higher quantities of viral RNA was still observed at the 
inoculation site compared to virus injected alone, suggesting that saliva facilitates 
enhanced viral replication at the inoculation site whilst simultaneously increasing 
viral dissemination. This suggests that increased virus at inoculation site is not just 
due to retained virus, but due to enhanced viral replication. Differences in quantity 








Figure 3.4. Kinetics of SFV4 infection in vivo 
In order to compare the time required for SFV4 to disseminate to draining lymph nodes 
following infection in the absence or presence of either mosquito bite exposure or saliva 
injection, mice were infected with 10,000 PFU SFV4 subcutaneously on its own (black), 
following exposure to up to 5 mosquito bites (red) or alongside 5 mosquitoes worth of 
Ae.aegypti saliva (green). Expression of viral gene SFV E1 was measured using RT-qPCR in 
the skin (A) and in the dLN (B) at 5, 10 and 24 hours post infection. Data are presented as 
box and whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the 
population median; whiskers extend to show the highest and lowest values. (n=6) (Kruskal 
Wallis test * p<0.05, ** p<0.01, ***p<0.001). 
 
3.4 Mosquito saliva causes upregulation of key inflammatory genes in 
the skin  
 
All previously published studies have assessed host immune response to either SGE 
or mosquito bites. Importantly, the effect on host responses of extracted mosquito 
saliva, in the absence of a mosquito bite, are largely unknown. Therefore, we wanted 
to investigate whether extracted mosquito saliva modulates expression of 
inflammatory genes in the skin of the inoculation site. Mice were injected with 1 
mosquitoes worth of saliva in the dorsal side of their left foot and the expression of 
inflammatory genes compared to mice injected with equal amounts of PBSA. Mice 
were culled and samples acquired 6 hours post inoculation. This time point was 
selected as it has previously been demonstrated that expression of many pro-
inflammatory gene transcripts, in response to Ae.aegypti bites, peak at 6 hours post 
exposure [95]. QPCR was conducted on the skin samples utilising primers targeting 
CXCL2, IL1β, CCL2, CCL5 and ISG15. These genes were chosen to represent 








































































exception of CCL5 and ISG15, which are instead prototypic ISGs activated by virus 
sensing). As can be observed in figure 3.5, CXCL2, IL1β and CCL2 were 
significantly upregulated by Ae.aegypti saliva whilst CCL5 and ISG15 were not. This 
is somewhat similar to the findings of Pingen et al, that observed a similar pattern of 
inflammatory gene modulation by mosquito bites, suggesting that mosquito saliva is 
responsible for activating expression of these cytokines following bites. 
 
Figure 3.5. Upregulation of key inflammatory genes in the skin in response to 
Ae.aegypti saliva 
In order to investigate whether Ae.aegypti upregulates key inflammatory genes in the skin, 
mice were inoculated subcutaneously in the the dorsal side of their left foot with 1μl PBSA 
to control for upregulation of genes in response to the trauma of inoculation (black), or 5 
mosquitoes worth of Ae.aegypti saliva in 1μl (green). Expression of CXCL2, IL1β, CCL2, 
CCL5 and ISG15 were measured using RT-qPCR in the skin 6 hours post inoculation. Data 
are presented as box and whisker plots: boxes extend from the 25th to the 75th percentile, 
with a line at the population median; whiskers extend to show the highest and lowest values. 
(n=6) (Kruskal Wallis test * p<0.05, ** p<0.01, ***p<0.001.) 
 
3.5 Extracted mosquito saliva, like mosquito bites, reduce mouse survival 
following SFV4 infection 
 
Following the confirmation that mosquito saliva enhances arbovirus infection in the 
absence of a mosquito bite at an early time point, we wanted to determine if 
mosquito saliva in the absence of a bite, affected mouse survival with SFV the same 
as mosquito bites. For this purpose, mice were injected with 40.000 PFU of SFV4 
with or without 5 mosquitoes worth of saliva, or pre-exposed to up to 5 mosquito 









































clinical signs. When mice reached a clinically defined and established endpoint (see 
chapter 2) they were euthanized in accordance with home office regulations. In this 
experiment, mice subjected to mosquito bites, or injected with mosquito saliva 
exhibited a significantly higher mortality rate than mice that were infected with 
SFV4 on its own in the absence of any salivary factors (see figure 3.6). Also, there 
was no significant difference in the mortality rates between mice subjected to 
mosquito bites or mosquito saliva. This supports the hypothesis that mosquito saliva 
alone is the factor responsible for the mechanism of arbovirus enhancement caused 
by mosquito bites. Mice were also weighed each morning in order to monitor 
changes in weight during the progression of the experiment (see figure 3.6). 
Monitoring of mice weights demonstrated that whilst the majority mice inoculated 
with SFV4 alongside Ae.aegypti saliva or bite exhibited a significant loss in weight 
following infection (the majority sometime between day 2 and 5 post infection), the 







Figure 3.6. Survival to SFV challenge following mosquito bite/saliva exposure 
To compare impact on mouse survival following exposure to mosquito bite or saliva mice 
were infected with 40,000 PFU SFV4 subcutaneously on its own (red), following up to 5 
mosquito bites (black) or alongside 5 mosquitoes worth of Ae.aegypti saliva (grey). Mice were 
then monitored for signs of a clinically defined endpoint. Mice were left for a maximum of 
14 days post infection. Graph (A) demonstrates the survival percentages whilst (B) illustrated 
the weight curves of acquired from daily weighing of each individual mouse. (n=10) (Mantel 
Cox test * p<0.05). 
SFV4 
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3.6 Mosquito saliva enhances infection of the flavivirus Zika virus 
independently of the type I IFN response  
 
Whilst the previous sections determined that mosquito saliva has the ability to 
enhance infection of the alphavirus SFV, we wanted to investigate whether mosquito 
saliva can enhance infection of an arbovirus of a different family. For this purpose, 
we utilised the flavivirus ZIKV. A ZIKV mouse model was established by Marieke 
Pingen and Clive McKimmie which encompasses the use of C57BL/6 mice injected 
with 1.5mg (per mouse) InVivoMAb anti-mouse IFNAR-1, a day prior to virus 
inoculation. This antibody is well known as an effective inhibitor Type I IFN 
receptor signalling in vitro and in vivo [152].  
 
As the ZIKV model relies on the blocking of the type I IFN response, we wanted to 
ensure that Ae.aegypti mosquito bites were still effective at enhancing SFV infection 
independently of an effective type I IFN response. Therefore, mimicking the 
developed ZIKV mouse model, mice were injected with 1.5 mg anti-mouse IFNAR-
1 1 day prior to infection. The following day, mice were exposed to up to 5 mosquito 
bites with 10,000 PFU of SFV4 injected immediately following biting. Quantity of 
virus was compared between mice subjected to virus injection in the presence and 
absence of mosquito bites 24 hours post infection. Titration of virus in the serum as 
well as quantification of viral RNA at the site of inoculation demonstrated that there 
was a significant enhancement of virus quantity when virus was injected alongside 
mosquito bites in comparison to when virus was injected on its own in the absence 
of a bite (see figure 3.7). This further suggests that the mechanism behind mosquito 





Figure 3.7. Bite mediated viral enhancement independent of type I IFN 
response 
 
To investigate whether mosquito bites retain their ability to enhance SFV4 infection devoid 
of a functional type I IFN response, mice treated with IFNAR-1 a day prior to infection were 
infected with 10,000 PFU SFV4 subcutaneously on its own or following exposure to up to 5 
mosquito bites. Infectious virus was quantified via plaque assay of serum at 24 hours post 
infection (A). Expression of viral gene SFV E1 was measured using RT-qPCR in the skin (B) 
at 24 hours post infection. Data are presented as dot plots where each dot represents an 
individual mouse, with a line at the population median; (n£6) (Mann Whitney test * p<0.05, 
** p<0.01) 
 
As mosquito bites enhanced SFV infection in the absence of the type I IFN response, 
next, using the same mouse model, we wanted to investigate whether Ae.aegypti saliva 
alone, in the absence of mosquito bites, could also successfully enhance ZIKV 
infection. In this experiment, the day following injection with anti-mouse IFNAR-1, 
mice were inoculated with 1000 PFU of ZIKV on its own, or pre-mixed with 5 
mosquitoes worth of saliva. Mice were sacrificed 24 hours later. qPCR data from 
skin from inoculation site, and plaque assays of viral titres in serum demonstrated 
that extracted Ae.aegypti saliva enhances ZIKV infection in this model, as significantly 
higher quantities of viral RNA was detected in the skin of mice which were injected 
with virus pre-mixed with saliva, in comparison to virus inoculated on its own. 
Similarly, higher titres of ZIKV were detected in mice which had been inoculated 









































































Figure 3.8. Extracted Ae.aegypti saliva enhances ZIKV infection in vivo 
To investigate whether extracted mosquito saliva enhances ZIKV infection, mice were 
infected with 1000 PFU ZIKV subcutaneously on its own or alongside 5 mosquitoes worth 
of saliva. Expression of viral gene ZIKV Env3 was measured using RT-qPCR in the skin (A) 
at 24 hours post infection. Infectious virus was quantified via plaque assay of serum at 24 
hours post infection (B). Data are presented as box and whisker plots: boxes extend from the 
25th to the 75th percentile, with a line at the population median; whiskers extend to show the 
highest and lowest values. (n=6) (Mann Whitney test * p<0.05.) 
 
3.7 Summary and Conclusions 
 
In this initial chapter we hypothesized that extracted mosquito saliva retained the 
ability to enhance arbovirus infection in the absence of a bite with the same efficacy. 
Mosquito probing of skin causes trauma in addition to the deposition of saliva, and 
it was not clear what role each had in modulating host susceptibility to virus infection. 
In order to investigate this, we set out to establish a mouse model utilising mosquito 
saliva which would then be utilised to determine the effect of mosquito saliva on viral 
dissemination and animal survival in comparison to that of mosquito bites. Whilst 
previous studies have investigated the effect of mosquito bites or extracted mosquito 
saliva or SGE on arboviral infection, to date no one has directly compared the 
efficacy of mosquito saliva in modulating arbovirus infection, to that of the mosquito 
bite.   
 
Comparing the ability of SGE, mosquito saliva derived via forced salivation and 






































































infection to a similar extent as mosquito bites. Therefore, even though the exact 
composition of the extracted mosquito saliva may differ slightly from that of the 
saliva injected by mosquitoes during probing, the factors responsible for viral 
enhancement are still present in the extracted saliva, thereby allowing us to use this 
in order to study mosquitoes saliva’s effect on arbovirus infection.  
 
Following this, a range of quantities of saliva were tested, as well as different time 
points in order to determine quantity and time required to reach peak viraemia of 
SFV4 in this model system. 5 mosquitoes worth of saliva resulted in high-titre 
viraemia with SFV4 by 24hpi. In concurrence with previously published work from 
the lab [95], SFV4 co-injected with mosquito saliva resulted in enhanced replication 
of virus in the skin whilst also resulting in enhanced dissemination to the draining 
lymph node. In addition, Ae.aegypti mosquito saliva injected in the absence of a 
mosquito bite, causes upregulation of key inflammatory genes previously determined 
to be upregulated by Ae.aegypti mosquito bites including CXCL2, CCL2 and IL1β. 
Additionally, a survival experiment concluded that mosquito saliva reduced mouse 
survival of SFV4 infection to a similar extent as mosquito bites. Also, mosquito saliva 
was found to significantly enhance infection of mice with ZIKV. Finally, by 
investigating the effect of needle trauma on virus infection we concluded that 
physical trauma did not affect virus infection. This, in combination with the saliva 
enhancing experiments, suggest that factors present in saliva are necessary and 
sufficient to explain enhancement of infection by bites, and that the skin trauma from 
the bite is not implicated in enhancing virus infection. 
 
In conclusion, we have established an in vivo mouse model utilising extracted 
mosquito saliva in order to study the mechanism of modulation of arbovirus infection 
by mosquito saliva. With this model system we have determined that Ae.aegypti 
mosquito saliva is responsible for the arbovirus infection enhancing mechanism 
displayed by Ae.aegypti mosquito bites. This model allows for a more controlled setting 
for the studying of arbovirus enhancement as quantity of mosquito saliva and virus 





CHAPTER 4: Mosquito saliva inhibits virus 
infection in vitro in a microbiota dependent 










It has been established that mosquito saliva enhances arbovirus infection. However, 
the mechanisms implicated in this remain unknown. In order to study the 
mechanisms involved further we wanted to establish an in vitro model system. In vitro 
models are high tractable and require the use of less animals. Here, we utilised cell 
types known to be key targets for alphavirus infection in the skin; macrophages and 
dermal fibroblasts [437]. It has been suggested that mosquito saliva may enhance 
virus infection of cells by either; directly aiding virus attachment to susceptible cells; 
or potentially by making cells more susceptible to infection [450]. Therefore, we 
decided to investigate whether mosquito saliva enhances arbovirus infection in vitro 
in cells as well as in explants of whole skin ex vivo. 
 
In addition, host inflammatory responses to mosquito bites have also been suggested 
to be necessary for enhancement of arbovirus infection in vivo. Accordingly, it has 
been hypothesized that pro-inflammatory microbiota present in mosquito saliva may 
contribute to the immune responses elicited against saliva. Thus, immune responses 
to microbiota in saliva could also indirectly aid virus infection. This hypothesis has 
been strengthened by the discovery that the salivary glands of Anopheles culicifacies 
mosquitoes harbour a larger diversity of microbiota than the gut which demonstrates 
the quantity and variety of microbes that are injected in to the skin during mosquito 
probing [452]. Therefore, bacteria injected into the skin alongside the mosquito 
saliva could be responsible for initiating the immune response that is responsible for 
enhancing virus infection. Therefore, we wanted to test this hypothesis using an in 
vitro model.  
 
Whilst the previous chapter determined that extracted mosquito saliva enhances 
arbovirus infection in vivo, this chapter asks the question whether mosquito saliva also 
enhances infection in isolated cell cultures, or in explanted skin as well as whether 
microbiota present in mosquito saliva modulates arbovirus infection. 
 
Therefore, the aims of this chapter was: 





2. To determine if extracted mosquito saliva enhances SFV 
infection in skin explants. 
3. Determine whether microbiota plays a role in modulating 
arbovirus infection in vitro and in vivo. 
 
4.2 Mosquito saliva inhibits virus infection in macrophages and 
fibroblasts 
 
As it has been suggested that mosquito saliva can enhance viral infection by either 
directly aiding virus attachment to susceptible cells or potentially by making cells 
more susceptible to infection, we decided to investigate whether mosquito saliva 
enhances SFV infection in vitro utilising cell types that are known as key targets for 
SFV infection; macrophages and dermal fibroblasts.  
 
For this purpose, a Gaussia Luciferase expressing SFV6 strain was used in order to 
more efficiently measure changes in virus quantities. As Gaussia luciferase is secreted 
by infected cells into the supernatant, it allows for an efficient method for tracking 
progression of viral infection over time. Also, this is an exceptionally sensitive system, 
with a high dynamic range, allowing detection of very low and high levels of virus 
replication. Initially MEF (Mouse Embryonic Fibroblasts) cells from C57BL/6 mice 
were treated with approximately 1.8 mosquitoes worth of saliva for 1 hour prior to 
infection with SFV6 with an MOI of either 1 or 5. Cells were left for 6 hours before 
supernatant was acquired and a luciferase assay conducted. Interestingly, the 
luciferase assay demonstrated that cells that had been pre-treated with mosquito 
saliva, had a significantly lower expression of luciferase than cells that had not 
received a pre-treatment with saliva, which is the opposite phenotype of what was 
expected. No difference between the two groups was observed in the cells infected 






Figure 4.1. Effect of mosquito saliva on SFV infection of MEF cells 
In an attempt to develop an in vitro model to study saliva mediated viral enhancement in 
MEF cells, MEF cells were infected with an MOI of 1 or 5 of SFV6 on its own or following 
pre-treatment with 1.8 mosquitoes worth of saliva per well for 1 hour prior to infection. 
Supernatant was collected 6 hours post infection and luminescence was measured via 
luciferase assay. Data is presented as dot plots with each dot representing a separate 
biological sample with a line at the population median. (n=6) (One-Way ANOVA test **** 
p<0.0001). 
 
Therefore, to determine the effects of saliva on virus infection at lower MOI, we then 
repeated with an MOI of 0.01, 0.1 and 1. In addition, to help elucidate how the 
mechanisms by which saliva modulates infection in vitro, cells were either pre-treated 
with saliva and then infected (as above, called “saliva to cells”), or saliva was pre-
mixed with the virus for 20min prior to its addition to the cells (referred to as “saliva 
to virus”). Supernatant was then acquired at 6, 24 and 48 hpi in order to monitor 
the progression of infection. Interestingly, in most cases mosquito saliva had an 
inhibitory effect on the early stages of SFV6 infection (see figure 4.2). At 48 hours 
post infection, all groups had reached the maximum detectable level of luciferase 
activity. This was surprising as a number of previous studies have demonstrated an 
enhancing effect of mosquito saliva in vitro. However, several of these studies utilised 
SGE rather than extracted mosquito saliva, which could potentially result in a 




















































Figure 4.2. Mosquito saliva inhibits SFV infection of MEF cells at lower MOI 
In order to investigate the effect of extracted mosquito saliva on the infection of MEF cells, 
MEF cells were infected with an MOI of 0.01, 0.1 or 1 of SFV6. In “Saliva to cells” groups, 
cells were treated with 1.8 mosquitoes worth of saliva 1 hour prior to infection (A, B and C) 
or, in “Saliva to virus” groups saliva was incubated with the virus 20 minutes before infection 
(D, E and F). Supernatant was collected 6, 24 and 48 hours post infection and luminescence 
was measured via luciferase assay. Data is presented as dot plots with each dot representing 
a separate biological sample, with a line at the population median. (n=6) (One-Way 
ANOVA test * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
 
Wanting to compare these findings to another cell type, the experiment was repeated 
utilising macrophages derived from mouse bone marrow precursors (differentiated 
with M-CSF). In this experiment, SGE was also used as an additional group in order 
to determine whether saliva acquired via forced salivation and SGE had different 
effects on virus infection. Mosquito ovaries were included to represent a random 
mosquito organ as a control for SGE in order to help control for any modulations in 
response to unrelated non-salivary proteins. Macrophages were either; 1.) pre-
treated with mosquito saliva, SGE or ovaries extract for 1 hour prior to infection 
with an MOI of 0.1; or 2.) infected with SFV pre-mixed with extracted mosquito 
saliva, SGE or ovaries extract. In concurrence with the data acquired from the MEF 
studies, extracted mosquito saliva inhibited SFV6 infection of macrophages (see 
figure 4.3). Interestingly, so did SGE, but only when macrophages were pre-treated 


















































































































































































































































































































pronounced when given to macrophages prior to infection. This suggests that a 
factor in saliva was modulating cell susceptibility to infection, rather than having a 
direct effect on virus.  
 
These data are in direct contrast with the findings of a study that demonstrated that 
SGE enhanced infection with DENV in macrophages and fibroblasts [450], as well 
as in keratinocytes [487]. We deliberately chose not to study keratinocytes, as their 
relevance in arbovirus infection is disputable as mosquitoes probe right through the 




Figure 4.3. Impact of extracted saliva and SGE on SFV infection of 
macrophages 
To investigate the effect of extracted mosquito saliva and SGE on the infection of 
macrophages, macrophages were infected with an MOI of 0.1 of SFV6. Cells were treated 
with 1.8 mosquitoes worth of saliva, 2 SGE or 2 ovaries extracts 1 hour prior to infection (A) 
or saliva/SGE/ovaries extract were pre-incubated with the virus for 20 minutes prior to 
infection (B). Supernatant was collected 6 hours post infection and luminescence was 
measured via luciferase assay. Data is presented as dot plots with each dot representing a 
separate biological sample, with a line at the population median. (n=5) (One-Way ANOVA 
test * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
 
4.3 Mosquito saliva does not enhance SFV infection in skin explants 
 
As cell culture models failed to mirror the phenotype observed in vivo, where 
mosquito saliva enhances infection, we developed an ex vivo model involving 




























































































placed in tissue culture media for ex vivo culture. Explanted mouse skin contains a 
mixed cell population of all relevant cell types that are present at the inoculation site, 
but lacks cell types that are recruited following infection e.g. neutrophils. Therefore, 
by investigating whether extracted mosquito saliva enhances infection in explanted 
skin, we would answer the question of whether mosquito saliva dependent viral 
enhancement can occur in isolated skin, in the absence of functional circulation, and 
recruited immune cells.  
 
For this purpose, mice were injected with either 10,000 or 100,000 PFU of SFV4 on 
its own, or virus mixed with 5 mosquitoes worth of saliva. Injection was done into 
the dorsal side of their hind feet immediately post cull in order to ensure cessation of 
circulation. Skin samples were then acquired 15min later and placed in complete 
DMEM media for 24h. qPCR from the explanted skin samples demonstrated that 
there was no difference in quantity of viral RNA between the 2 samples (see figure 
4.4) which means that mosquito saliva does not enhance SFV infection when skin is 
isolated from the circulation system. This suggests that mosquito saliva dependent 
arbovirus enhancement is dependent on factors and/or processes that only occur in 




Figure 4.4. Saliva does not enhance SFV infection of skin explants 
To investigate whether extracted mosquito saliva enhances infection of skin explants, 
recently culled mice were infected with wither 10,000 PFU SFV4 (A) or 100,000 PFU SFV4 
(B) on its own or alongside 5 mosquitoes worth of saliva. Skin was explanted 15 minutes 
following infection. Data is presented as dot plots with each dot representing a separate 


































































4.4 Validation of antibiotic treatment 
 
It is not clear which factors present in saliva are responsible for modulating level of 
virus infection, either in vitro or in vivo. The presence of microbiota in mosquito saliva 
may influence severity of virus infection. In order to test whether microbiota present 
in mosquito saliva modulates viral infection in vitro or in vivo we had to firstly establish 
a treatment that effectively removed microbiota from adult Ae.aegypti mosquitoes. 
This treatment consisted of a mixture of penicillin/streptomycin at 200 U per ml, 
gentamycin at 200 µg/ml, and tetracycline at 100 µg/mL. Treatment was placed in 
water of pupae and added to sugar from which adult mosquitoes fed on for 1 week 
prior to salivation/use (larval stage mosquitoes could not be treated with antibiotics 
as we found this to be lethal). Treatment was validated via the collection of several 
randomly selected female mosquitoes which were then dipped in ethanol to remove 
external microbiota, dried and placed in PBS. After shaking with metal beads, 
samples were plated on agar plates in serial 10-fold dilutions. An example of this can 
be seen in figure 4.5 where plates of untreated mosquitoes exhibited large quantities 
of 103 CFU/ml of bacteria (average of 28,000 CFU counted per mosquito), whilst 
no bacteria grew on plates of antibiotic treated mosquitoes. Previous studies using 
similar antibiotic treatments have counted up to 40,000 CFU per mosquito [488] 
whilst others have counted similar CFUs as observed here (ie. 24000 CFU) [213]. 
Mosquitoes were also collected for qPCR analysis investigating quantities of 16S 
RNA conducted which also demonstrated a significant decrease of 16S RNA in 








Figure 4.5. Validation of mosquito antibiotic treatment 
To validate the efficacy of the developed antibiotic treatment which comprised of 
penicillin/streptomycin at 200 U per ml, gentamycin at 200 µg/ml, and tetracycline 
at 100 µg/mL, mosquitoes were taken from the untreated control group (A) and the Abx 
treated group (B) and dipped in ethanol, dried and placed in PBS. Mosquito extract was 
plated on agar plates in 10-fold dilutions. CFU/ml was calculated 24 hours later. Data is 
presented as selected representative pictures (A and B) and dot plots (C) with each dot 
representing a separate biological sample, with a line at the population median. (n=4) (Mann 
Whitney test). 
 
4.5 Microbiota present in mosquito saliva is responsible for inhibition of 
virus infection in vitro 
 
Following the validation of the efficiency of the removal of microbiota by the 
developed antibiotic treatment of the Ae.aegypti mosquitoes, we wanted to investigate 
whether microbiota present in mosquito saliva modulates arbovirus infection. 
Initially this was investigated in vitro with macrophages and MEF cells. As previously, 
virus was pre-mixed with saliva acquired from untreated or antibiotic treated 
mosquitoes before infecting the cells with an MOI of 0.1 of SFV6 Gluc virus. Cells 
were left for 6 hours before tissue culture supernatant was acquired. Surprisingly, 
luciferase assays demonstrated that whilst saliva acquired from untreated 
microbiota-sufficient mosquitoes inhibited infection of both macrophages and 
fibroblasts, saliva from antibiotic treated microbiota depleted mosquitoes did not 
inhibit infection of fibroblasts, and in macrophages it inhibited infection significantly 
less than untreated saliva (see figure 4.6). This suggests that microbiota present in 
mosquito saliva is responsible for inhibition of virus infection of macrophages and 
























Figure 4.6. Microbiota depleted saliva does not inhibit virus infection of 
macrophages and MEF cells 
To investigate whether salivary microbiota modulates virus infection in vitro, macrophages 
(A) and MEF cells (B) were infected with an MOI of 0.1 of SFV6 on its own or alongside 1.8 
mosquitoes worth of saliva from untreated or Abx treated Ae.aegypti mosquitoes. Supernatant 
was collected 6 hours post infection and luminescence was measured via luciferase assay. 
Data is presented as dot plots with each dot representing a separate biological sample, with 
a line at the population median. (n=8 macrophages) (n=6 MEF cells) (One-way ANOVA 
test * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001). 
 
4.6 Inhibition of virus infection in vitro by microbiota is reversed by 
inhibiting type I IFN signalling 
 
As microbiota present in mosquito saliva was discovered to inhibit arbovirus 
infection of key cell types, we wanted to further investigate the mechanisms behind 
this. We hypothesized that microbiota in saliva helps trigger an immune response 
which could also inhibit the infection of the virus. To test this, macrophages were 
treated with either 0.1 MOI of SFV6 Gluc, saliva of untreated mosquitoes or saliva 
from antibiotic treated mosquitoes in the absence of any virus. Cells were lysed 6 
hours post treatment. QPCR analysis of the lysed cells demonstrated that CXCL2 
was significantly upregulated by saliva acquired from untreated mosquitoes but not 
from antibiotic treated mosquitoes. CXCL10, CCL5, IL1β and ISG15 were all 
upregulated to a similar extent by both untreated and treated mosquitoes saliva 
whilst no IFNβ could be detected, although this is perhaps not unusual as this gene 


























































































Figure 4.7. Microbiota in extracted saliva causes upregulation of CXCL2 in 
macrophages 
To investigate whether salivary microbiota causes upregulation of key inflammatory genes 
in macrophages, macrophages were treated with saliva from untreated (WT saliva) or 
antibiotic treated (Abx saliva) mosquitoes. Expression of CXCL2, CXCL10, CCL5, IL1β, 
ISG15 and IFNβ were measured using RT-qPCR 6 hours post treatment. Data is presented 
as dot plots with each dot representing a separate biological sample, with a line at the 
population median. (n=6) (Kruskal Wallis test * p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001). 
 
We hypothesised that despite the inability to detect obvious IFN-β expression, 
microbiota may be triggering innate immune IFN responses that make them more 
refractory to infection with virus. Therefore, as a second experiment, IFNAR-1 
antibody was used to block expression of type I IFN signalling in macrophages. 

























































































































































































































with an MOI of 1 of SFV6 Gluc with 1.5 mosquitoes worth of saliva added to each 
well. Anti-mouse IFNAR-1 was added at a concentration of 1μg/ml for 30min prior 
to infection. Cells were either infected with; SFV6 on its own; SFV6 infection with 
mosquito saliva (plus/minus Abx); all with or without IFNAR pre-treatment of cells. 
Cells were left for 6 hours following infection. As previously, a luciferase assay on 
media supernatant collected 6 hours post infection demonstrated that mosquito 
saliva significantly inhibited SFV6 infection, whilst saliva acquired from antibiotic 
treated mosquitoes did not. However, by blocking the expression of type I IFN in 
macrophages prior to the addition of extracted mosquito saliva, inhibition of virus 
infection by mosquito saliva was prevented (see figure 4.8). In fact, there was no 
significant difference in luminescence between the virus alone group and the SFV6 
+ extracted mosquito saliva following IFNAR treatment. This suggests that 
microbiota present in mosquito saliva triggers a type I IFN response which results in 
inhibition of virus replication in vitro. 
 
Figure 4.8. Salivary microbiota upregulates type I IFN responses resulting in 
inhibition of virus infection in vitro  
To investigate whether salivary microbiota inhibits virus infection via a type I IFN response, 
macrophages were pre-treated IFNAR-1 for 1 hour prior to infection. Cells were then 
infected with an MOI of 0.1 of SFV6 on its own or alongside saliva from untreated or Abx 
treated mosquitoes, with or without pre-treatment with IFNAR-1. Supernatant was 
acquired 6 hours post infection and luminescence measured via plaque assays. Data is 
presented as dot plots with each dot representing a separate biological sample, with a line at 


























































4.7 Microbiota depleted saliva is less inflammatory than untreated saliva 
in vivo 
 
Following the discovery that salivary microbiota causes inhibition of virus infection 
in vitro in macrophages and fibroblasts, we wanted to investigate whether salivary 
microbiota has an impact on the modulation of arbovirus infection in vivo. Initially, 
in order to investigate whether depletion of salivary microbiota alters the 
upregulation of inflammatory genes in the skin, mice were exposed to up to 5 
mosquito bites of antibiotic treated or untreated mosquitoes on a small section on 
the dorsal side of their foot and left for 5 hours. Gene expression of a selection of 
genes previously identified to be upregulated by mosquito saliva (section 3.4) was 
compared to that of unbitten resting skin via qPCR. Data showed that whilst bites 
from untreated mosquitoes resulted in a significant upregulation of CXCL2, IL1β 
and CCL2, mosquito bites from antibiotic treated mosquitoes only significantly 
upregulated CCL2; the expression of which was still lower than that of untreated 
mosquito bites (see figure 4.9). This suggests that at least some of the upregulation of 
inflammatory genes in response to mosquito saliva, is due to the microbiota present 
in the saliva. 
 
Figure 4.9. Upregulation of key inflammatory genes in the skin in response to 
salivary microbiota 
In order to investigate whether salivary microbiota upregulates key inflammatory genes in 
the skin, mice were inoculated subcutaneously in the dorsal side of their left foot with 1μl 
PBSA to control for upregulation of genes in response to the trauma of inoculation (black), 
or 5 mosquitoes worth of saliva from untreated (green) or Abx treated (red) Ae.aegypti in 1μl. 
Expression of CXCL2, IL1β and CCL2 were measured using RT-qPCR in the skin 5 hours 
post inoculation. Data are presented as box and whisker plots: boxes extend from the 25th to 
the 75th percentile, with a line at the population median; whiskers extend to show the highest 





















































































































4.8 Microbiota does not play a role in facilitating saliva-induced 
arbovirus enhancement 
 
Following the discovery that microbiota depleted saliva is less inflammatory than 
untreated microbiota-sufficient saliva, we wanted to investigate whether salivary 
microbiota modulates levels of SFV infection in vivo. For this purpose, mice were 
anesthetised and exposed to 3 to 5 mosquito bites of either untreated or antibiotic 
treated Ae.aegypti mosquitoes in the dorsal side of their left foot, before being injected 
with 250 PFU of SFV6. SFV6 was used for data to be comparable to in vitro data 
where SFV6 had been used. 24 hours post infection mice were culled and skin, serum 
and spleen were collected. Quantification of viral RNA at the inoculation site and 
spleen demonstrated no significant difference in amount of viral RNA between mice 
exposed to antibiotic treated or untreated mosquito bites (see figure 4.10). Similarly, 
no difference was observed in viral titres detected in the serum as both antibiotic 
treated and untreated mosquito bites significantly enhanced viral infection. This 
suggests that salivary microbiota does not play a significant role in modulating viral 
infection in vivo.  
 
 
Figure 4.10. Salivary microbiota does not affect mosquito saliva’s ability to 
enhance infection 
In order to investigate whether salivary microbiota affects the modulation of arbovirus 
infection, mice were inoculated subcutaneously in the dorsal side of their left foot with 250 
PFU SFV6 on its own (black), or alongside 5 mosquitoes worth of saliva from untreated 
(green) or Abx treated (red) Ae.aegypti. Expression of viral SFV E1 gene was measured using 
RT-qPCR in the skin (A) and spleen (B) 24 hours post infection. Data are presented as box 
and whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the 
population median; whiskers extend to show the highest and lowest values. Infectious virus 
was quantified via plaque assay of serum at 24 hours post infection (C). Data is presented as 
dot plots with each dot representing a separate biological sample. (n=8) (Kruskal Wallis test 


















































































































4.9 Summary and Conclusions 
 
In this chapter we developed an in vitro model system for the study of mosquito saliva 
dependent virus enhancement. However, utilising murine macrophages and dermal 
fibroblasts we demonstrated that, in vitro, mosquito saliva does not enhance virus 
infection; instead, mosquito saliva significantly inhibits infection of SFV in vitro. A 
similar observation was made using SGE by Conway et al. 2016 [467] for DENV 
infection of U937 cells. In this paper they attributed this inhibition to salivary protein 
D7. However, we demonstrated that saliva-induced inhibition occurs due to the 
presence of microbiota in the saliva, as saliva acquired from antibiotic treated 
mosquitoes did not inhibit virus infection. Pre-treatment of macrophages with an 
interferon blocking antibody also prevented salivary mediated inhibition of virus 
infection in vitro. This suggests that microbiota triggers a type I IFN response that 
makes cells more refractory to virus infection. In contrast, others have observed an 
enhanced virus infection in response to mosquito saliva in keratinocytes [448]. 
However, it is debatable how relevant these observations are as during mosquito 
probing, the mosquito probes through the keratinocyte layer and therefore these cells 
are unlikely to be important targets of virus infection in vivo. 
 
Furthermore, as mosquito saliva, in the absence or presence of salivary microbiota, 
did not enhance virus infection in vitro, it suggests that saliva does not directly aid 
virus infection by directly aiding virus attachment to susceptible cells or by making 
cells more susceptible to infection. By utilising explanted mouse skin, we also 
demonstrate that mosquito saliva activates responses that only occur in vivo for viral 
enhancement to occur. This was because no enhancement of SFV infection was 
observed in mouse skin injected with virus/saliva, but then cultured ex vivo i.e. 
following the caseation of circulation and plasma-derived factors. Together, this 
suggests that the mechanisms involved in facilitating arbovirus 
enhancement by mosquito saliva is dependent on an intact circulation 
and possibly by the influx of fluid or recruited immune cells [310] [95]. 
 
Finally, it has previously been suggested that microbiota present in mosquito saliva 
could modulate arbovirus infection in vivo by eliciting inappropriate immune 




whether mosquito salivary microbiota were responsible for the virus enhancing effect 
that mosquito saliva exhibits. Utilising our newly developed antibiotic treatment, we 
demonstrate for the first time, that microbiota present in mosquito saliva does not 
modulate virus infection in vivo as both microbiota depleted and untreated mosquito 
bites successfully enhanced infection to a similar extent. Ideally this experiment 
should be repeated utilising extracted mosquito saliva from Abx treated and 
untreated mosquitoes. However, we can conclude that the salivary microbiome do 
not make up the factors in mosquito saliva responsible for enhancing virus infection; 








CHAPTER 5: Mosquito salivary components 
responsible for arbovirus enhancement are not 












In the previous chapter it was demonstrated that microbiota is not involved in 
modulating arbovirus infection in vivo; therefore another factor in mosquito saliva 
must be implicated in facilitating mosquito saliva dependent arbovirus enhancement. 
Blood feeding in mosquito species is a mechanism used exclusively by females of 
certain mosquito species to facilitate oviposition. Transcriptomic analysis of female 
and male Ae.aegypti mosquitoes have demonstrated that certain salivary transcripts 
appear to exhibit differential expression between males and females with 207 
transcripts present in the salivary gland that are female specific [458]. This 
differential expression of transcripts could alter Ae.aegypti saliva’s ability to enhance 
arbovirus infection. Differences in the ability of male, compared to female, saliva to 
modulate virus infection in mice might suggest that these more limited number of 
differentially expressed salivary genes are responsible. To further complicate the 
interpretation of our results, the act of blood feeding by a female mosquito leads to 
alteration in the levels of some salivary transcripts [460]. Therefore, blood-fed 
mosquitoes may salivate saliva that differs in its ability modulate arbovirus infection 
in mammals. This suggests that the act of blood feeding could alter the ability of 
saliva to facilitate arbovirus enhancement. 
 
Furthermore, there are several species of blood feeding mosquitoes, many of which 
are of medical relevance due to the arboviruses they transmit. There have been 
several studies investigating whether different mosquito species can enhance the 
infection of a specific virus that they transmit, including Ae.aegypti enhancing SFV 
and RVFV [490], Culex tarsalis which has been demonstrated to enhance WNV [447] 
whilst Cache-Valley (CV) virus infection severity has been demonstrated to be 
increased by the bites of Aedes triseriatus, Ae.aegypti, and Culex pipiens [491]. Also, Aedes 
triseriatus mosquito bites/saliva have also been found to enhance vesicular stomatitis 
New Jersey virus (VSNJV) [492]. Importantly however, it remains unknown whether 
different blood feeding mosquito species enhance virus infection in a similar way. 
Nor is it known whether the ability of their saliva to enhance arbovirus infection is 
restricted to the specific arboviruses they transmit. Therefore, in this chapter we 
wanted to investigate whether extracted saliva acquired from different blood feeding 




enhancing effect of Ae.aegypti saliva was compared to that of the closely related 
Ae.albopictus which belongs to the same genus, as well as Cx.pipens which is a mosquito 
species that commonly transmits arboviruses including WNV and JEV. In addition, 
two species from the Anopheles genus were selected, An.gambiae and An.stephensi, as 
Anopheles blood feeding mosquitoes have been demonstrated to be inefficient vectors 
of the majority of arboviruses. To date, no one has investigated whether Anopheles 
mosquito bites and/or saliva are capable at enhancing arbovirus infection.  
 
Therefore the aims of this chapter were: 
 
1. To determine whether male Ae.aegypti saliva enhances arbovirus 
infection to the same extent as female saliva. 
2. To investigate whether the act of prior blood feeding alters 
mosquito saliva in a way that impacts the modulation of 
arbovirus infection. 
3. To determine if salivary factors responsible for arbovirus 
infection are proteins. 
4. To determine if mosquito saliva from different mosquito species 
differ in their ability to enhance arbovirus (SFV and ZIKV) 
infection. 
 
5.2 Male mosquito saliva does not enhance SFV infection as efficiently 
as female mosquito saliva 
 
As mentioned, male Ae.aegypti mosquitoes do not feed on blood whilst female 
mosquitoes do. Transcriptome analysis of female and male salivary glands have 
demonstrated differences in the expression of genes in the salivary glands. Therefore, 
we wanted to determine whether male mosquito saliva to enhances SFV infection. 
To do this, mice were injected subcutaneously with 5 mosquitoes worth of extracted 
mosquito saliva from either male or female Ae.aegypti mosquitoes alongside 10,000 
PFU of SFV4. 24h post infection mice were culled and tissues collected. Quantity of 
SFV RNA at the inoculation site was significantly higher in mice injected with female 




female Ae.aegypti saliva caused a significant increase in virus titres detected in the 
serum, compared to virus alone, male saliva did not. 
 
Figure 5.1. Male Ae.aegypti saliva does not enhance SFV infection in vivo 
In order to investigate whether male Ae.aegypti saliva enhances arbovirus infection, mice were 
inoculated subcutaneously in the dorsal side of their left foot with 10,000 PFU SFV4 on its 
own (black), or alongside 5 mosquitoes worth of saliva from female (green) or male (red) 
Ae.aegypti. Expression of viral SFV E1 gene was measured using RT-qPCR in the skin (A) 
and spleen (B) 24 hours post infection. Data are presented as box and whisker plots: boxes 
extend from the 25th to the 75th percentile, with a line at the population median; whiskers 
extend to show the highest and lowest values. Infectious virus was quantified via plaque assay 
of serum at 24 hours post infection (C). (n=6) (Kruskal Wallis test * p<0.05, ** p<0.01). 
 
As there was some concern regarding the potential difference in the total quantity of 
mosquito saliva injected between male and female mosquitoes the experiment was 
repeated following a measurement of protein concentration via nanodrop. The 
quantity of protein injected was then controlled for. In this experiment quantity of 
viral RNA at the inoculation site and in the spleen as well as viral titres in the serum, 
were compared between mice inoculated with 10,000 PFU of SFV4 in combination 
with female or male Ae.aegypti saliva. Similarly to what was previously observed 
above, the quantity of viral RNA in the skin was significantly lower in mice 
inoculated with male mosquito saliva to those injected with female saliva (see figure 
5.2). Similarly, there was significantly less infectious virus present in the serum of 
mice injected with male mosquito saliva in comparison to mice injected with female 
saliva. No significant difference in quantity of viral RNA was observed in the spleen. 
This could simply be due to the fact that spleens are more subject to variation than 

















































































































experiments suggest a role for salivary factors associated with blood feeding in virus 
enhancement. 
 
Figure 5.2. Significant difference in quantity of SFV infection following co-
inoculation with female or male Ae.aegypti saliva 
In order to control for the impact on virus infection by the quantity of male saliva, male and 
female saliva was quantified via nanodrop. The same quantity of salivary protein was then 
injected into both groups. Mice were infected subcutaneously with 10,000 PFU SFV4 
alongside female (black), or male (green) saliva. Expression of viral SFV E1 gene was 
measured using RT-qPCR in the skin (A) and spleen (B) 24 hours post infection. Infectious 
virus was quantified via plaque assay of serum at 24 hours post infection (C). Data are 
presented as box and whisker plots: boxes extend from the 25th to the 75th percentile, with a 
line at the population median; whiskers extend to show the highest and lowest values. (n=6) 
(Mann Whitney test * p<0.05, ** p<0.01). 
 
5.3 Act of prior blood feeding does not alter mosquito saliva’s ability to 
enhance SFV infection 
 
As male mosquito saliva proved to be less efficient at enhancing arbovirus infection 
than female saliva, next we wanted to investigate whether the act of blood feeding in 
female mosquitoes has an impact on the ability of the saliva for modulating arbovirus 
infection in mammals. For this experiment, saliva was extracted from exclusively 
sugar fed mosquitoes as well as from mosquitoes that had received a blood meal twice 
previously at weekly intervals. 5 mosquitoes worth of either saliva was then injected 
alongside 10,000 PFU of SFV4 into mice. 24h later mice were sacrificed and tissues 
acquired. Interestingly, no significant difference in quantity of viral RNA or viral 
titres were detected between the mice inoculated with saliva from exclusively sugar 
fed or saliva from blood fed mosquitoes (see figure 5.3). Importantly, this suggests 


























































































mosquitoes following blood feeding has no impact on Ae.aegypti saliva’s ability to 
enhance arbovirus infection. 
 
 
Figure 5.3. No difference in terms of modulation of infection between saliva 
from blood fed and non-blood fed mosquitoes 
To investigate whether the act of blood feeding alters female Ae.aegypti saliva’s virus 
modulatory effect, mice were infected subcutaneously with 10,000 PFU SFV4 alongside 
saliva acquired from exclusively sugar fed female Ae.aegypti mosquitoes (black), or from blood 
fed female Ae.aegypti mosquitoes (green). Expression of viral SFV E1 gene was measured using 
RT-qPCR in the skin (A) and spleen (B) 24 hours post infection. Infectious virus was 
quantified via plaque assay of serum at 24 hours post infection (C). Data are presented as 
box and whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the 
population median; whiskers extend to show the highest and lowest values. (n=6) (Mann 
Whitney test). 
 
5.4 Prior heat treatment of saliva suggests salivary factor is proteinaceous 
 
Heat treatment of mosquito saliva prior to inoculation was conducted in order to 
denature any proteins present. Mice were co-inoculated with either 
natural/untreated or heat-treated Ae.aegypti saliva, and 10,000 PFU of SFV4. 
Analysis of tissues and serum acquired at 24hpi, demonstrate that heat treatment of 
Ae.aegypti saliva completely inhibits saliva mediated viral enhancement (see figure 
5.4). This suggests that one or several proteins are implicated in facilitating 








































































































Figure 5.4. Heat treatment of mosquito saliva inactivates saliva’s ability to 
enhance viral infection 
To investigate whether the factor responsible for arbovirus enhancement in female Ae.aegypti 
saliva is heat sensitive, mice were infected subcutaneously with 10,000 PFU SFV4 on its own 
(black), alongside 5 mosquitoes worth of untreated (green) or heat treated (red) Ae.aegypti 
saliva. Expression of viral SFV E1 gene was measured using RT-qPCR in the skin (A) and 
spleen (B) 24 hours post infection. Infectious virus was quantified via plaque assay of serum 
at 24 hours post infection (C). Data are presented as box and whisker plots: boxes extend 
from the 25th to the 75th percentile, with a line at the population median; whiskers extend to 
show the highest and lowest values. (n=6) (Kruskal Wallis test * p<0.05, ** p<0.01, *** 
p<0.001). 
 
5.5 Saliva from different mosquito species differ in its ability to enhance 
SFV infection 
 
Following the discovery that the salivary factor responsible for facilitating saliva-
dependent viral enhancement are likely proteins associated with female mosquito 
blood feeding, the next step was to determine whether these factors, and the ability 
to enhance viral infection, are present in other blood feeding mosquito species. 
Initially, the enhancing effect of Ae.aegypti saliva on SFV4 infection was compared to 
that of a related mosquito species within the same genus; Ae.albopictus. Both species 
are competent in transmitting alphavirus and flavivirus arboviruses and as such we 
hypothesised that both species’ saliva would possess the ability to enhance arbovirus 
infection in mammals. In order to test this, 5 mosquitoes worth of saliva extracted 
from Ae.aegypti or Ae.albopictus mosquitoes were inoculated subcutaneously in the 
dorsal side of the left foot of the mouse alongside 10,000 PFU of SFV4 and samples 












































































































































species caused a significant and similar level increase in SFV4 infection in 
comparison to virus administered on its own in the absence of mosquito saliva (see 
figure 5.5). As there was no difference in quantity of viral RNA or viral titres between 
mice inoculated with Ae.aegypti or Ae.albopictus saliva, this confirmed our hypothesis 
that Ae.albopictus saliva possesses the same ability to enhance virus infection in 
mammals as Ae.aegypti. 
 
Figure 5.5. Ae.albopictus saliva enhances SFV infection 
To investigate whether Ae.albopictus saliva enhances SFV infection, mice were infected 
subcutaneously with 10,000 PFU SFV4 on its own (black), alongside 5 mosquitoes worth of 
Ae.aegypti (green) or Ae.albopictus (red) saliva. Expression of viral SFV E1 gene was measured 
using RT-qPCR in the skin (A) 24 hours post infection. Infectious virus was quantified via 
plaque assay of serum at 24 hours post infection (B). Data are presented as box and whisker 
plots: boxes extend from the 25th to the 75th percentile, with a line at the population median; 
whiskers extend to show the highest and lowest values. (n=6) (Kruskal Wallis test * p<0.05, 
** p<0.01, *** p<0.001). 
 
Following this, we wanted to investigate whether mosquito saliva of a blood feeding 
mosquito of a different genus also has the ability to enhance arbovirus infection. For 
this purpose the mosquito species Cx.pipiens was selected. Culex mosquitoes are 
widespread across large portions of the globe and are competent to transmit 
arboviruses such as WNV, JEV and St. Louis encephalitis virus [226] [227]. Whilst 
studies have already confirmed that Culex mosquito bites can enhance infection of 
WNV [447], we wanted to determine if Culex mosquitoes can enhance infection of 
SFV4, even though Culex mosquitoes are not capable of transmitting alphaviruses 
such as the closely related CHIKV [493]. Importantly, by doing so it would enable 





















































































to Aedes mosquitoes. Therefore, mice were inoculated with 5 mosquitoes worth of 
saliva of either Ae.aegypti or Cx.pipiens mosquitoes alongside 10,000 PFU of SFV4. At 
24 hours post infection mice inoculated with Cx.pipiens saliva exhibited a significant 
enhancement of SFV4 infection to a similar extent as the mice inoculated with 
Ae.aegypti saliva (see figure 5.6).  
 
Figure 5.6. Cx.pipiens saliva enhances SFV infection 
To investigate whether Cx.pipiens saliva enhances SFV infection, mice were infected 
subcutaneously with 10,000 PFU SFV4 on its own (black), alongside 5 mosquitoes worth of 
Ae.aegypti (green) or Cx.pipiens (red) saliva. Expression of viral SFV E1 gene was measured 
using RT-qPCR in the skin (A) 24 hours post infection. Infectious virus was quantified via 
plaque assay of serum at 24 hours post infection (B). Data are presented as box and whisker 
plots: boxes extend from the 25th to the 75th percentile, with a line at the population median; 
whiskers extend to show the highest and lowest values. (n=6) (Kruskal Wallis test * p<0.05, 
** p<0.01, *** p<0.001). 
 
As both Ae.albopictus and Cx.pipens saliva were found to enhance SFV4 infection to a 
similar extent as Ae.aegypti, next, we wanted to look at a genus of a more distantly 
related blood feeding mosquito species that are known to be inefficient vectors of 
most arboviruses; the Anopheles mosquitoes. As mentioned in the introduction, 
Anopheles mosquitoes are mainly known for their ability to transmit malaria. In terms 
of arbovirus transmission though, they are known to be inefficient vectors of the 
majority of arboviruses, with the exception of one; ONNV which is predominantly 
spread by An.gambiae. It is not clear why Anopheles are such poor vectors of arbovirus, 
considering they routinely would sample viraemic individuals in arbovirus endemic 


















































































Anopheles harbour a large number of different medically relevant arboviruses such as 
VEEV, WEEV, SFV, WNV and JEV. However, to date no studies have shown 
successful transmission of any of these viruses by Anopheles mosquitoes. This makes it 
clear that Anopheles species are incapable of transmitting and maintaining the 
circulation of arboviruses in the wild, with the interesting exception of ONNV [234].  
 
Keeping this in mind, we wanted to investigate whether saliva  from female, blood-
feeding competent, Anopheles mosquitoes could enhance arbovirus infection in 
mammals. To achieve this, saliva acquired from 2 species of the Anopheles genus was 
used; An.gambiae and An.stephensi. The effect of 5 mosquitoes worth of mosquito saliva 
on SFV4 infection from either An.gambiae or An.stephensi mosquitoes was compared to 
that of Ae.aegypti saliva at 24 hours post infection. Interestingly, there was no 
significant increase in the level of viral RNA at either the inoculation site or in the 
spleen in mice co-inoculated with SFV4 and either of the Anopheles mosquitoes saliva, 
compare to injection with virus alone (see figure 5.7). Thus, the level of viral RNA 
was significantly lower in mice injected with Anopheles compared to Aedes mosquito 
saliva. The same pattern was reflected in the viral titres detected in the serum.  
 
Figure 5.7. Anopheles saliva fails to enhance SFV infection 
To investigate whether Anopheles saliva enhances SFV infection, mice were infected 
subcutaneously with 10,000 PFU SFV4 on its own (black), alongside 5 mosquitoes worth of 
Ae.aegypti (green), An.gambiae (red) or An.stephensi (blue) saliva. Expression of viral SFV E1 gene 
was measured using RT-qPCR in the skin (A) and spleen (B) 24 hours post infection. 
Infectious virus was quantified via plaque assay of serum at 24 hours post infection (C). Data 
are presented as box and whisker plots: boxes extend from the 25th to the 75th percentile, 
with a line at the population median; whiskers extend to show the highest and lowest values. 



























































































































































Following the discovery that Anopheles mosquito saliva is incapable of enhancing SFV 
infection in vivo, the next step was to confirm that the same applies for other 
arboviruses as well. As SFV is an alphavirus, we decided to utilise a medically 
relevant arbovirus from a different virus family, therefore, as a representative 
flavivirus, ZIKV was used. For this experiment, the ZIKV in vivo model described in 
section 3.6 was used, which relies on blocking expression of type I IFN via the use of 
an IFNAR blocking antibody. Mice were injected with the anti-mouse IFNAR-1 
antibody 24 hours before the start of the experiment. These mice were then 
inoculated with 1000 PFU of ZIKV on its own or pre-mixed with 5 mosquitoes 
worth of either Ae.aegypti or An.gambiae saliva. Viral titres of ZIKV in the serum of 
mice 24 hours post infection demonstrated that whilst Ae.aegypti saliva significantly 
enhances ZIKV infection, An.gambiae saliva did not, with a similar trend observed 
with the quantity of viral RNA detected in the skin acquired from the site of 
inoculation (see figure 5.8).    
 
Figure 5.8. Anopheles saliva fails to enhance ZIKV infection 
To investigate whether Anopheles saliva enhances ZIKV infection, mice were infected 
subcutaneously with 1000 PFU ZIKV on its own (black), alongside 5 mosquitoes worth of 
Ae.aegypti (green) or An.gambiae (red) saliva. Expression of viral ZIKV Env3 gene was 
measured using RT-qPCR in the skin (A) 24 hours post infection. Infectious virus was 
quantified via plaque assay of serum at 24 hours post infection (B). Data are presented as 
box and whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the 
population median; whiskers extend to show the highest and lowest values. (n=6) (Kruskal 
























































































In order to eliminate the possibility that the mosquito bite of An.gambiae mosquitoes 
could somehow compensate for An.gambiae saliva’s lack of ability to modulate 
arbovirus infection, the SFV and ZIKV experiments above were repeated with mice 
exposed to aproximately 2 mosquito bites on the dorsal side of their foot replacing 
the injections of mosquito saliva. Mosquitoes were left until fully engorged. Injection 
of 10,000 PFU of SFV4 or 1000 PFU of ZIKV was conducted at the bite site 
immediately following the completion of mosquito feeding. Similarly, as observed 
before, Ae.aegypti bites significantly enhanced SFV4 infection in the skin and serum 
whilst An.gambiae bites did not (see figure 5.9). 
 
Figure 5.9. An.gambiae bites unable to enhance SFV4 infection 
To investigate whether An.gambiae bites can compensate for their saliva’s inability to enhance 
SFV4 infection, mice were infected subcutaneously with 10,000 PFU SFV4 on its own, or 
immediately following exposure to approximately 2 mosquito bites of Ae.aegypti  or An.gambiae 
mosquitoes. Expression of viral SFV E1 gene was measured using RT-qPCR in the serum 
(A) and skin (B) 24 hours post infection. Data are presented as dot plots: with each dot 
representing a separate biological sample (n=6) (One way ANOVA (serum) and Kruskal 
Wallis test (skin) * p<0.05). 
 
In the same way, whilst Ae.aegypti bites significantly enhanced ZIKV infection, 
An.gambiae bites did not (see figure 5.10). These experiments further support the 




















































































Figure 5.10. An.gambiae bites unable to enhance ZIKV infection 
To investigate whether An.gambiae bites can compensate for their saliva’s inability to enhance 
ZIKV infection, mice were infected subcutaneously with 1000 PFU ZIKV on its own (black), 
or immediately following exposure to approximately 2 mosquito bites of Ae.aegypti (green) or 
An.gambiae (red) mosquitoes. Expression of viral ZIKV Env3 gene was measured using RT-
qPCR in the serum (A) and spleen (B) 24 hours post infection. Data are presented as box 
and whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the 
population median; whiskers extend to show the highest and lowest values. (n=6) (Kruskal 
Wallis test * p<0.05, ** p<0.01). 
 
5.6 Different effects on mouse survival following virus co-injection with 
Aedes or Anopheles saliva 
 
Following the discovery that Anopheles saliva does not enhance virus infection at 24 
hours, we wanted to ensure that An.gambiae saliva did not enhance severity of 
infection at a later time point than was previously studied by ensuring that An.gambiae 
saliva does not have an impact on mouse survival following SFV4 infection. 
 
For this purpose, mice were injected with 40.000 PFU of SFV4 with or without 5 
mosquitoes worth of either Ae.aegypti or An.gambiae saliva. (“Virus alone” and “Aedes 
saliva” data presented previously in section 3.5). Mice were then left for up to 14 
days and monitored for signs of illness. When mice reached a clinically defined and 
established endpoint (see chapter 2) they were euthanized in accordance with home 
















































































percentage of surviving mice when SFV4 was administered alongside Ae.aegypti saliva 
(see figure 5.11). However, no reduction in mouse survival was observed in the group 
inoculated with An.gambiae saliva. In fact, the groups that received SFV4 with or 
without An.gambiae saliva did not differ from each other in terms of mouse survival. 
 
Figure 5.11. Survival to SFV challenge following inoculation with Anopheles or 
Aedes saliva 
To compare impact on mouse survival following exposure to Anopheles or Aedes saliva, mice 
were infected with 40,000 PFU SFV4 subcutaneously on its own (grey), alongside 5 
mosquitoes worth of Ae.aegypti saliva (black) or An.gambiae saliva (red). Mice were then 
monitored for signs of a clinically defined endpoint. Mice were left for a maximum of 14 
days post infection. Graph demonstrates the survival percentages. Control groups presented 
previously in graph 3.6 (n=10) (Mantel Cox test * p<0.05). 
 
Secondly, in order to investigate when a difference in virus quantity can successfully 
be detected at the site of inoculation following infection with SFV alongside Ae.aegypti 
or An.gambiae saliva, an experiment was conducted aiming to follow virus quantity 
progression at 5 hours, 10 hours and 24 hours post infection. By defining the time 
post inoculation that saliva modulates level of virus, it will help define whether its 
mechanism of action is direct/immediate or indirect/delayed in nature. For this 
purpose, mice were inoculated with SFV4 on its own or alongside Ae.aegypti or 
An.gambiae saliva. At 5 hours post infection, no difference in quantity of viral RNA at 
the inoculation site was detected between the 3 treatment groups. Differences were 
first detected 10 hours post infection where, mice inoculated with SFV4 pre mixed 
with Ae.aegypti saliva, had significantly higher quantities of viral RNA at the 
inoculation site than the groups treated with virus alone and virus pre mixed with 
SFV4 Survival
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An.gambiae saliva (see figure 5.12). This supports the experiment in chapter 3 (figure 
3.4) where Ae.aegypti saliva caused significant upregulation of virus in the skin at 10h 
and 24h post infection. In that experiment we concluded that Ae.aegypti saliva 
facilitates enhanced viral replication at the inoculation site whilst simultaneously 
increasing viral dissemination. Therefore, the differences observed in figure 5.12 in 
terms of quantity of viral RNA, are most likely due to differences in replication levels. 
 
Figure 5.12. Time-course of SFV infection following inoculation with 
An.gambiae saliva 
To investigate the kinetics of viral infection following inoculation with An.gambiae, mice were 
infected subcutaneously with 10,000 PFU SFV on its own, or alongside 5 mosquitoes worth 
of Ae.aegypti or An.gambiae saliva. Expression of viral SFV E1 gene was measured using RT-
qPCR in the skin at 5 hours (A), 10 hours (B) or 24 hours (C) post infection. Data is presented 
as dot plots with each dot representing a separate biological sample, with a line at the 
population median. (n=8) (Kruskal Wallis test * p<0.05, ** p<0.01). 
 
5.6 Summary and Conclusions 
 
Responses of the mammalian host to the bite of blood feeding arthropods enhance 
infection of the viruses they transmit, and this is due to the injection of saliva during 
feeding. From our studies it appears as if the viral enhancing effect of arthropod 
saliva has co-evolved with the act of blood feeding. Within the mosquito insect group 
not all mosquito species feed on blood and out of the select mosquito species that do 
blood feed, only the female will ingest blood; never the males. Also, there is a huge 





































































































































Transcriptome analyses on salivary glands of mosquitoes have discovered differences 
in the transcriptome of male and female Ae.aegypti mosquitoes. Transcriptomic 
differences have also been detected following the ingestion of a blood meal by the 
female Ae.aegypti mosquito. Therefore, in this chapter we sought to investigate 
whether the differences observed in the transcriptome of male and female Ae.aegypti, 
and the changes in gene expressions following the acquisition of a blood meal, affect 
the modulatory effect of saliva on virus infection. Our data demonstrate that female 
Ae.aegypti saliva causes a significant enhancement of SFV4 infection whilst saliva 
acquired from male Ae.aegypti mosquitoes does not. Because the majority of 
differentially expressed salivary genes in females are thought to be associated with 
blood-feeding, these data would suggest that those factors evolved to facilitate blood 
feeding are also responsible for enhancing infection with arbovirus in mammals. 
However, the act of blood feeding itself conducted by female Ae.aegypti mosquitoes 
does not appear to affect the mosquitoes saliva’s ability to enhance infection during 
any subsequent feeds. This is important as presumably, unless the virus was 
transmitted via vertical transmission, a large portion of blood feeding mosquitoes will 
only become infected following a blood meal and will therefore only be able to 
transmit the arbovirus during a secondary blood meal. 
 
After narrowing down that the salivary factors implicated in enhancement of 
arbovirus infection are only present in female mosquitoes which unlike the males, 
are capable of blood feeding behaviour, we sought to investigate whether the factors 
implicated are sensitive to heat treatment. In chapter 4, it was determined that 
microbiota present in mosquito saliva does not enhance arbovirus infection. A heat 
treatment of extracted mosquito saliva would kill bacteria present, but potential 
PAMPs including LPS and other lipids and carbohydrates should remain. However, 
a heat treatment would denature any proteins present and inhibit their 
function/activity. In this chapter, we demonstrate that heat treatment of mosquito 
saliva inactivates the salivary factors responsible for arbovirus enhancement as mice 
inoculated with virus alongside heat treated saliva exhibited no enhanced virus 
infection in comparison to when virus was inoculated on its own. This suggests that 





Finally, utilising mosquito saliva extracted from a range of blood feeding mosquito 
species including Ae.albopictus, Cx.pipiens, An.gambiae and An.stephensi, we demonstrate 
that the factors involved in mosquito saliva dependent viral enhancement, are not 
present in all blood feeding mosquito species. Our data suggests that Anopheles 
mosquito species such as An.stephensi and An.gambiae are incapable of enhancing 
arbovirus infections. We also ruled out the possibility that An.gambiae saliva enhanced 
virus infection severity at a later time point than Ae.aegypti by conducting a survival 
experiment with SFV4. The experiment, which compared the lethality of SFV4 
infection in mice following virus inoculation on its own or when co-inoculated with 
either Ae.aegypti or An.gambiae saliva, demonstrated that whilst Ae.aegypti saliva 
significantly reduced the possibility of survival following infection, co-inoculation of 
An.gambiae saliva with SFV4 had no significant impact on mouse survival in 
comparison to virus inoculated on its own. This confirms the discovery that 
An.gambiae saliva does not enhance severity of arbovirus infection. This observation 
could help explain why the blood feeding Anopheles mosquitoes are inefficient vectors 
of the majority of arboviruses as a lack of a viral enhancing effect during virus 
transmission from the vector to the mammalian host, could prove detrimental for 







CHAPTER 6: Differences in host responses to 












In the previous chapter it was established that the salivary factors implicated in 
causing enhancement of arboviral infection are heat sensitive which suggests that it 
is made up of one or several proteins. Furthermore, these factors do not appear to 
be prevalent in all blood feeding mosquito species saliva, as saliva from Anopheles 
mosquitoes failed to enhance both SFV and ZIKV infection in mice. We 
hypothesised that differences by which the host responds to Aedes and Anopheles saliva 
underlies their ability to modulate virus infection in mammals.  
 
Therefore, as a next step, host responses elicited against Aedes and Anopheles were 
compared. This was done in order to determine which host responses are vital for 
the enhancement of arbovirus infection by Aedes saliva. Indeed, we suggest that any 
responses elicited by both types of saliva can be ruled out from being responsible for 
enhancing of arbovirus infection. In comparison, any potential differences observed 
in host responses triggered by Aedes and Anopheles mosquito saliva, may help us 
elucidate the mechanistic basis by which Aedes saliva enhances virus infection.   
 
As part of this, based on the findings in chapter 3 were we demonstrate that Ae.aegypti 
saliva causes significant upregulation of pro-inflammatory genes at the site of 
inoculation, we wanted to compare the impact of An.gambiae saliva on pro-
inflammatory genes in the skin to that of Ae.aegypti. This was done as any differences 
observed could potentially help explain lack of viral enhancement observed in 
response to An.gambiae saliva.  
 
As discussed in section 1.6, mosquito bites can trigger early and late phase cutaneous 
inflammation accompanied by vascular leakage and the formation of oedema and 
pruritic lesion at the site of inflammation. Also, as has already been mentioned, 
mosquito bites and saliva induce vascular leakage, which can break down the 
extracellular matrix of fibroblasts which increases the permeability of endothelial 
cells [310] [444]. Enhanced permeability of blood vessels could allow for an increase 
in the extravasation of monocytes and neutrophils to the site of infection which can 





Therefore, the aims for this chapter were to answer the following questions: 
 
1. Is there a difference in the upregulation of inflammatory genes 
caused by Aedes and Anopheles saliva? 
2. Is there a difference in the amount of oedema formation 
following injection with either Aedes or Anopheles saliva? 
 
6.2 Inclusion of Aedes saliva compensates for the inability of Anopheles 
saliva to enhance infection 
 
In order to gain a better understanding of the mechanisms involved in causing 
arboviral enhancement, we wanted to ask whether Anopheles saliva actively inhibited 
viral infection thereby cancelling out any enhancing effect that could have been 
triggered via a specific host response. To achieve this, Ae.aegypti and An.gambiae saliva 
were mixed together and their combined effect on SFV4 infection in mice compared. 
Therefore, mice were inoculated with 10,000 PFU of SFV4 on its own or in 
combination with 5 mosquitoes worth of Ae.aegypti and/or An.gambiae saliva. At 24 
hours post infection relevant tissues were harvested and expression of viral gene E1 
was measured via qPCR and viral titres in serum via plaque assays. Viral RNA 
expression in the skin and spleen of mice was similar in mice injected with Aedes saliva 
irrespective of inclusion of Anopheles saliva. As before, mice inoculated with only 
Anopheles saliva exhibited similar levels of viral E1 expression as the groups that had 
received virus alone (see figure 6.1). Similar patterns of virus levels between groups 





Figure 6.1. Ae.aegypti saliva compensates for An.gambiae saliva’s inability to 
enhance infection 
To investigate whether the addition of Ae.aegypti saliva to An.gambiae is sufficient cause viral 
enhancement, mice were infected subcutaneously with 10,000 PFU SFV4 on its own (black), 
alongside 5 mosquitoes worth of saliva from Ae.aegypti (green), An.gambiae (red) or a mixture 
of both (blue). Expression of viral SFV E1 gene was measured using RT-qPCR in the skin 
(A) and spleen (B) 24 hours post infection. Infectious virus was quantified via plaque assay of 
serum at 24 hours post infection (C). Data are presented as box and whisker plots: boxes 
extend from the 25th to the 75th percentile, with a line at the population median; whiskers 
extend to show the highest and lowest values. (n=6) (Kruskal Wallis test * p<0.05, ** p<0.01) 
 
This suggests that Anopheles saliva does not actively inhibit virus infection. Instead, it 
appears as if it lacks one, or several factors, that are present in Aedes mosquito saliva 
that enhances infection with SFV. 
 
6.3 An.gambiae saliva upregulates key inflammatory genes more than 
Ae.aegypti saliva. 
 
After establishing that Anopheles saliva, unlike Aedes, does not modulate outcome of 
infection with SFV4 in immunocompetent mice, we wanted to compare host 
responses to either type of saliva. Differences in host response to each saliva could 
highlight the key mechanism responsible for enhancement of infection in mammals. 
As previous studies have looked at the influence of Ae.aegypti bites on the expression 
of inflammatory genes, and after us determining that Ae.aegypti saliva on its own in 
the absence of a bite mirrors the upregulation of genes observed by mosquito bites 










































































































































































and An.gambiae saliva cause different modulation of pro-inflammatory gene 
responses.  
 
For this purpose, the same genes that were looked at in section 3.4 were used (bite-
associated IL1β, CCL2, CXCL2; and antiviral ISGs CCL5 and ISG15) as well as 
other key ISGs; CXCL10, viperin, IFIT2. It is noteworthy that these ISGs were 
previously shown not to be upregulated in the skin by Ae.aegypti mosquito bites in the 
absence of a virus. However, when SFV infection was accompanied by mosquito 
bites the expression of these genes was further enhanced in comparison to their 
expression in response to virus inoculated on its own [95]. Thus, there may be a 
poorly defined role for mosquito saliva in enhancing ISG expression in response to 
virus sensing. Even though Aedes mosquito bites have never been demonstrated to 
cause upregulation of IFNs in the absence of any virus, we also included IFNα, IFNβ 
and IFNγ in order to rule out the possibility that An.gambiae induces an interferon 
response.  
 
For this experiment mice were inoculated subcutaneously with a total of 1μl of 5 
mosquitoes worth of saliva of either Ae.aegypti saliva or An.gambiae saliva in PBSA on 
the upper part of their hind foot. Expression of pro-inflammatory genes were 
measured 6 hours post injection and expression was compared to skin inoculated 
with 1μl of PBSA as a control. This time point was selected as it has previously been 
demonstrated that expression of pro-inflammatory genes in response to Ae.aegypti 
bites peak at 6 hours post exposure [95]. In figure 6.2 (A) the expression of all genes 
looked at are listed. Overall, the expression of pro-inflammatory genes was higher in 
response to An.gambiae saliva in comparison to Ae.aegypti saliva. However the 
difference in expression of genes between Ae.aegypti saliva and An.gambiae was not 
always significant. Neither Ae.aegypti or An.gambiae saliva triggered a detectable IFN 
response. Figure 6.2 (B) provides a closer look at the genes which were found to be 
significantly more expressed in response to An.gambiae saliva than to Ae.aegypti saliva. 
As can be seen in the graphs in figure 6.2, An.gambiae saliva caused a significantly 
higher upregulation of IL1β, CXCL2, CXCL10 and CCL5. The gene most 







Figure 6.2. Differences in the upregulation of key inflammatory genes in the 
skin in response to Aedes and Anopheles saliva 
To investigate Aedes and Anopheles cause differential modulation of the expression of key pro-
inflammatory genes in the skin, mice were inoculated subcutaneously in the dorsal side of 
their left foot with 1μl PBSA to control for upregulation of genes in response to the trauma 
of inoculation (black), or with 5 mosquitoes worth of saliva from Ae.aegypti (green) or 
An.gambiae (red) mosquitoes in 1μl. Expression of IL1β, CCL2, CCL5, CXCL2, CXCL10, 
IFNα, IFNβ, IFNγ, ISG15, viperin and IFIT2 were measured using RT-qPCR in the skin 
5 hours post inoculation. Data is presented via 2 separate methods; (A) All genes investigated 
are included and presented as median + range; (B) Data from genes where significant 
difference was observed between Ae.aegypti and An.gambiae groups are presented as box and 
whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the population 
median; whiskers extend to show the highest and lowest values. (n=6) (Kruskal Wallis test * 
p<0.05, ** p<0.01, ***p<0.001). 
 
We also wanted to investigate whether An.gambiae saliva still significantly enhanced 
key inflammatory genes more than Ae.aegypti saliva when co-inoculated alongside 
virus. Therefore, 10,000 PFU of SFV4 was inoculated subcutaneously alongside 
either Ae.aegypti or An.gambiae saliva in the dorsal side of the foot of C57BL/6 mice. 
Skin samples were then acquired 10 hours and 24 hours post infection. qPCR 









































































































































































































































CCL5, viperin as well as IFNα. Their expression was normalised against 
housekeeping gene 18S as well as against quantity of viral gene E1 in order to ensure 
differences in expression levels were not due to virus quantity. As can be observed in 
figure 6.3, significant difference was observed in the expression of CCL5, viperin and 
IFNα between the group inoculated with Ae.aegypti and An.gambiae saliva at 24 hours 
post infection, with An.gambiae saliva causing a significantly higher expression of all 
three genes investigated. No significant difference was observed at 10 hours post 
infection. Together, this demonstrates that An.gambiae saliva causes a more robust 
upregulation of some key anti-viral genes than Ae.aegypti; especially CCL5 and 
viperin. 
 
Figure 6.3. Differences in the upregulation of key inflammatory genes in the 
skin in response to virus inoculation alongside Aedes and Anopheles saliva 
To investigate whether Anopheles saliva is more inflammatory than Ae.aegypti in presence of 
virus, mice were infected subcutaneously with 10,000 PFU SFV4 alongside 5 mosquitoes 
worth of saliva from Ae.aegypti (red) or An.gambiae (green) mosquitoes. Expression of CCL5, 
IFNα and viperin were measured using RT-qPCR in the skin 10 and 24 hours post 
inoculation. Data are presented as box and whisker plots: boxes extend from the 25th to the 
75th percentile, with a line at the population median; whiskers extend to show the highest 
and lowest values. (n=6) (Mann Whitney * p<0.05, ** p<0.01, ***p<0.001.) 
 
6.4 Ae.aegypti saliva and bites cause significantly more oedema than 
An.gambiae saliva 
 
As mosquito bites are known to trigger early and late phase cutaneous inflammation 
we wanted to investigate whether An.gambiae saliva and mosquito bites differed to 
Ae.aegypti saliva and bites, in terms of amount of the oedematous response they 











































































Blue dye, which binds covalently to serum albumin. Endothelial cell barriers lining 
blood vessels, under normal physiological conditions, prevent passage of albumin 
into tissues. However during inflammation, endothelial barrier function is disrupted, 
allowing macromolecules such as albumin to pass through the barrier, including 
Evans Blue bound serum albumin. By measuring the concentration of Evans Blue 
dye present at the site of inflammation, it is possible to measure amount of oedema 
at the site. 
 
For the purpose of comparing oedema formation, mice were injected subcutaneously 
in the neck with 200μl of 1% Evans Blue. The dye was allowed to spread systemically 
in the blood for 1 hour, after which saliva was injected into the skin (subcutaneously 
in the dorsal side of their hind feet). Mice were injected with 5 mosquitoes worth of 
either Ae.aegypti or An.gambiae saliva and oedema levels was compared to resting skin 
controls. Samples were collected at 30min, 3 hours or 6 hours post inoculation of 
saliva. Immediately following cull, a blood sample was taken for normalisation 
purposes. Then, prior to the acquisition of tissue samples, whole body perfusions 
were conducted immediately in order to ensure the complete removal of any residual 
dye from the blood in the skin tissues. Skin samples of the saliva inculcation site were 
then left to soak in formamide overnight. Dye concentration was then measured 
normalised against the concentration of dye detected in the blood. 
 
Interestingly, Ae.aegypti saliva caused significant amounts of oedema whilst An.gambiae 
saliva did not (see figure 6.4). These differences in oedema quantity were more 
substantial at earlier time points. This was also the case following mosquito biting; 
mice were exposed to 1 or 2 of either An.gambiae or Ae.aegypti mosquito bites 1 hour 
after the injection of 200μl of 1% Evans Blue. Skin and blood samples were acquired 
at the earlier time points, 30min and 3 hours post exposure (as informed by the 
studies with saliva alone). Interestingly, whilst An.gambiae mosquito bites did cause a 
oedema by 3 hours post exposure to bites, this was significantly lower than the 
oedema induced by Ae.aegypti bites (see figure 6.5). At 30 minutes post bite exposure, 
no significant formation of oedema was observed by An.gambiae mosquito bites, whilst 







Figure 6.4. Quantity of oedema following Aedes and Anopheles saliva exposure 
To investigate whether Aedes and Anopheles saliva have a different effect on oedema formation, 
mice were inoculate subcutaneously with 5 mosquitoes worth of saliva from Ae.aegypti (green) 
or An.gambiae (red). Quantity of oedema was compared to resting skin (black). Oedema was 
measured 30min (A), 3 hours (B) and 6 hours (C) post exposure. Oedema was measured via 
colorimetric assay. Data are presented as box and whisker plots: boxes extend from the 25th 
to the 75th percentile, with a line at the population median; whiskers extend to show the 




Figure 6.5. Quantity of oedema following Aedes and Anopheles bite exposure 
To investigate whether Aedes and Anopheles bite have a different effect on oedema formation, 
mice were exposed to 1 or 2 bites from Ae.aegypti (green) or An.gambiae (red). Quantity of 
oedema was compared to resting skin (black). Oedema was measured 30min (A) and 3 hours 
(B) post exposure. Oedema was measured via colorimetric assay. Data are presented as box 
and whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the 
population median; whiskers extend to show the highest and lowest values. (n=6) (Kruskal 






































































































































































































































6.5 Summary and Conclusions 
 
Following the discovery in the previous chapter, that Anopheles mosquitoes bite/saliva 
are incapable of enhancing SFV and ZIKV infection in mice, in this chapter we 
sought to compare host responses to Ae.aegypti and An.gambiae in an attempt to better 
understand the mechanisms involved in facilitating enhancement of arbovirus 
infection by Ae.aegypti saliva. As such, Anopheles saliva provides a naturally-occurring 
functional knockout for arbovirus enhancement. Although many factors present in 
both species saliva will have similar functions, Anopheles lacks the ability to induce the 
host response that enhances virus. We therefore decided to define if there were any 
key differences in host response to each species’ saliva.  
 
Host responses to Aedes mosquito bites have previously been shown to enhance 
arbovirus infection partly via its ability to recruit virus-susceptible myeloid cells to 
the bite site, which become infected and replicate virus. Therefore, the inability of 
Anopheles saliva to enhance virus infection may be a result of reduced leukocyte 
recruitment. However, instead of a reduced induction of chemokine expression, our 
studies demonstrate that An.gambiae saliva causes significantly higher upregulation of 
key pro-inflammatory genes in the skin at 6 hours post injection including IL1β, 
CCL5, CXCL2 and CXCL10. When saliva was co-inoculated with virus, An.gambiae 
saliva was still found to cause a significantly higher upregulation of inflammatory 
genes than Ae.aegypti, but only at 24 hours post infection, which is likely too late to 
affect host susceptibility to infection.  
 
It should be noted that Anopheles saliva also induced higher expression of some ISGs, 
and this may partly explain the reduced level of virus levels in mice. Indeed, 
An.gambiae saliva caused a significantly higher upregulation of IFNα than Ae.aegypti. 
However, this cannot exclusively account for the phenotype, as virus infection 
(ZIKV) was enhanced in IFN-signalling deficient mice (Figure 5.8 and 5.10). In 
addition, as the mixing of Ae.aegypti saliva and An.gambiae saliva resulted in a similar 
enhancement of infection as observed by Ae.aegypti saliva inoculation on its own, this 
suggests that An.gambiae saliva does not actively inhibit virus infection (eg via IFN 
expression). Instead, it seems more likely that An.gambiae saliva simply lacks one, or 




Therefore it seems unlikely that the reason An.gambiae saliva does not exhibit a virus 
enhancing effect in vivo is due to an enhanced upregulation of an antiviral response, 
as this would have presumably inhibited viral infection when in the presence of 
Ae.aegypti saliva as well.  
 
Instead, oedema formation by Ae.aegypti saliva and not by An.gambiae saliva is arguably 
more likely to be the mechanism responsible for causing enhancement of viral 
infection. Indeed, Ae.aegypti saliva/bites, unlike Anopheles saliva/bites, caused 
significant amounts of oedema in the skin, particularly at earlier time points. 
Mosquito biting by both mosquito species caused some limited oedema – although 
this is to be expected, as probing will puncture blood vessel walls. What this data 
implies, is that Aedes saliva has additional factors present that impairs endothelial 
barrier function. Together, this data suggests that oedema formation may be the key 
aspect of the mechanism by which Aedes saliva enhances arbovirus infection. 
Although previous work has suggested mosquito bite-induced oedema may affect 
virus dissemination to draining lymph nodes, it is not clear how or in what way this 
manifests. Hypothetically, oedema may retain virus in the skin for a longer period of 
time, thereby facilitating the infection of dermal cells [95]. In contrast, another study 
suggested oedema may enhance viral dissemination to the draining lymph nodes. 
Another possibility is that an increase in vascular permeability of blood vessels could 
allow for an increase in the extravasation of monocytes and neutrophils to the site of 
infection, which can indirectly aid virus by providing additional cellular targets for 
infection [310]. Thus, in this case, oedema may not directly enhance infection itself, 
but rather by indicative of endothelial barrier dysfunction that additionally leads to 






CHAPTER 7: Role of oedema in the modulation 









In the previous chapter, differences in host responses against Ae.aegypti and An.gambiae 
saliva were investigated in an attempt to uncover potential differences that could 
help explain the host mechanism involved in facilitating arbovirus enhancement by 
Ae.aegypti mosquito saliva. One major difference that was observed between the two, 
was the significant oedema in the skin following inoculation with Ae.aegypti saliva, and 
the lack of oedema in response to inoculation of An.gambiae saliva in naïve C57BL/6 
mice. A similar trend was observed in the skin in response to exposure to either 
Ae.aegypti or An.gambiae mosquito bites, where whilst both mosquito species triggered 
significant oedema formation, Ae.aegypti bites proved to be significantly more 
oedematous than An.gambiae. This observation indicated a possible role for oedema 
in the enhancement of arbovirus infection by mosquito bites. 
 
In order to investigate whether oedema, and/or the endothelial barrier dysfunction 
that it represents, is responsible in facilitating arbovirus enhancement, we decided to 
approach the question in two separate ways. Firstly by investigating whether oedema 
triggered in the absence of any mosquito factors causes viral enhancement; and 
secondly, whether it is possible to inhibit saliva induced oedema and whether this is 
sufficient to block arbovirus infection. To successfully develop an oedema blocking 
treatment that would prevent the occurrence of saliva mediated arbovirus infection 
enhancement, it is vital to understand the mechanisms responsible for oedema 
formation in response to mosquito saliva. Whilst it is known that mosquito bites cause 
oedema formation, the exact mechanisms involved in facilitating this remain 
unclear. Mosquito bites could be triggering oedema in a number of different ways, 
which could either be; immune mediated; or via a direct pharmacological action 
affecting endothelial cell permeability. Considering what we know about host 
responses to mosquito bites, immune mediated mechanisms could include: histamine 
release from mast cells, neutrophil-mediated oedema, and also allergy enhanced 
responses in saliva-experienced individuals.  
 
In summary, we wanted to determine which host responses are responsible for 
oedema in response to mosquito saliva. In order to investigate whether histamine is 




Secondly, to define any additional routes to oedema that are present in previously 
saliva-sensitised hosts, we wanted to investigate whether pre-exposure to Ae.aegypti 
saliva additional altered host susceptibility to infection, and whether pre-sensitization 
to saliva had any impact on oedema formation. This is important as whilst all 
previous experiments were conducted in mosquito bite naïve mice, it is important to 
note that the majority of individuals who are at risk of suffering from arbovirus 
infection (especially individuals residing in arbovirus endemic areas), will have had 
prior exposure to saliva. Due to this, it is important to establish whether previous 
exposure and sensitisation to Ae.aegypti mosquito saliva and the subsequent adaptive 
immune responses, alter the virus enhancing effect of saliva which is observed in 
naïve mice.    
 
Therefore, in this chapter we wanted to determine whether: 
 
1. Oedema induced in the absence of any mosquito derived factors 
can enhance arbovirus infection. 
2. Inhibition of mosquito bite oedema using anti-histamines can 
modulate saliva mediated arbovirus enhancement. 
3. Oedema formation in response to mosquito saliva differs 
between naïve and sensitised hosts.  
 
7.2 Histamine induced oedema causes viral enhancement in the absence 
of any mosquito factors 
 
In order to test whether oedema is sufficient for facilitating enhancement of arbovirus 
infection, we wanted to test whether oedema triggered in the absence of any 
mosquito factors enhanced arbovirus infection. For this purpose, purified histamine 
was used, as histamine is commonly used to trigger a local cutaneous oedema at the 
site of injection. The histamine preparation used was the same that is commonly 
used by health professionals as a positive control during a “skin prick test” for 
diagnosing allergies. In this way, experimentally introduced histamine acts directly 
to disrupts endothelia barrier function.  Initially, in order to validate whether purified 
histamine causes oedema formation in the skin of mice, mice were injected with 1μl 




1% Evans Blue as done previously. 30 min post injection of histamine, skin samples 
were acquired. After leaving samples to soak in formamide overnight dye 
concentration was measured which confirmed that purified histamine causes 
oedema in mice (see figure 7.1). 
 
Figure 7.1. Histamine induces oedema in mice 
To investigate whether purified histamine can successfully induce oedema in mice, mice 
were injected with 1μl of 10mg/ml of histamine dihydrochloride. Quantity of oedema was 
compared to resting skin. Oedema was measured 30min post exposure. Oedema was 
measured via colorimetric assay. Data is presented as dot plots with each dot representing a 
separate biological sample, with a line at the population median. (n=2) (Mann Whitney test, 
***p<0.001). 
 
Following the confirmation that purified histamine triggers the formation of oedema 
in C57BL/6 mice, we wanted to determine whether histamine induced oedema 
could enhance infection of SFV. To define whether histamine alone is sufficient to 
induce arbovirus enactment, mice were infected with 10,000 PFU of SFV4 alone or 
with either Ae.aegypti saliva, histamine, An.gambiae saliva or a mixture of these. Mice 
were culled 24 hours post infection and skin, spleen and serum samples were 
collected. Viral titres in the serum and quantification of viral RNA via qPCR 
demonstrated that purified histamine alone significantly enhanced arbovirus 
infection in the absence of any mosquito factors. This occurred to a similar extent as 
Ae.aegypti saliva, indicating that endothelia barrier dysfunction is sufficient to result in 
enhanced arbovirus infection (see figure 7.2). Interestingly however, injection of a 
mixture of An.gambiae saliva and histamine did not enhance virus infection to the 
same extent as histamine alone. This suggests that An.gambiae saliva may contain 





































Figure 7.2. Histamine enhances SFV infection 
To investigate whether histamine enhances SFV infection, mice were infected 
subcutaneously with 10,000 PFU SFV4 on its own (black), alongside 5 mosquitoes worth of 
Ae.aegypti saliva (green), 1μl of 10mg/ml of histamine dihydrochloride (red), or An.gambiae 
saliva (blue) or a combination of An.gambiae saliva and histamine (purple). Infectious virus 
was quantified via plaque assay of serum at 24 hours post infection (A). Expression of viral 
SFV E1 gene was measured using RT-qPCR in the skin (B) and spleen (C) 24 hours post 
infection. Data are presented as box and whisker plots: boxes extend from the 25th to the 
75th percentile, with a line at the population median; whiskers extend to show the highest 
and lowest values. (n=6) (Kruskal Wallis test * p<0.05, ** p<0.01). 
 
7.3 Inhibition of saliva induced oedema with adrenaline not sufficient to 
prevent arbovirus enhancement  
 
As histamine induced oedema was shown to enhance SFV4 infection as efficiently as 
Ae.aegypti saliva, this suggests that oedema plays a key role in facilitating saliva 
dependent arbovirus enhancement. Therefore, next we wanted to investigate 
whether inhibiting the formation of oedema could prevent the occurrence of viral 
enhancement. As a first step we wanted to investigate whether an injection of 
adrenaline inhibits Ae.aegypti bite and saliva mediated oedema. In order to do this, 
mice were injected with Evans Blue as done previously. Adrenaline treated mice 
were then injected with 4μl of Adrenaline (Epinephrine) Xylocaine 1%, containing 
lidocaine and adrenaline 1:200,000. Subcutaneous injection was made locally. Mice 
were then exposed to Ae.aegypti biting or injections of 5 mosquitoes worth of saliva. 
Mice were culled 30 min post exposure to mosquito bite or saliva injection. Samples 
















































































































































































Measuring the concentration of Evans Blue demonstrated that adrenaline injections 
were efficiently inhibiting oedema formation caused by bites and saliva (see figure 
7.3).   
 
Figure 7.3. Adrenaline inhibits mosquito induced oedema 
To investigate whether adrenaline can successfully inhibit mosquito induced oedema in 
mice, mice were exposed to up 5 mosquito bites or 5 mosquitoes worth of saliva injections 
in the absence or following of a 4μl adrenaline injection. Quantity of oedema was compared 
to resting skin. Oedema was measured 30min post exposure. Oedema was measured via 
colorimetric assay. Data is presented as dot plots with each dot representing a separate 
biological sample, with a line at the population median. (n=2) (Mann Whitney test, *p<0.05, 
**p<0.01). 
 
Next, in order to investigate whether the inhibition of salivary induced oedema from 
Ae.aegypti saliva by adrenaline injection is sufficient to prevent saliva dependent 
arbovirus enhancement, mice were inoculated with 10,000 PFU of SFV4 on its own 
or pre-mixed with 5 mosquitoes worth of Ae.aegypti saliva. One group of mice were 
pre-treated with 4μl of Adrenaline prior to saliva injections. Adrenaline was 
administered in the same dose again, 3 hours later. Mice were sacrificed 24 hours 
post infection. Viral titres in the serum and viral RNA quantified from the 
inoculation site and the spleen demonstrated that adrenaline injection does not 
prevent the occurrence of arbovirus enhancement following Ae.aegypti saliva injection 
(see figure 7.4). Strangely, saliva on its own did not significantly enhance quantity of 
viral RNA in the skin or spleen in this experiment, however, the experiment clearly 
demonstrates that adrenaline is not effective in preventing arboviral enhancement. 
This suggests that adrenaline activates other pathways that are pro-viral that makes 
oedema irrelevant in defining outcome to infection. Alternatively, and perhaps more 


























































fluid flow in vessels), adrenalin may not directly prevent endothelial barrier 
dysfunction induced by Aedes saliva. This suggest again that oedema per-se is not 
involved in enhancing virus infection, but is instead marker of barrier dysfunction 
induced by Aedes saliva.  
 
 
Figure 7.4. Adrenaline ineffective in prevention of arbovirus enhancement by 
mosquito saliva 
To investigate whether adrenaline could prevent arbovirus enhancement, mice were 
infected subcutaneously with 10,000 PFU SFV4 on its own (black), alongside 5 mosquitoes 
worth of Ae.aegypti saliva in the absence (green) or following a 4μl adrenaline injection (red). 
Infectious virus was quantified via plaque assay of serum at 24 hours post infection (A). 
Expression of viral SFV E1 gene was measured using RT-qPCR in the skin (B) and spleen 
(C) 24 hours post infection. Data are presented as box and whisker plots: boxes extend from 
the 25th to the 75th percentile, with a line at the population median; whiskers extend to show 
the highest and lowest values. (n=6) (Kruskal Wallis test * p<0.05, ** p<0.01). 
 
7.4 Inhibition of oedema with antihistamines does not prevent arbovirus 
enhancement triggered by mosquito saliva 
 
As adrenaline injections proved ineffective in preventing virus enhancement by Aedes 
saliva, the next step was to test the use of antihistamines. As was discussed in section 
1.6.2.1, histamines are a known mediator of the allergic response and play a key role 
in instigating early phase immune reactions, especially in antigen-experienced 
individuals. As part of the cutaneous immune response, in the skin, histamine acts 
on H1 receptors of local blood vessels triggering an increase in vascular permeability 










































































































































endings resulting in vasodilation of local blood vessels which leads to reddening of 
the skin and potentially the formation of skin lesions as part of the wheal and flare 
reaction [426]. As some mosquito bites have been demonstrated to cause 
degranulation of mast cells and the subsequent release of histamine, we decided to 
investigate whether the use of antihistamines could prevent bite/saliva mediated 
enhancement of arbovirus infection. For this purpose a mixture of three different 
antihistamines were used; Cetirizine dihydrochloride, Loratadine and Fexofenadine 
hydrochloride which are all part of a family of second-generation antihistamines. 
Cetirizine is an antihistamine commonly used to treat hay fever which acts as an 
agonist of the histamine H1 receptor [494]. Cetirizine has been shown to bind to 
albumin with high affinity, allowing it to easily reach oedematous sites [495]. 
Loratadine and Fexofenadine, like Cetirizine, act as H1 receptor agonists. Final 
concentration of antihistamines injected were as follows: 0.5mg Cetirizine in 100μl, 
0.02mg Loratadine in 100μl (aprox. 1mg/kg) [496] and 0.1mg of Fexofenadine in 
200μl (aprox. 5mg/kg) [497]. Cetirizine and Fexofenadine were pre-mixed and 
given as a 300μl IP injection whilst Loratadine was given as a separate IP injection 
of 100μl. Infection with 10,000 PFU of SFV4 and saliva injections were made 1 hour 
post antihistamine treatment. Mice were culled 24 hours post infection.  
 
Viral titres in the serum and quantity of viral E1 at the inoculation site demonstrate 
that antihistamine treated mice had equally high viral titres in the serum and 
quantity of viral E1 at the inoculation site suggesting that antihistamines are 
insufficient in preventing enhancement of SFV4 infection (see figure 7.5). 
Interestingly there was a significantly lower quantity of viral E1 detected in the spleen 
of mice treated with antihistamines. However, as the quantity of viral E1 detected in 
the spleen of all three groups is very low it is uncertain if the significance is of 








Figure 7.5. Antihistamines ineffective in prevention of arbovirus enhancement 
by mosquito saliva 
To investigate whether antihistamines could prevent arbovirus enhancement, mice were 
infected subcutaneously with 10,000 PFU SFV4 on its own (black), alongside 5 mosquitoes 
worth of Ae.aegypti saliva in the absence (green) or 1 hour following antihistamine treatment 
(red). Infectious virus was quantified via plaque assay of serum at 24 hours post infection (A). 
Expression of viral SFV E1 gene was measured using RT-qPCR in the skin (B) and spleen 
(C) 24 hours post infection. Data are presented as box and whisker plots: boxes extend from 
the 25th to the 75th percentile, with a line at the population median; whiskers extend to show 
the highest and lowest values. (n=6) (Kruskal Wallis test * p<0.05, ** p<0.01). 
 
As antihistamines proved inefficient at preventing arbovirus enhancement, we 
wanted to determine whether antihistamines successfully inhibited Ae.aegypti saliva 
mediated oedema. Mice were injected with Evans Blue and the same antihistamine 
treatment as previously. 1 hour later mice were injected with either saliva or 
histamine which was used as a control. Importantly, whilst antihistamines efficiently 
prevented the formation of histamine induced oedema, the administered 
antihistamine treatment only partially inhibited saliva-mediated oedema (see figure 
7.6). This could explain why antihistamines are ineffective at preventing saliva 
mediated enhancement of arbovirus infection. This also suggests that saliva mediated 
oedema formation occurs predominantly independently of histamine release and 












































































































































Figure 7.6. Antihistamines only partially inhibit saliva induced oedema 
To investigate whether antihistamines can successfully inhibit mosquito induced oedema in 
mice, mice were injected with 5 mosquitoes worth of saliva or histamine injections in the 
absence or following antihistamine treatment. Quantity of oedema was compared to resting 
skin. Oedema was measured 30min post exposure. Oedema was measured via colorimetric 
assay. Data is presented as dot plots with each dot representing a separate biological sample, 
with a line at the population median. (n=4) (n=2) (Mann Whitney test, *p<0.05, **p<0.01). 
 
7.5 Pre-sensitization to Ae.aegypti saliva does not alter saliva dependent 
modulation of arbovirus infection  
 
Whilst all previous experiments were conducted in mosquito bite naïve mice, it is 
important to note that most individuals at risk of suffering from arbovirus infection, 
will not be. The majority of people will have been exposed to mosquito bites during 
their life time, and people inhabiting countries were arboviruses are endemic will 
have been sensitised to local mosquito species. Therefore it is important to investigate 
whether previous exposure and sensitisation to mosquito saliva, and the subsequent 
adaptive immune responses, alter the virus enhancing effect of saliva which is 
observed in naïve mice. In addition, it is important to note that antibodies that are 
generated against saliva may also inhibit their function, in addition to activating 
hypersensitivity reactions. Therefore, it is hard to predict how prior immune 
sensitisation might affect the ability of saliva to induce oedema and/or virus 





























































As was briefly discussed in section 1.7.1.4  it remains unclear whether the adaptive 
immune response plays a role in mosquito bite dependent arboviral enhancement. 
A previous study investigating the pre-sensitization of mice to Culex tarsalis mosquito 
saliva in C57BL/6 mice and its subsequent effect on WNV infection by mosquito 
saliva, observed no significant difference between naïve and pre-sensitised mice 
[447]. Similarly, Pingen et al 2016, also demonstrated that pre exposure of C57BL/6 
mice to mosquito bites lead to no change in arbovirus enhancement of SFV by 
mosquito bites. However, as C57BL/6 mice are largely considered incompetent at 
mounting a Th2 response, we wanted to investigate whether pre-sensitization to 
mosquito saliva of a mouse strain that are competent at mounting a successful Th2 
response, leads to a difference in the severity of virus infection, compared to that of 
naïve mice [498]. As histamine release was determined not to be the cause of saliva 
mediated oedema, the next step was to determine whether oedema formation is 
aggravated by an allergic response. 
 
For this purpose, BALB/C mice, which can readily activate Th2 immune responses, 
were used. Although, prior mosquito biting of these mice with Aedes mosquitoes did 
appear to worsen infection with WNV [499], the effect of pre-sensitization of 
BALB/c mice to mosquito saliva has not previously been investigated. Mice were 
pre-exposed to mosquito saliva for 4 consecutive weeks. On the 5th week mice were 
then re-challenged with saliva with or without virus in the inoculum. To validate that 
mice were primed to activate Th2 responses following repeated injection with saliva, 
cytokine expression of skin injection site was assessed by qPCR for IL-5 and IL-13 







Figure 7.7. IL-13 and IL-5 expression in saliva sensitized mice  
To validate that mice were primed to activate Th2 responses following repeated injection 
with saliva, cytokine expression of skin injection site was assessed by qPCR for IL-13 (A) and 
IL-5 (B). Data is presented as dot plots with each dot representing a separate biological 
sample, with a line at the population median. (n=6) (Kruskal Wallis test * p<0.05, ** p<0.01, 
*** p<0.001). 
 
As can be observed in figure 7.7, mice sensitized to mosquito saliva exhibited a 
significantly enhanced expression of IL-13 and IL-5. No significant difference was 
observed between mice sensitised to Aedes, Abx treated Aedes or Anopheles saliva. In 
figure 7.8, mice inoculated with Ae.aegypti saliva alongside SFV4 which were pre-
sensitised to Ae.aegypti saliva, exhibited a significantly higher quantity of cells present 
in the lymph node than non-sensitised mice co-inoculated with Ae.aegypti saliva and 
SFV4. No significant difference was observed in number of cells present in non-
sensitised uninfected, virus only or virus co-inoculated alongside Ae.aegypti saliva. A 
slightly higher serum IgE response could be detected in sensitised mice as well in 
comparison to naïve. Interestingly, mice pre-sensitised to saliva acquired from 
antibiotic treated mosquitoes did not exhibit a detectable IgE response, suggesting 























































































































































































Figure 7.8. Adaptive immune responses to mosquito saliva 
To investigate whether sensitisation of mice to mosquito saliva triggered a successful 
adaptive immune response, mice were infected with 10,000 PFU of SFV alone or alongside 
5 mosquitoes worth of mosquito saliva. Mice were either naïve or pre-exposed to mosquito 
saliva weekly for 4 consecutive weeks prior to infection. Cellularity of lymph nodes of 
uninfected, virus infected, naïve infected alongside mosquito saliva and sensitised infected 
alongside saliva were compared 24 hours post infection (A). IgE concentration of serum was 
measured 24 hours pi via ELISA (B). Data is presented as dot plots with each dot 
representing a separate biological sample, with a line at the population median. (n=8) 
(Kruskal Wallis test * p<0.05, ** p<0.01, ***p<0.001). 
 
We next wanted to investigate whether pre-sensitization had an impact on oedema 
formation in BALB/c mice. Therefore, as done previously, mosquito naïve and pre-
sensitised mice were injected with 200μl of 1% Evans Blue subcutaneously 1 hour 
prior to saliva inoculation. 5 mosquitoes worth of Ae.aegypti saliva was injected 
subcutaneously in to the skin of the dorsal side of their hind feet. Mice were culled 
at 30 min and 6 hours post inoculation and perfusion was conducted. Skin samples 
were acquired and placed in formamide overnight with dye concentration measured 
the following day.  
 
Interestingly, no detectable oedema was observed in naïve BALB/c mice 30 min 
post inoculation with saliva whilst significant amounts of oedema was observed in 



































































































































significant oedema by this timepoint (as shown above). At 6 hours post injection both 
naïve and pre-sensitised BALB/c mice exhibited significant amounts of oedema, and 
no difference was observed between oedema quantified in naïve and pre-sensitised 
mice (see figure 7.9). This suggests that naïve BALB/c mice exhibit a delayed 
oedematous response following exposure to Ae.aegypti saliva in comparison to 
C57BL/6 mice, but that prior exposure to saliva enhances early oedema formation.    
 
Figure 7.9. Impact of pre-exposure on oedema formation 
To investigate whether pre-exposure to mosquito saliva alters oedema formation, sensitized 
or naïve mice were injected with 5 mosquitoes worth of saliva. Quantity of oedema was 
compared to resting skin. Oedema was measured 30min (A) or 6 hours (B) post exposure via 
colorimetric assay. Data is presented as dot plots with each dot representing a separate 
biological sample, with a line at the population median. (control n=4) (first challenge n=8) 
(pre exposure n=16) (Kruskal Wallis test, *p<0.05, **p<0.01, ****p<0.0001). 
 
In order to determine whether pre-sensitization to mosquito saliva is restricted locally 
to the site where pre-exposure had occurred or whether pre-sensitization was 
systemic, the samples from the pre-exposed mice acquired from the previous 
experiment were divided into two groups; left and right foot. All pre-exposure 
inoculations with mosquito saliva had been conducted previously into the dorsal side 
of their left foot. During the experiment, saliva was inoculated into the dorsal side of 
both hind feet 1 hour post Evans Blue injection. As can be observed in figure 7.10, 
no significant difference was observed in quantity of oedema detected at the site of 
pre-sensitisation in comparison to the distal foot. This demonstrates that sensitisation 
































































































Figure 7.10. Sensitization to mosquito saliva is systemic 
To investigate whether pre-exposure to mosquito saliva causes a systemic or local change in 
oedema formation, sensitized mice were injected with 5 mosquitoes worth of saliva in pre-
exposed skin (left foot) or in naïve skin (right foot). Quantity of oedema was compared to 
resting skin. Oedema was measured 30min (A) or 6 hours (B) post exposure via colorimetric 
assay. Data present previously in graph 7.10. Data is presented as dot plots with each dot 
representing a separate biological sample, with a line at the population median. (control 
n=4) (left and right n=8) (Kruskal Wallis test, *p<0.05, **p<0.01). 
 
In order to investigate whether prior immune sensitisation affects the ability of saliva 
to induce virus enhancement naïve BALB/c mice and pre-exposed mice were 
injected with SFV4 on its own or in the presence of 5 mosquitoes worth of Ae.aegypti 
saliva. Mice were culled 24 hours post infection and serum, skin and spleen samples 
were acquired to define level of virus. Plaque assays conducted to titrate virus in 
serum demonstrated a significant increase in virus infection in mice co-inoculated 
with Ae.aegypti saliva in comparison to mice injected with virus on its own. No 
difference in viral titres was observed between naïve and pre-sensitised mice. A 
similar pattern of virus quantity was reflected at the inoculation site, where, there 
was a significantly higher quantity of viral E1 detected in mice where virus was 
inoculated alongside Ae.aegypti saliva, with no significant difference between naïve 
and pre-sensitised mice. No enhancement of infection was observed in the spleen (see 
figure 7.11). This suggests that pre-sensitisation to mosquito saliva does not alter 






















































































Figure 7.11. Pre-sensitisation to mosquito saliva does not alter viral 
enhancement by mosquito saliva 
To investigate whether pre-sensitization to mosquito saliva alters mosquito saliva’s ability to 
enhance infection, pre-sensitized mice were exposed to 5 mosquitoes worth of saliva 
injections once weekly for 4 weeks prior to infection. Non-sensitised mice were infected with 
10,000 PFU SFV4 on its own or alongside 5 mosquitoes worth of saliva. Sensitised mice 
were inoculated with 10,000 PFU of SFV4 alongside 5 mosquitoes worth of saliva. Infectious 
virus was quantified via plaque assay of serum at 24 hours post infection (A). Expression of 
viral SFV E1 gene was measured using RT-qPCR in the skin (B) and spleen (C) 24 hours 
post infection. Data is presented as dot plots with each dot representing a separate biological 
sample, with a line at the population median. (n=6) (Kruskal Wallis test * p<0.05, ** p<0.01, 
***p<0.001). 
 
In order to ensure that pre-sensitisation to Anopheles saliva did not cause Anopheles 
saliva to enhance infection, BALB/c mice were pre-sensitised as described 
previously, to either Aedes or Anopheles saliva once a week for 4 weeks prior to the 
experiment date. Mice were then injected with SFV4 on its own or alongside Aedes 
or Anopheles saliva. Similar to what was demonstrated in chapter 5 utilising naïve 
C57BL/6 mice, skin acquired from the inoculation site 24 hours post infection 
demonstrate Anopheles saliva did not cause an enhancement of  virus infection in 
sensitised BALB/c mice (see figure 7.12). As was demonstrated in figure 7.7, 
sensitization to Aedes and Anopheles saliva both caused an enhanced expression of IL-


































































































































































Figure 7.12. Pre-sensitization to Anopheles saliva does not alter lack of viral 
enhancement by Anopheles saliva 
To investigate whether pre-sensitization to Anopheles saliva alters Anopheles saliva’s inability to 
enhance infection, pre-sensitized mice were exposed to 5 mosquitoes worth of saliva of either 
Aedes or Anopheles injections once weekly for 4 weeks prior to infection. Mice were inoculated 
with 10,000 PFU of SFV4 on its own or alongside 5 mosquitoes worth of Aedes or Anopheles 
saliva. Expression of viral SFV E1 gene was measured using RT-qPCR in the skin 24 hours 
post infection. Data is presented as dot plots with each dot representing a separate biological 
sample, with a line at the population median. (n=6) (Kruskal Wallis test * p<0.05). 
 
Whilst section 7.4 demonstrated that antihistamines in saliva-naïve mice were 
insufficient at preventing saliva mediated oedema or modulating virus infection. 
Here, we wanted to investigate whether antihistamine was more effective in pre-
sensitised mice. This is because pre-sensitisation elicited an adaptive immune 
response, which could involve IgE primed mast cell degranulation and the 
subsequent release of histamine. To investigate the efficacy of antihistamines at 
inhibiting oedema formation in response to Ae.aegypti saliva in pre-sensitised BALB/c 
mice, Evans Blue and antihistamines were administered 1 hour prior to saliva 
inoculations. Skin samples acquired 30 min post inoculation demonstrated that 
antihistamines significantly reduced oedema formation in pre-sensitised mice 
exposed to Ae.aegypti saliva (see figure 7.13 B). Oedema formation was not completely 
inhibited however, suggesting that antihistamines are only partially effective at 






















































We also investigated whether antihistamines were effective against virus 
enhancement. Therefore, using pre-sensitised BALB/c mice, mice were inoculated 
with virus on its own or in the presence of 5 mosquitoes worth of Ae.aegypti saliva. 
One group was also pre-treated with antihistamines, as described above, 1 hour prior 
to saliva inoculation and again at 6 hours post infection. Mice were culled 24 hours 
post infection with SFV. Quantification of viral RNA at the inoculation site 
demonstrated that mice treated with antihistamines exhibited no significant 
difference in virus levels, compared to untreated mice, or virus alone group (see 
figure 7.13). Thus, the variation in data makes it hard to state definite conclusions.  
However, as mentioned above, oedema formation does not appear to be completely 
inhibited as some oedema could still be detected in some mice. This pattern of 
incomplete oedema inhibition, where oedema is only completely inhibited in some 
mice, could explain why we only observe a slight reduction in virus infection in 
antihistamine treated mice comparison to untreated mice.   
 
Figure 7.13. Antihistamines partially effective in prevention of oedema 
formation and arbovirus enhancement in pre-sensitized mice.  
To investigate whether antihistamines are effective at preventing arbovirus enhancement in 
mice sensitised to mosquito saliva, sensitised mice were injected with 10,000 PFU SFV4 on 
its own or alongside 5 mosquitoes worth of Aedes saliva in the absence of, or following 
antihistamine treatment. Expression of viral SFV E1 gene was measured using RT-qPCR 
in the skin 24 hours post infection (A). To investigate the effectiveness of antihistamines in 
prevention of salivary mediated oedema in sensitised mice, mice were inoculated with 5 
mosquitoes worth of saliva in in the absence of, or following antihistamine treatment. 
Quantity of oedema was compared to resting skin. Oedema was measured 30min post 
exposure (B). Oedema was measured via colorimetric assay. Data is presented as dot plots 
with each dot representing a separate biological sample, with a line at the population 













































































































7.6 Summary and Conclusions 
 
In the previous chapter we identified oedema as a potential instigator for viral 
enhancement caused by mosquito saliva as only Ae.aegypti saliva was discovered to 
cause detectable oedema in the skin whilst An.gambiae saliva did not. Therefore, as 
Ae.aegypti saliva has been determined to enhance virus infection whilst An.gambiae 
saliva appears to lack the factors responsible for causing viral enhancement, we 
decided to investigate whether oedema causes arbovirus enhancement. For this 
purpose, we sought to answer whether oedema induced in the absence of any 
mosquito derived factors could successfully enhance infection. Oedema triggered 
utilising purified histamine, significantly enhanced arbovirus infection to a similar 
extent as Ae.aegypti saliva, a phenomenon that supports our hypothesis that oedema 
and/or endothelial barrier dysfunction, is responsible for causing saliva-
enhancement of arbovirus infection.  
 
Whilst it is known that mosquito bites cause oedema, the exact mechanisms involved 
in facilitating this remain unclear. Mosquito bites could trigger oedema in a number 
of different ways, which could either be immune-mediated or via a direct 
pharmacological action that affect endothelial cell permeability. In order to 
successfully develop a potential treatment that would prevent enhancement of 
arbovirus infection from occurring, it is important to understand the mechanisms 
involved in oedema formation in response to mosquito saliva. 
 
In an attempt to inhibit oedema in order to investigate whether 
inhibition/prevention of saliva induced oedema prevented the occurrence of 
arbovirus enhancement, two separate methods of oedema inhibition were tested; the 
use of adrenaline, and the use of antihistamines. However, neither proved to 
effectively modulate severity of virus infection. Whilst adrenaline proved successful 
at inhibiting histamine-induced oedema, the treatment of mice with adrenaline 
injection did not prevent arbovirus enhancement. In fact, some levels of virus were 
higher in adrenalin treated mice.  Adrenaline has multiple effects on physiology and 
may act in ways that are hard to predict, including the enhancement of infection via 
an alternative mechanism. In terms of antihistamine, antihistamines were not found 




in virus infection was observed in mice treated with antihistamines. This also suggests 
that Ae.aegypti saliva triggers oedema in a histamine-independent manner in saliva-
naïve mice.  
 
As all previous experiments had been conducted utilising naïve mice, we wanted to 
determine whether previous exposure to mosquito saliva had an impact on the 
outcome of infection. This is because, as was discussed in section 1.7.1.4, it remains 
uncertain whether the adaptive immune  to saliva can further modulate the arbovirus 
infection enhancement effect elicited by blood feeding mosquito species saliva. A 
previous study investigating the pre-sensitization of mice to Culex tarsalis saliva and 
its subsequent effect on WNV infection by mosquito saliva in C57Bl/6 mice, 
observed no significant difference between naïve and pre-sensitised mice [447]. 
Similarly, pre exposing C57BL/6 mice to Ae.aegypti bites resulted in no change in 
arbovirus enhancement of SFV by mosquito bites, as pre-sensitised and naïve mice 
exhibited a similar level of enhanced infection when virus was inoculated in the 
presence of a mosquito bite [95]. However, both of these previous experiments were 
conducted utilising C57BL/6 mice and as C57BL/6 mice are largely considered 
incompetent at mounting a Th2 response, we wanted to investigate whether pre-
sensitization to mosquito saliva in mice competent at mounting a successful Th2 
response, leads to a difference in the severity of virus infection to that of naïve mice 
[498]. Therefore, we utilised BALB/c mice for this purpose.  
 
In our experiments we demonstrated that there was no difference in the level of SFV 
infection following co-injection of virus alongside Ae.aegypti mosquito saliva, 
comparing naïve and pre-sensitised BALB/c mice. Oedema formation triggered in 
response to Ae.aegypti saliva in BALB/c mice differed than what has previously been 
observed in C57BL/6. Interestingly, as was demonstrated in previous chapters, 
significant oedema was detected by 30min post Ae.aegypti saliva exposure in naïve 
C57BL/6 mice, whilst no detectable oedema could be observed at 30min post 
exposure in naïve BALB/c. This suggests that naïve BALB/c mice respond 
differently to Aedes mosquito saliva, making comparison to our data generated 
previously with C57BL/6 mice difficult.  Significant levels of oedema were exhibited 
at 30min post exposure in BALB/c mice previously exposed to Ae.aegypti saliva. 




primed mice. Importantly, both naïve and pre-sensitised BALB/c mice exhibited 
enhanced virus infection to the same level by 24 hours post infection, following co-
inoculation of SFV4 alongside Ae.aegypti.  This suggests that not all forms of oedema 
are pro-viral or that oedema formation following virus inoculation at time points 
later than 30 minutes post exposure are most important in defining outcome to 
infection.   
 
The use of antihistamines in an attempt to prevent arboviral enhancement in 
sensitised mice proved to be ineffective. This likely reflects the inability of 
antihistamines to prevent saliva-induced oedema. The use of adrenaline, which acts 
by restriction of blood vessels, resulted in significantly decreased oedema. However, 
treating mice with adrenaline had no effect on modulating the success of virus 
infection. This may be via a separate mechanism of action however, as adrenaline 
appeared to worsen infection in some tissues. Importantly, adrenaline is effective at 
inhibiting oedema, presumably via the restriction of blood vessel dilation. Adrenalin 
may not, however, prevent other aspects of endothelial dysfunction. Therefore, 
mosquito saliva from Ae.aegypti mosquitoes may enhance infection via an increase in 
endothelial cell permeability, independent of fluid leakage per se. Further research 









CHAPTER 8: ONNV virus infection is not 












In previous chapters we have demonstrated that the effect of mosquito saliva 
mediated arbovirus enhancement is not prevalent in all blood feeding mosquito 
species. We found that Anopheles mosquitoes were incapable of causing saliva/bite 
mediated enhancement of infection for both SFV4 and ZIKV in mice. Previous 
studies have demonstrated that Anopheles mosquitoes, which primarily transmit 
malaria, are very inefficient transmitters of the majority of arboviruses, with the 
exception of one virus; ONNV. ONNV is primarily transmitted by An.gambiae 
mosquitoes. Even though viral RNA of several arboviruses have been detected in 
Anopheles mosquitoes, no study has sufficiently proven that Anopheles mosquitoes can 
successfully transmit these viruses to a mammalian host. The reason why Anopheles 
mosquitoes are unsuccessful transmitters of the majority of arboviruses remains 
unclear. Several putative mechanisms have been hypothesised to explain these 
differences in vector competence including; difference in mosquito species tissue 
barriers; microflora; or molecular determinants required for viral replication [235]. 
The latter suggestion has some evidential support, as differences in the sequence of 
nsP3 gene is sufficient to confer infection of An.gambiae with CHIKV under 
laboratory conditions [130]. However, this alone is insufficient to explain the 
refractory nature of Anopheles to transmit the full gamut of genetically-distinct 
arboviruses, suggesting there exists another fundamental reason that prevents these 
mosquitoes from efficiently transmitting virus to the mammalian host. 
 
In an attempt to understand why An.gambiae mosquitoes can successfully transmit 
ONNV virus we hypothesized that An.gambiae saliva could enhance the infection of 
ONNV. As was briefly discussed in section 1.3.3.5, ONNV is a neglected tropical 
disease, which means very little is known about this virus as very few studies have 
been conducted investigating ONNV. To the best of our knowledge, to date, only 
one previous study has investigated ONNVs ability to replicate in mice. This study 
determined that ONNV does not replicate in WT mice [136]. No study to date has 
investigated whether mosquito saliva has an impact on virus infection. We therefore 






Therefore, the aims of this chapter are: 
 
1. To develop an ONNV virus mouse model. 
2. To use the developed ONNV in vivo model in order to determine 
if Aedes or Anopheles saliva enhance ONNV infection. 
 
8.2 Development of ONNV mouse model 
 
Due to limited studies previously conducted on ONNV, initially, an ONNV mouse 
model had to be developed. The groups tested were as follows:  
• adult female C57BL/6 mice exposed to mosquito bites prior to infection 
• adult female C57BL/6 mice pre-injected with anti-mouse IFNAR-1, exposed 
to mosquito bites 
• 3 week old  female C57BL/6 mice pre-injected with IFNAR-1, inoculated 
with Ae.aegypti saliva 
• 3 week old male C57BL/6 mice pre-injected with IFNAR-1, inoculated with 
Ae.aegypti saliva 
• 3 week old  female CD1 mice pre-injected with IFNAR-1, inoculated with 
Ae.aegypti saliva 
 
The specific groups were chosen as previous observations have suggested that 
infection may differ in male and female mice as well as between CD1 and C57BL/6 
mice. Similarly, younger mice are sometimes found to be more susceptible to 
alphavirus infection. Also, the IFNAR-1 blocking antibody was used, as a previous 
study had determined lack of successful infection in WT mice, and because the 
closely related CHIKV replicate to far higher levels in the absence of IFN signalling.  
 
All groups were inoculated with 200,000 PFU of ONNV on its own or pre mixed 
with 5 mosquitoes worth of Ae.aegypti saliva. IFNAR-1 was administered 24 hours 
prior to infection as an IP injection at a concentration of 1.5mg per mouse. The 
groups with adult female C57BL/6 mice were conducted as a separate experiment 
on a separate day from the rest and were culled 24 hours post infection. The 
remaining groups were culled 48 hours post infection. Quantification of viral ONNV 




in the group with 3-week-old female mice. In terms of viral titres in the serum, no 
virus was detected in the groups containing the adult mice, whilst the remaining 
three groups all exhibited high titres of virus within the serum. As 3-week-old female 
C57BL/6 mice previously injected with IFNAR-1 exhibited the highest viral titres 
of ONNV, this model system was selected for future experiments (see figure 8.1).     
 
 
Figure 8.1. Establishing of ONNV in vivo model 
In order to establish an ONNV in vivo model, mice were exposed to up to 5 Ae.aegypti bites 
or 5 mosquitoes worth of Ae.aegypti saliva alongside 200,000 PFU of ONNV. With the 
exception of the first group, all other mice were pre-treated with IFNAR-1 one day prior to 
infection. Infectious virus was quantified via plaque assay of serum at 24 hours (first 2 groups) 
or 48 hours (remaining groups) post infection (A). Expression of viral ONNV E1 gene was 
measured using RT-qPCR in the dLN (B) and skin (C) 24 hours post infection. Data is 
presented as dot plots with each dot representing a separate biological sample, with a line at 
the population median. (n=2).  
 
Next, we wanted to determine in which tissues ONNV replicates. Using the 
parameters of the ONNV mouse model selected above, 3-week-old C57BL/6 mice, 
24 hours post IP injection with IFNAR-1, were injected with 200,000 PFU of 
ONNV. 48 hours later mice were culled and a wide range of tissues were collected 
including skin taken from site of virus inoculation, foot joint, spleen, pancreas, 
draining lymph node, popliteal non-draining lymph node, as well as the inguinal 
non-draining lymph node. Virus level was then quantified via qPCR. Whilst high 
amounts of ONNV E1 expression was detected in the skin, foot joint, dLN as well as 
some expression in the spleen, no E1 was detected in the pancreas or either of the 
































































































































































































































































Figure 8.2 Sites of ONNV replication  
To establish where ONNV replicates in the established in vivo model, mice were infected 
with 200,000 PFU of ONNV 1 day post injection with IFNAR-1. Expression of viral ONNV 
E1 gene was measured using RT-qPCR in the skin, foot (joint), spleen, pancreas, dLN, 
popliteal non dLN and inguinal non dLN at 48 hours post infection Data are presented as 
box and whisker plots: boxes extend from the 25th to the 75th percentile, with a line at the 
population median; whiskers extend to show the highest and lowest values. (n=6).  
 
8.3 ONNV infection not enhanced by mosquito saliva 
 
After establishing a functional in vivo model utilising ONNV infection, next, we 
wanted to determine whether Ae.aegypti or An.gambiae bites enhanced ONNV 
infection. Therefore, 3 week old, IFNAR-1 treated C57BL/6 mice were inoculated 
with 200,000 PFU of ONNV in to resting skin, or following exposure to 
approximately 2 mosquito bites of either Ae.aegypti or An.gambiae bites. Mice were 
culled 48 hours later and serum and tissues were collected including skin taken from 
site of virus inoculation, foot joint, spleen, pancreas, draining lymph node, popliteal 
non-draining lymph node as well as inguinal non-draining lymph node. As can be 
observed in figure 8.3 there was no significant difference in viral titres detected in the 
serum or in the quantification of viral RNA in any of the tissues collected between 
any of the groups. This suggests that neither Ae.aegypti bites nor An.gambiae bites 





















































Figure 8.3. Mosquito bites from Aedes and Anopheles does not enhance ONNV 
infection in vivo 
 
To investigate whether Aedes or Anopheles bites modulate ONNV infection, mice pre-treated 
with IFNAR-1 were infected with 200,000 PFU ONNV on its own (black) or following 2 
mosquito bites from Aedes (green) or Anopheles (red). Infectious virus was quantified via plaque 
assay of serum at 24 hours post infection (A). Expression of viral SFV E1 gene was measured 
using RT-qPCR in the dLN (B), spleen (C), skin (D) and joint (E) 48 hours post infection. 
Data are presented as box and whisker plots: boxes extend from the 25th to the 75th 
percentile, with a line at the population median; whiskers extend to show the highest and 
















































































































































































































Figure 8.4. Mosquito saliva from Aedes and Anopheles does not enhance 
ONNV infection in vivo 
To investigate whether Aedes or Anopheles saliva modulate ONNV infection, mice pre-treated 
with IFNAR-1 were infected with 200,000 PFU ONNV on its own (black) or alongside 5 
mosquitoes worth of Aedes (green) or Anopheles (red) saliva. Infectious virus was quantified via 
plaque assay of serum at 24 hours post infection (A). Expression of viral SFV E1 gene was 
measured using RT-qPCR in the skin (B), spleen (C), joint (D), distal joint (E) and brain (F) 
48 hours post infection. Data are presented as box and whisker plots: boxes extend from the 
25th to the 75th percentile, with a line at the population median; whiskers extend to show the 























































































































































































































































































We next determined whether mosquito saliva, in the absence of a bite could 
modulate outcome to infection with SFV. Mice were inoculated with 5 mosquitoes 
worth of saliva from either Ae.aegypti or An.gambiae saliva. All other experimental 
parameters were kept the same as above. 48 hours post infection mice were culled 
and the following samples were collected: serum, spleen, skin from the inoculation 
site, joint, brain and distal joint. As limited studies have been conducted on ONNV, 
dissemination and replication of virus in vivo remains poorly understood. Therefore, 
as ONNV is closely related to CHIKV which is known to replicate well in joints, the 
distal joint was acquired as well in order to investigate whether viral RNA can be 
detected in the distal joint 48 hours post infection with ONNV. Brain samples were 
also collected to investigate whether ONNV crosses the blood brain barrier 48 hours 
post infection.  
 
Similarly to the experiment above involving mosquito bites, neither Ae.aegypti nor 
An.gambiae saliva significantly enhanced infection of ONNV (see figure 8.3 and 8.4).  
Also, no viral RNA was detected in the brain, suggesting that ONNV either is 
incapable of affecting the brain, or it does so only after 48 hours post infection. 
Interestingly, viral RNA was detected in the distal joint at 48 hours post infection. 
 
8.4 Summary and Conclusions 
 
In this chapter we successfully developed an infectious ONNV in vivo model utilising 
C57BL/6 mice with the use of the IFNAR-1 antibody to temporally inhibit IFN 
signalling. We demonstrate for the first time that ONNV does not replicate in WT 
immunocompetent C57BL/6 mice, irrespective of the presence of Ae.aegypti 
mosquito bites/saliva. Instead, blocking of type I IFN responses are necessary for 
replication of virus to occur. We also show that we can detect ONNV at the 
inoculation site, spleen, joint, distal joint and dLN at 48 hours post infection. 
 
Utilising the developed ONNV mouse model we demonstrate for the first time that 
ONNV infection is not enhanced by either Ae.aegypti saliva or bites, and therefore is 
quite distinct to the majority of other arboviruses. This is interesting considering the 
close sequence homology of ONNV to SFV and CHIKV, which have both been 




An.gambiae bites and/or saliva does not modulate the level of ONNV infection. This 
is interesting as majority of previously studied arboviruses appear to rely on mosquito 
saliva for effective transmission, infection and dissemination to occur. Together, this 
suggests that ONNV has evolved not to rely on mosquito saliva dependent arbovirus 
enhancement, and can therefore be more easily transmitted via other mosquito 
species that lack the salivary factors involved. This observation could also provide a 
further reason to account for the inability of An.gambiae mosquitoes to vector the 














Emerging and re-emerging infectious arthropod borne viruses have a tremendous 
impact on global health as they constitute an ongoing threat due to limited 
availability of treatments and vaccines. Due to this, development of novel treatments 
are urgently required. The recent discovery that mosquito borne virus infections can 
be enhanced by mosquito bites, allows for the potential development of treatments 
that specifically target and inhibit this aspect of virus infection. Directly inhibiting 
virus enhancement has the potential to decrease the likelihood of serious disease 
development commonly associated with mosquito-borne virus infections. Research 
investigating the mechanistic principles responsible for virus enhancement by 
mosquito bites is therefore required to discover therapeutic targets. 
 
The overall aims of this thesis was to increase our limited understanding of the 
mechanisms involved in arbovirus enhancement, as well as addressing key questions 
in the field. More specifically we were interested in investigating which components 
of mosquito saliva are responsible for saliva-dependent virus enhancement as well as 
which aspects of the host responses elicited against mosquito saliva that are required 
for virus enhancement to occur. Finally, we wanted to understand if all mosquito 
species saliva is capable of enhancing virus infection, and whether the host 
mechanisms and salivary components implicated are the same for all mosquito 
species. It is important to understand whether this is the case if we are to successfully 
develop a treatment targeting multiple arbovirus infections. It is possible that the 
enhancement of virus infections are highly species/virus specific. As a side, such 
factors could also have an impact on the determination of mosquito vector 
competence.  
 
Therefore, the overall aims of this thesis were: 
 
1. To investigate which components of the mosquito saliva are 





2. To investigate which aspects of the host response against 
mosquito saliva are important in facilitating arbovirus 
enhancement.  
 
3. To investigate whether the ability of mosquito saliva to modulate 
infection has an impact on mosquito vector competence. 
 
 
9.2 Ae.aegypti saliva alone retains efficacy of mosquito-bite driven 
enhancement of virus infection 
 
In this thesis we sought to determine whether mosquito saliva enhanced virus 
infection with the same efficacy as mosquito bites. Whilst previous works have 
demonstrated that mosquito bites and mosquito saliva enhance virus infection of 
several arboviruses, to date, no one has compared the efficacy of mosquito bites to 
that of saliva. Therefore, in chapter 3 our main aims were: 
 
1. To establish a mouse model that includes injection of mosquito 
saliva with virus. By determining the efficacy of mosquito saliva 
at enhancing arbovirus infection, this work aims to establish 
quantities of saliva required, method of salivary extraction and 
relevant time point post infection for assessing viral titres.  
 
2. Utilising the model system developed, determine the effect of 
mosquito saliva on viral dissemination and animal survival in 
comparison to mice inoculated with virus at mosquito bites. 
 
In chapter 3 we hypothesized that mosquito saliva alone, was sufficient to enhance 
arbovirus infection with the same efficacy in the absence of a bite. During mosquito 
probing, the skin suffers from tissue trauma in addition to the deposition of saliva, 
and it remained unclear what role each had in the modulation of host susceptibility 
to virus infection. To investigate this, we established a mouse model utilising SFV 
and C57BL/6 mice and mosquito saliva, which was then used to determine the effect 




mosquito bites. Whilst previous studies have investigated the effect of mosquito bites, 
mosquito saliva or SGE on arboviral infection, to date no one has directly compared 
the efficacy of each in modulating arbovirus infection. By comparing the ability of 
SGE, mosquito saliva derived via forced salivation and mosquito bites, we 
demonstrate that mosquito saliva enhances SFV infection to a similar extent as 
mosquito bites. Importantly, this allowed us to utilise mosquito saliva, derived by 
forced salivation, to study mosquitoes saliva’s effect on virus infection. We 
hypothesised that, even though the exact composition of the extracted mosquito 
saliva may differ slightly from that of the saliva voluntarily injected by mosquitoes 
during probing, the functional factor responsible for viral enhancement are present 
in our saliva preparation. 
 
The quantity of saliva, and time post infection, required to reach peak viraemia of 
SFV4 in this model system were determined. The highest SFV4 titre was detected at 
24hpi with 5 mosquitoes worth of saliva. Co-injection of mosquito saliva with SFV4 
resulted in enhanced virus replication in the skin as well as simultaneous enhanced 
dissemination to the dLN. Also, injection of Ae.aegypti saliva causes upregulation of 
key inflammatory genes previously determined to be upregulated by Ae.aegypti 
mosquito bites including CXCL2, CCL2 and IL1β. In addition, a survival 
experiment concluded that mosquito saliva reduced mouse survival of SFV4 
infection to a similar extent as 5 mosquito bites. Also, mosquito saliva was found to 
significantly enhance infection of mice with ZIKV. Finally, we investigated whether 
skin trauma induced by repeated needle tick injury modulated virus infection and 
concluded that tissue trauma on its own does not enhance virus infection.  
 
In conclusion, in chapter 3, we established an in vivo mouse model utilising mosquito 
saliva acquired via forced salivation used for the study of the mechanisms of 
arbovirus infection enhancement by mosquito saliva. With this model system we 
have determined that Ae.aegypti mosquito saliva is responsible for the arbovirus 
infection enhancing mechanism displayed by Ae.aegypti mosquito bites, as mosquito 
saliva on its own in the absence of the bite is sufficient for the modulation of virus 
infection. This model allows for a more experimentally-controlled/tractable 




and virus inoculated can be carefully controlled e.g. in comparison to transmitting 
virus to mice by way of infected mosquitoes 
 
The main conclusions from chapter 3 are: 
• Mosquito saliva alone is sufficient at enhancing virus infection in the absence 
of bite trauma. 
• Tissue trauma in the absence of mosquito saliva does not modulate virus 
infection. 
 
9.3 Virus infection enhancing salivary proteins are most likely those that 
have evolved to facilitate blood feeding and are not present in all 
mosquito species. 
 
To date, it remains unknown which factors within mosquito saliva are responsible 
for causing enhancement of virus infection. Whilst several studies have suggested the 
implication of different specific components, as salivary components are numerous 
and highly diverse, the proteins that have been suggested to be implicated in salivary 
dependent virus enhancement, sometimes appear to counter act each other; with 
some factors enhancing or inhibiting immune responses. This suggests that it is 
unlikely that one single salivary factor is responsible for viral enhancement. Instead 
it is more likely that several factors and the subsequent total effect they have on the 
host immune response are important in facilitating virus enhancement. Due to this, 
in this study, we decided not to focus on specific components but rather on the nature 
of components implicated in virus enhancement.   
 
For this purpose, initially it was important to determine whether the factors 
responsible for virus enhancement are salivary components or microbiota present 
within the mosquito saliva. Utilising a developed antibiotic treatment, we 
demonstrate for the first time that antibiotic sensitive microbiota present in injected 
mosquito saliva, does not modulate virus infection as exposure of mice to bites from 
untreated and antibiotic treated Ae.aegypti bites showed no difference in virus 
enhancement. Interestingly, heat treatment of extracted mosquito saliva inactivated 
saliva’s modulatory effect on virus infection. As a heat treatment results in the lysing 




associated PAMPs, such as LPS, and other immune agonists, a heat treatment would 
effectively denature and inactivate any proteins present. We demonstrate that heat 
treatment of mosquito saliva successfully inactivates the mosquito saliva factors 
implicated in enhancement of virus, as mice inoculated with virus alongside heat 
treated saliva exhibited no enhanced virus infection. These observations 
demonstrate that microbiota within mosquito saliva are not responsible for virus 
enhancement; instead the factors implicated in saliva dependent virus enhancement 
are most likely heat sensitive-proteinaceous factors. 
 
As the majority of female salivary components have a role in hematophagy in blood 
feeding mosquito species, we hypothesised that salivary components implicated in 
virus enhancement have co-evolved to facilitate blood feeding. To investigate this, 
we compared the effect of female and male Ae.aegypti saliva on virus infection. We 
demonstrate that female Ae.aegypti saliva causes significant enhancement of SFV 
infection whilst male mosquito saliva does not. This is of importance as only female 
Aedes mosquitoes are hematophagous whilst males are exclusively sugar feeding. This 
suggests that the virus infection enhancing components within female mosquito 
saliva are those that have evolved to facilitate blood feeding. As a side, it was also 
important to clarify whether the act of blood feeding by female Ae.aegypti mosquitoes 
modulated the ability of female Ae.aegypti mosquitoes saliva to enhance infection. We 
were able to conclude this as we observe no difference in modulation of virus 
infection by saliva acquired from blood fed or exclusively sugar fed mosquitoes.   
 
Finally, we demonstrate for the first time that the salivary components responsible 
for virus enhancement are not present in all blood feeding mosquito vectors. By 
comparing the ability of several blood feeding mosquito vectors to enhance virus 
infection we observe that whilst Aedes and Culex mosquito species successfully enhance 
infection, Anopheles does not. This provides us with a new tool for studying the 
mechanisms of saliva-dependent virus enhancement, as Anopheles can be used as an 
important comparator for our studies with Aedes saliva that does enhance infection.  
 
The main conclusions from chapter 4 and 5 are: 





• Modulation of virus infection by Ae.aegypti saliva does not occur in explanted 
skin. 
• Antibiotic sensitive microbiota not implicated in enhancement of virus 
infection. 
• Aedes saliva factor implicated with virus enhancement is associated with blood 
feeding behaviour and is proteinaceous. 
• Virus infection enhancing saliva factor is not present in all blood feeding 
mosquito species. 
 
9.4 Oedema formation in response to mosquito saliva is likely a key 
response required for virus enhancement 
 
Based on the discovery that saliva from blood feeding Aedes mosquitoes enhance 
infection, whilst saliva from blood feeding Anopheles mosquitoes do not, and based on 
the assumption that host responses elicited against saliva are important in facilitating 
virus enhancement; we decided to compare host responses against Aedes and Anopheles 
saliva. This was done in order to discover differences in host responses which could 
be responsible for modulation of virus infection. The identification of specific host 
responses (oedema) were then studied further. 
 
Therefore the aims of chapters 6 were to determine whether: 
 
1. There is a difference in the upregulation of inflammatory genes 
caused by Aedes and Anopheles saliva. 
2. There is a difference in the amount of oedema formation 
following injection with either Aedes or Anopheles saliva. 
 
Initially we sought to compare the upregulation of pro-inflammatory cytokines in the 
skin in response to An.gambiae and Ae.aegypti saliva. Hypothetically, Anopheles saliva 
could be less inflammatory. This is key as some host inflammatory responses to 
mosquitoes bites enhance arbovirus infection. However, the studies here 
demonstrate for the first time that An.gambiae saliva causes higher upregulation of key 
pro-inflammatory cytokines in the skin at 6 hours post injection than Ae.aegypti with 




inoculation of virus with An.gambiae saliva caused a significantly higher upregulation 
of ISGs such as Viperin and CCL5, as well as IFNα itself, compared to Ae.aegypti at 
24 hours post infection. This might suggest that differential type I IFN responses by 
the host may underlie the differences observed in the ability of saliva to enhance 
infection. 
 
However, as we observe that mixing of Ae.aegypti saliva and An.gambiae saliva resulted 
in a similar enhancement of infection as observed by Ae.aegypti saliva inoculation on 
its own, this suggests that An.gambiae saliva does not actively inhibit virus infection 
(e.g. via IFN expression). Therefore it is unlikely that An.gambiae saliva enhances virus 
infection due to an upregulated antiviral IFN response, as this would have inhibited 
virus infection when Anopheles was co-inoculated with Ae.aegypti saliva. We also found 
that Aedes saliva could enhance ZIKV and SFV infection in the absence of type I IFN 
signalling. Instead, it seems likely that An.gambiae saliva simply lacks one, or several 
factors, that are necessary to cause enhancement of arbovirus infection.  
 
Next, we studied differences in oedema formation in response to Aedes and Anopheles 
saliva/bites. We demonstrate that Ae.aegypti saliva (and bites) cause significant 
amounts of oedema in the skin at 30min, 3h and 6h post exposure with differences 
more pronounced at earlier time points. In contrast, An.gambiae saliva caused no 
detectable formation of oedema at the inoculation site at any time point investigated, 
and An.gambiae bites only triggered significant formation of oedema 30min post 
exposure. Oedema formation by An.gambiae bites was significantly less than that 
caused by Ae.aegypti bites. This suggests that oedema formation may be implicated in 
facilitating arbovirus enhancement. Based on these observations, oedema in 
response to Ae.aegypti saliva and the lack of oedema exhibited in response to 
An.gambiae saliva is a more likely candidate for causing enhancement of viral 
infection. 
 
Therefore, in chapter 7 we wanted to further investigate whether: 
1. Oedema induced in the absence of any mosquito derived factors 
can enhance arbovirus infection. 
2. Inhibition of mosquito bite oedema using anti-histamines can 




3. Oedema in response to mosquito saliva differs between naïve 
and sensitised hosts.  
 
Following the discovery of differences in oedema by Aedes and Anopheles saliva, we 
further wanted to investigate whether oedema is implicated in modulation of virus 
infection. For this purpose, the impact of oedema, triggered experimentally in the 
absence of saliva factors, on virus infection, was investigated. Utilising purified 
histamine, we demonstrate that histamine induced oedema is sufficient in enhancing 
virus infection in vivo. This suggests that oedema in response to mosquito bite/saliva 
is important in virus infection modulation. 
 
Although oedema in response to Ae.aegypti saliva appears to be key in facilitating virus 
enhancement, the mechanisms involved in triggering oedema formation in response 
to Ae.aegypti saliva remain unknown. Saliva mediated oedema could be immune 
mediated; either via acute histamine release by resident cells; or via histamine release 
mediated by recruited cells (e.g. Leukocytes). Alternatively, saliva mediated oedema 
could be a direct result from an enhanced permeability of the endothelial cells lining 
the blood vessels. Utilising a combination of antihistamines to investigate whether 
oedema formation is instigated via histamine release, we demonstrate that 
antihistamines are insufficient at inhibiting saliva mediated oedema and 
consequently incapable of preventing salivary mediated virus enhancement. This 
suggests that oedema formation in response to Ae.aegypti mosquito saliva occurs 
independently of histamine release. Instead we hypothesised that Ae.aegypti saliva 
causes enhanced permeability of endothelial cells lining blood vessels resulting in 
oedema. This hypothesis is supported anecdotally by the fact that we cannot observe 
virus enhancement in vitro in macrophages, fibroblasts and skin explants as, these lack 
a functional blood vasculature system. Further studies are required to determine the 
mechanisms involved in Ae.aegypti saliva mediated oedema to allow for the 
identification of potential treatment targets. 
 
In terms of the mechanisms by which oedema enhances virus infection, a previous 
study speculate that oedema formation may help retain virus in the skin [95]. 
Retention of virus in the skin could have two main advantages to the virus; 1.) by 




immune activation in the draining lymph node. By studying the kinetics and 
dissemination of virus when accompanied by mosquito bites and mosquito saliva, we 
demonstrate that whilst Ae.aegypti bites demonstrate delayed dissemination of virus to 
the dLN, Ae.aegypti saliva does not. In fact, mice inoculated with virus alongside 
extracted mosquito saliva exhibited enhanced dissemination of virus to the dLN 
whilst simultaneously exhibiting enhanced virus replication in the skin. As we have 
previously demonstrated that mosquito saliva enhances virus infection with the same 
efficacy as bites, we can conclude that oedema does not enhance infection by 
retaining virus in the skin e.g. where it can replicate in susceptible dermal cells and 
simultaneously delaying immune activation in draining lymph nodes.  
 
As all our experiments had been conducted using naïve mice, we wanted to also 
investigate whether pre-sensitization to mosquito saliva altered oedema formation 
and subsequently the modulation of virus infection by saliva. In our experiments we 
demonstrated that there was no difference in the level of SFV infection following co-
injection of virus alongside Ae.aegypti mosquito saliva, comparing naïve and pre-
sensitised BALB/c mice. Oedema formation in response to Ae.aegypti saliva in 
BALB/c mice differed from what we previously observed in C57BL/6. As was 
demonstrated in previous chapters, Ae.aegypti saliva exposure in naïve C57BL/6 mice 
results in significant oedema formation by 30min post exposure, whilst in naïve 
BALB/c mice no detectable oedema could be observed at 30min post exposure. This 
suggests an alternative host response in naïve BALB/c mice in response to Aedes 
mosquito saliva, making comparison to our data generated previously with C57BL/6 
mice difficult. However, significant levels of oedema were exhibited at 30min post 
exposure in BALB/c mice previously exposed to Ae.aegypti saliva, although levels of 
oedema were similar by 6 hours post exposure, compared to non-primed mice. 
Importantly, both naïve and pre-sensitised BALB/c mice exhibited enhanced virus 
infection to the same level by 24 hours post infection, following co-inoculation of 
SFV4 alongside Ae.aegypti.  This suggests that not all forms of oedema are pro-viral 
or that oedema formation following virus inoculation at time points later than 30 
minutes post exposure are most important in defining outcome to infection. It may 
also be that it is not oedema per se that enhances infection, but rather that this 
leakage of fluid it reflects a general state of endothelial barrier dysfunction, and that 





Main conclusions from chapter 6 and 7: 
• An.gambiae saliva causes significantly higher upregulation of key pro-
inflammatory genes in the skin at 6 hours post injection than Ae.aegypti saliva. 
• Ae.aegypti saliva triggers significant oedema formation but An.gambiae saliva 
does not. 
• Histamine induced oedema is sufficient to enhance virus infection. 
• Saliva mediated oedema is histamine independent as antihistamines are 
insufficient at blocking saliva mediated oedema. 
• Pre-sensitization to mosquito saliva does not further modulate saliva 
mediated virus enhancement. 
 
9.5 Lack of modulation of ONNV infection by mosquito saliva may 
explain ONNV mosquito vector competence  
 
 
Discovering that Anopheles mosquito saliva/bites are incapable of enhancing SFV4 
and ZIKV in mice, and as it has been established that Anopheles mosquitoes are very 
inefficient transmitters of the majority of arboviruses, with the exception of ONNV; 
we next wanted to investigate whether Anopheles could modulate infection ONNV. 
We hypothesized that the saliva factor implicated in virus enhancement affects 
mosquito vector competence and may explain why this mosquito species is such a 
poor vector for most arboviruses. 
 
Therefore, the aims of chapter 8 were: 
 
1. To develop an ONNV virus mouse model. 
2. To use the developed ONNV in vivo model in order to determine 
if Aedes or Anopheles saliva enhance ONNV infection. 
 
In chapter 8, an infectious ONNV in vivo model utilising C57BL/6 mice with the use 
of the IFNAR-1 antibody to temporally inhibit IFN signalling was developed. We 
demonstrate for the first time that ONNV does not replicate in WT 
immunocompetent C57BL/6 mice, irrespective of the presence of Ae.aegypti 




replication of virus to occur. We also show that we can detect ONNV at the 
inoculation site, spleen, proximal joint, distal joint and dLN at 48 hours post 
infection.  
 
Utilising the developed ONNV mouse model we demonstrate for the first time that 
ONNV infection is not enhanced by either Ae.aegypti saliva or bites, unlike other 
mosquito borne viruses. This is very interesting, considering the close sequence 
homology of ONNV to SFV and CHIKV, which have both been demonstrated 
previously to be enhanced by Ae.aegypti bites. Furthermore we also demonstrate that 
An.gambiae bites/saliva do not modulate ONNV infection. Together, these 
observations suggest that ONNV has evolved not to rely on mosquito saliva 
dependent arbovirus enhancement, and can therefore be transmitted via mosquito 
species that lack the salivary factors necessary for virus enhancement. This 
observation could provide a further reason for the inability of An.gambiae mosquitoes 
to vector the majority of arboviruses with the exception for ONNV. 
 
9.6 Conclusions and future directions 
 
In this thesis we have demonstrated for the first time that mosquito saliva is sufficient 
for the phenomenon of mosquito-bite mediated enhancement of virus infection. The 
saliva factor implicated in the modulation of virus enhancement is a proteinaceous 
factor implicated in blood feeding. This factor is not present in all blood feeding 
mosquitoes as we find that Anopheles species saliva does not enhance virus infections. 
Via a comparative study of host responses towards Ae.aegypti and An.gambiae mosquito 
saliva we demonstrate the importance of oedema formation in the modulation of 
virus enhancement. We also demonstrate that saliva mediated oedema is histamine 
independent.  
 
Further work is required to further determine the mechanisms involved in oedema 
formation by Ae.aegypti saliva. Specifically, we need to study the impact of Aedes and 
Anopheles saliva on endothelial cell permeability. By identifying the specific 
mechanisms involved we can develop treatments that specifically target and block 
saliva mediated oedema and subsequently virus enhancement from occurring. 




mosquito saliva mediated oedema inhibitors and their efficacy in prevention of virus 
enhancement and disease severity.  
 
In terms of saliva factors implicated in virus enhancement we demonstrated that this 
factor is not saliva microbiota, but instead a proteinaceous factor. Comparative 
transcriptomic analyses of salivary glands of mosquito species that enhance infection 
to mosquito species that do not (Anopheles), could highlight potential factors 
responsible for virus enhancement. Subsequent gene knockout Ae.aegypti mosquitoes, 
were potential candidate genes have been knocked out, could then be used to 
investigate impact of specific genes on saliva mediated enhancement. 
 
In addition, we also demonstrate for the first time that saliva factors implicated in 
modulation of virus infection may be key for defining mosquito vector competence. 
Further studies should be conducted investigating the genetic differences between 
ONNV and other closely related arboviruses such as CHIKV and SFV in order to 
determine which genetic differences allow ONNV to replicate (and presumably 
transmit) independently of saliva mediated enhancement.    
 
The understanding of the mechanisms implicated in saliva mediated virus 
enhancement allows for the development of a treatment that prevents oedema, virus 
enhancement and subsequently prevention of severe disease. To conclude, I would 
argue that this concept could be used for the development of a treatment and/or 
vaccine that targets the key mosquito saliva factor involved. Potentially, this could 
be useful against the vast majority of arbovirus infections, to be used in combination 
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Appendix 1: Protein concentration of female Ae.aegypti saliva.  
Dot plot illustrating the protein concentration of female Ae.aegypti saliva acquired via forced 
salivation of mosquitoes. Each dot represents the average quantity of 1 mosquitoes worth of 
saliva estimated from the concentration measured from saliva pooled from a group of 
mosquitoes. Saliva protein concentration was measured via nanodrop. Concentrations 




Appendix 2: Antibiotic treatment validation.  
Quantity of 16S RNA was measured in whole mosquitoes of untreated (black) and antibiotic 
treated mosquitoes (grey).  
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